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Abstract: 
Rationale: 
Current asthma guidelines recommend reducing inhaled corticosteroid 
(ICS) therapy dose by 50% in patients with mild to moderate asthma 
who have demonstrated three months of good symptom control 
however there is evidence to suggest that this does not occur. 
Objectives: 
We tested whether exhaled nitric oxide (FeNO) measurements or other 
clinical indices could be utilised to predict a safe reduction of ICS dose, 
without provoking loss of symptom control or exacerbation within 3 
months. We also investigated relationships between airway 
inflammation and asthma symptoms in the mild to moderate asthma 
cohort. 
Methods: 
191 patients with stable asthma were recruited from primary care. 
Patients had their FeNO level measured at baseline and then had their 
inhaled corticosteroid (ICS) dose reduced by 50%. FeNO 
measurements were reassessed seven days later. The primary 
outcomes were whether baseline FeNO or a change in FeNO following 
ICS dose reduction could predict asthma stability at 3 months. 
Results: 
128/191 patients (67%) completed the ICS dose reduction successfully 
at three months. 63/191 patients (33%) suffered from either a loss of 
control or an exacerbation. Baseline Fe NO, or change in FeNO (post 
step-down minus pre step-down) were not statistically significantly 
different between the two groups. 
Conclusion: 
67% of patients with well-controlled asthma can safely reduce their ICS 
dose by half without suffering from a loss of control or exacerbation 
within three months; however neither baseline nor change in FeNO 
measurements or routine clinical indices can be used to predict which 
patients can or cannot successfully tolerate a reduction in ICS dose. 
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Chapter 1 - Introduction: 
Asthma is a disease defined as "a chronic inflammatory disorder of the 
airways. The disease is usually "associated with widespread yet 
variable airway obstruction and an increase in airway sensitivity and 
response to a variety of stimUli" (1). However, these definitions remain 
somewhat controversial in clinical practice due to the fact that the 
presentation of symptoms in asthma are highly variable and the British 
Thoracic Society state that "the absence of a gold standard definition (of 
asthma), means that it is not possible to make clear evidence-based 
recommendations on how to diagnose asthma" (2). 
Central to all definitions of asthma is the presence of symptoms and 
variable airflow obstruction. These symptoms include wheeze, 
breathlessness, chest tightness and cough. More recent definitions of 
asthma also include airway hyperresponsiveness and airway 
inflammation as disease components. How all these features of the 
disease inter-relate and how they subsequently contribute to the clinical 
manifestations of asthma (due to the variability of the disease) is 
questioned (2). Because of these clinical uncertainties, guideline lead 
definitions of asthma serve to tell us very little about the disease course 
or the risk and progression of exacerbation. Although quantifiable 
measures of airway hyperresponsiveness and airway inflammation are 
becoming more common in secondary care and research environments, 
time and cost constraints prevent the simple transition of such tests into 
primary care. In practice, many decisions are made based upon the 
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presence or absence of symptoms despite the fact that extensive 
research has shown that symptoms are a poor predictor of outcome (3). 
Only airflow obstruction is quantified and measured for diagnostic and 
management purposes in primary care centres. This means that there 
still remains a need to develop a marker of disease (feasible in primary 
care) which can be used to inform clinicians about diagnosis, 
medication response (particularly to oral and inhaled steroids) and 
exacerbation risk. 
The UK has one of the highest incidence rates of asthma of any country 
in the world. Development of such a marker of disease would be 
particularly beneficial to clinicians and patients in the UK. There are 
approximately 5.2 million people with asthma in the UK, and of these, 
1.1 million are children. It is estimated that one in five British 
households are affected by asthma and every year these patients 
account for 4.1 million GP consultations and one hospital admission 
every 7.5 minutes (4). Despite the high level of medical intervention 
dedicated to the care of these patients, asthma is still responsible for 
1400 deaths in the UK each year. These facts point to a definite need 
for more specific diagnostic and management tools in UK asthma care. 
Asthma costs the UK over £2.3 billion a year, of this, approximately 
£889 million is through NHS costs (prescriptions, dispensing, hospital 
admissions and GP consultations). £1.2 billion is the estimated non-
NHS cost of asthma to the UK government. This mainly derives from 
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loss of productivity through 12.7 million lost work days per year, 
however, an additional £260 million is spent by the government each 
year in social benefits to asthma sufferers. The biggest expenditure on 
asthma for the NHS is medication costs: totalling over £659 million a 
year (Refer to appendix section7 for medication costs in England and 
Wales). In 1969, Ventolin® (salbutamol) was introduced into the UK 
market followed by other short-acting beta2 ( ~ 2 ) ) agonist bronchodilators 
to reverse asthma induced bronchoconstriction. In 1972, the first 
inhaled corticosteroid (ICS) medication was prescribed (Becotide® 
beclomethasone dipropionate) as a treatment for airway inflammation 
and a preventer for asthma exacerbation. In more recent years 
additional medications including long-acting ~ 2 2 agonists, newer inhaled 
corticosteroid preparations and combined inhalers have been 
introduced. Monoclonal anti-lgE antibodies have also been marketed in 
the past five years. These drugs use the anti-lgE antibody to bind IgE 
molecules in the blood stream allowing the body to remove them. 
New treatments for asthma are largely developed to reduce airway 
inflammation effectively but many clinical decisions are made based 
upon the presence or absence of asthma symptoms despite the fact 
that there is poor correlation between symptoms and airway 
inflammation (3). If a clinical marker could be developed to assess 
airway inflammation in a safe, cost-effective and simple test; 
personalised asthma plans and medication regimes could be 
implemented more readily in UK primary care. The marker would ideally 
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need to be useful in predicting future exacerbation likelihood, saving 
money by preventing over-treatment and provide beneficial additional 
clinical information which is not currently available in primary care. 
Unlike the pharmacological progression in asthma medications; the 
methods used to diagnose, predict and prevent exacerbations, as well 
as evaluate responses to medication, have not dramatically changed 
since the introduction of the peak flow meter in 1959 by Wright and 
McKerrow. Peak flow monitoring is regularly used in primary and 
secondary care to predict exacerbation, however the use of peak flow 
monitoring has been questioned in a study by Harrison et al. (2004) (5) 
which concluded that using a combination of a falling peak flow with a 
doubling dose of inhaled corticosteroid therapy medication cannot 
prevent an asthma exacerbation (5). Preventing, predicting and treating 
asthma exacerbation is important as exacerbations cause patients deep 
concern and distress, cost a disproportionate amount and can lead to 
sudden death (6-8). 
Post-mortem studies show that airway inflammation is prominent in 
asthma associated deaths (9), and the question is raised as to whether 
the assessment of airway inflammation using non-invasive techniques 
may lead to better recognition and management of patients at risk of 
exacerbation. 
The use of invasive techniques to assess airway inflammation such as 
bronchial lavage are available in secondary care, however, they are 
time-consuming and expensive procedures requiring theatre staff input 
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and patient sedation. Less invasive techniques such as sputum analysis 
are used more extensively now especially in research settings, but they 
are still expensive and highly involved techniques. It is unlikely that they 
will ever be feasible and affordable options in primary care. Blood 
eosinophil count and blood eosinophiliC cationic protein are also used 
as measures of inflammation in asthma, however the evidence is to 
date inconclusive as to the validity of these measurements in diagnosis 
and managing asthma, and sputum eosinophil count is the more 
accurate marker of eosinophilic airway inflammation (10). A non-
invasive technique is required for accurate assessment of airway 
inflammation in primary care. The question as to whether a non-
invasive marker is feasible has become particularly pertinent since it 
has become clearer that the pattern of treatment responsiveness of 
airway inflammation in asthma is heterogeneous (11). 
The relationship between airway inflammation, airway dysfunction and 
symptoms is weak (12). There have been some recent advances in 
assessment of airway inflammation using non-invasive techniques. 
These tools have provided opportunities to try and predict and prevent 
asthma exacerbations and further explore the heterogeneity of asthma. 
Such tools of non-invasive assessment of airway inflammation need 
further testing and clarification of their use and efficacy before they are 
widely invested in. 
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This thesis examines exhaled nitric oxide as a non-invasive biomarker 
of airway inflammation and its potential to be a clinical tool for asthma 
diagnosis and management in primary care; the heterogeneity and 
importance of airway inflammation monitoring will also be discussed. 
The content of the first section will review and explore the concept of 
exhaled nitric oxide as a biomarker of airway inflammation and the 
feasibility for use in UK primary care. The second section will 
concentrate on a pilot study and related sub-group analyses evaluating 
the use of exhaled nitric oxide as a non-invasive biomarker of airway 
inflammation in the prediction of over-treatment and exacerbation in 
primary care patients with well-controlled asthma. 
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1.1 - Introduction to asthma: 
Asthma is a chronic inflammatory condition of the airways. 
Breathlessness, tightness of the chest and wheezing are characteristics 
of reduced lung function caused by this obstructive airways disease. 
Acute exacerbations can be rapid or gradual in onset, and may become 
life threatening. Microscopic examination reveals extensive 
inflammatory infiltration of the airways with oedema due to 
vasodilatation. Biopsies have shown increased numbers of leukocytes, 
particularly eosinophils, mast cells and T -lymphocytes, in the airways, 
and increases in the markers of lymphocyte activation. Structural 
changes resulting from chronic inflammation include bronchial smooth-
muscle hypertrophy and hyperplasia. New vessel formation, interstitial 
collagen deposition resulting in basement membrane thickening, and 
airway wall remodelling have also been noticed (13, 14). 
The mechanism of asthma and allergic response: 
In the majority of cases, asthma is an allergic response disorder which 
is controlled in large-part by IgE mediated mechanisms. Allergens such 
as dog and cat hair, house-dust mite and aspergillus are common 
stimulators of the asthmatic allergic response. Once an individual has 
been exposed to an allergen, there is an uptake of this allergen and 
presentation by dendritic cells, activation of T -helper lymphocytes, 
cytokine release from T -helper cells and subsequent secretion of 
allergen specific IgE antibodies from 8-lymphocytes. At this point, the 
allergen-specific IgE binds to mast cells leading to the release of 
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inflammatory mediators (14). Exposure to these allergens can also 
provoke T-cell activation, cytokine and chemokine release, and again, 
production of inflammatory mediators by IgE independent mechanisms. 
In short, inflammatory mediators released in either of these ways leads 
to damage of the epithelium, stimulation of the nerves, swelling, mucus 
secretion and contraction of the airway smooth muscle. Chronic 
inflammation, which results from release of inflammatory mediators 
leads to two principal disorders of lung function in patients with asthma. 
These are bronchial hyperresponsiveness and limitation of airflow. 
Patients with asthma have demonstrated increased bronchoconstrictor 
responses to direct airway smooth muscle stimuli such as histamine 
and methacholine, and to indirect stimuli including exercise, adenosine 
monophosphate and cold/dry air. All these stimuli lead to airway 
narrowing secondary to the initial release of inflammatory mediators. 
The consequences of this are, increased variability in airway diameter 
and lung function measurements, including PEF (which can fluctuate 
more than 20% between morning and evening measurements) (2, 14, 
15). Acute bronchoconstriction may result from airway swelling, mucus 
plugging or airway wall remodelling. Allergen-induced release of 
inflammatory mediators (such as histamine, prostaglandins and 
leukotrienes) can lead to acute bronchoconstriction, while swelling of 
the walls of the airways is caused by oedema, (this can occur with or 
without bronchoconstriction). Hypersecretion of mucus leading to 
plugging of the airways and airway remodelling can also be caused by 
chronic airway inflammation (2, 16). At first exposure to allergen, the 
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mast cells are primarily involved and produce a response within minutes 
of allergen detection, and acute symptoms typically peak at around 10-
15 minutes post-exposure. It is believed that micro-localisation of mast 
cells in the smooth muscle and subsequent interactions between the 
two are responsible for the typical disordered airway function 
characteristic in asthma. When the mast cell surface-bound IgE is 
cross-linked by the antigen, the mast cell is activated and degranulation 
occurs releasing the inflammatory mediators by exocytosis. 
Bronchospasm and constriction are induced and an early phase 
response such as this may result in more than a 25% reduction in FEV 1 
(13, 14). After 4-6 hours, the allergic response moves into the "late 
phase" at which point, T -cells, B-cells and eosinophils are recruited. 
Like mast cells, eosinophils too contain inflammatory mediators which 
can induce airway damage and contribute to airway 
hyperresponsiveness. It has also been demonstrated that as well as 
inflammatory mediators, eosinophils also generate leukotrienes, 
cytokines, matrix metalloproteinase and reactive oxygen species, which 
could contribute to the overall symptoms of airway obstruction, injury 
and damage which are characteristic of asthma. As the late phase of 
the allergy progresses, nasal congestion and urticaria may also develop. 
At this point a reduction in FEV1 by as much as 75% may be seen (13, 
14). 
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1.2 - The diagnosis and management of asthma: 
The diagnosis of asthma in primary care (and some secondary care) 
settings depends upon evaluations of variable airflow obstruction with 
spirometry (and reversibility), peak flow measurements / variability and 
assessment of symptom control. In the majority of instances, airway 
inflammation and hyperresponsiveness are not assessed despite being 
important characteristic features of asthma (17). The result of this is that 
many patients often commence treatment for asthma without there 
being sufficient evidence to justify doing so (18). The implications can 
be serious, and if misdiagnosed, patients can potentially be taking 
therapy unnecessarily before a correct alternative diagnosis is made 
(19). Current research aims to find more definitive methods of 
diagnosing asthma to avoid these situations arising during the 
subsequent management of the disease (16). 
Asthma management is defined as "accurate initial diagnosis with 
effective control of the symptoms (including nocturnal and exercise-
induced symptoms), prevention of further exacerbation (without 
inducing too many other side-effects), maintenance of pulmonary 
function levels (as close to normal as possible), maintenance of 
"normal" activity levels, prevention of development of irreversible 
airways damage and prevention of asthma mortality." (2) 
The overall aim of asthma management is to optimise control whilst 
maintaining the lowest doses of medication possible to achieve this. 
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The Official American Thoracic Society I European Respiratory Society 
Statement: Asthma Control and Exacerbations defines asthma control 
as "the extent to which the various manifestations of asthma have been 
reduced or removed by treatment. This includes two components: 
1. The level of clinical asthma control, which is gauged from 
features such as symptoms and the extent to which the 
patient can carry out activities of daily living and achieve 
optimum quality of life, and 
2. The risk of future adverse events including loss of control, 
exacerbations, accelerated decline in lung function, and 
side-effects of treatment" (20). 
Successful management of asthma comes from a combination of 
attention to preventative measures, such as allergy avoidance and 
effective medication use to prevent and lor treat acute attacks. Asthma 
management depends upon both control of day-to-day symptoms and 
prevention and treatment of asthma exacerbations. Symptom control 
depends in the most part on bronchodilation and allergen avoidance as 
well as use of inhaled corticosteroids (ICS) to reduce airway 
inflammation. ICS are also used to prevent exacerbations which are 
dependent on an increase in symptoms not responding to an increase 
in short-acting ~ 2 2 agonist (SABA) use. Most exacerbations are virally 
induced and once established, an asthma exacerbation is controlled by 
systemic steroid use. There are still problems which remain in asthma 
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management which the previous aims attempt to minimalise, however, 
some patients are still either, misdiagnosed and unnecessarily treated 
with asthma medication or poorly controlled patients, or patients who 
appear to be well-controlled but could potentially remain well-controlled 
on lower doses of medication (16). 
Another problem faced by patients and clinicians is that some patients 
who appear to be well-controlled on their medication may still 
demonstrate evidence of airway inflammation and hyperresponsiveness 
(21, 22) and therefore may be at risk of developing an exacerbation, 
therefore just assessing a patient as "well-controlled" on medication 
may not be sufficient and the exacerbation risk also needs to be 
quantified (13). 
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1.2.1 - The management of asthma through medication: 
Asthma management medication is typically classified into two groups: 
controller medications (also known as preventer medications) and 
reliever medications (also known as rescue medications). Controller 
medications are those which patients take on a daily basis over the 
long-term to control asthma symptoms, prevent loss of control and 
prevent exacerbation. Reliever medications are those which patients 
take "when required" to relieve bronchoconstriction (23). 
Short-acting beta2 Uh) agonists (SABAs): 
Salbutamol and terbutaline are examples of SABAs. SA BAs are used to 
reduce bronchoconstriction and are the primary choice for treatment of 
acute exacerbations and exercise-induced asthma. There are other 
forms of reliever medication, however, SABAs are the best drugs for 
relieving acute bronchospasm, and increased dependence on SABA is 
a good indication that a patient is not well-controlled on their preventer 
medication. However, SABA is not recommended for long-term use as 
there is evidence that a refractory response may develop and thus the 
asthma may worsen (23). 
Long-acting beta2 Uh) agonists (LABAs): 
Salmeterol and formoterol are examples of LABAs. LABAs typically act 
for over 12 hours, by relaxing the smooth muscle in the airway, 
enhancing mucociliary clearance, and decreasing vascular permeability. 
It is also believed that LABAs may be involved in moderating 
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inflammatory mediator release from mast cells and basophils. 
Treatment with LABA improves lung function and nocturnal asthma, and 
is shown to particularly benefit those patients who do not obtain 
adequate symptom control using starting doses of ICS alone. LABAs 
should not be administered without an ICS in combination {23}. 
Combination inhalers containing LABAs and ICS are now available 
such as Seretide® and Symbicort® in single devices. These are 
beneficial as they improve medication compliance in patients. 
Inhaled corticosteroids (leS): 
Beclomethasone dipropionate and budesonide are examples of ICS. 
ICS are currently the most effective anti-inflammatory medications 
available. They reduce airway inflammation, allowing lung function and 
asthma symptoms to improve, bronchial hyperresponsiveness to 
decrease and exacerbation frequency and severity to lessen. ICS affect 
the signalling pathway for the production of pro-inflammatory molecules. 
This is mainly achieved through the down-regulation of genes which 
express inflammatory mediators and the up-regulation of those genes 
expressing anti-inflammatory mediators. ICS are favoured over oral 
corticosteroids where possible as there are fewer systemic side effects 
{23}. 
Systemic corticosteroids: 
Prednisolone is an example of a systemic corticosteroid. It can be 
administered either orally or parenterally. Short courses of 5-7 days are 
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often used in patients with uncontrolled asthma, or during periods of 
exacerbation. It is accepted that long-term oral treatment may be 
necessary in patients demonstrating severe, persistent asthma with 
poor control. However it is recommended that specialists alone initiate 
this form of treatment after all other avenues have been explored (23). 
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1.3 - Asthma control and severity: 
One of the difficulties physicians face when treating asthma and also 
designing clinical trials, is differentiating between asthma control, 
severity and exacerbations. These terms are typically used 
interchangeably but actually mean different things. This difficulty is 
further worsened by the fact that patients respond in different ways to 
treatment and asthma symptoms can change over time (20). 
Cockcroft and Swystun, 1996 (24) defined good asthma control as 
"minimal symptoms with minimal use of rescue J32 agonist with near 
normal lung function, little resting bronchoconstriction and a small 
response to bronchodilator" (24). This definition fits broadly with the 
Global Initiative for Asthma (GINA) guidelines for optimal management 
of asthma (25) and the ATS/ERS guidelines (20). Asthma severity was 
defined as the "minimum amount of medication needed to achieve 
adequate control", rather than defining it solely on symptoms alone. 
This means that it would be possible to have severe but well-controlled 
asthma or poorly controlled mild asthma. The former would be on high 
doses of inhaled and/or oral corticosteroids and experience few 
symptoms, whilst the latter would have symptoms but only require low 
doses of corticosteroids to alleviate them. These differences become 
important when designing and recruiting into clinical trials, as inclusion 
criteria may often require the patient to demonstrate particular levels of 
control, but because asthma is a variable episodic condition, 
spontaneous improvement or decline is often likely. 
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Reddel et al. (1999) (26) evaluated the differences between asthma 
control and severity using changes in peak flow variability. The 
hypothesis that asthma exacerbations had the same degree of peak 
flow variability as episodes of poor asthma control was tested (26). The 
results showed that poor asthma control and asthma exacerbations 
differed in their response to short-acting 132 agonist use. During periods 
of poor asthma control (before treatment with inhaled corticosteroids) 
the average post-bronchodilator peak expiratory flow was 28% higher 
than the pre-bronchodilator value, whilst during an asthma exacerbation 
there was no response to bronchodilator and therefore no difference 
between pre and post bronchodilator peak flow. Most exacerbations 
were associated with evidence of viral infection, this lead the authors to 
draw the conclusion that asthma exacerbations were not the same as 
poor asthma control (26). This study had a high rate of viral 
exacerbation and did not take into account asthma severity so the view 
that exacerbations and poor control are linked still persists. 
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1.4 - Asthma exacerbations: 
The incidence of asthma exacerbations in studies varies depending on 
the definition used and the baseline severity and control of the study 
population. Criteria used to define an exacerbation in previous studies 
have included: a drop in peak flow from a pre-determined baseline, 
need for rescue oral corticosteroids, increase in the use of short-acting 
~ 2 2 agonist, night time awakening and increased symptom scores. 
Exacerbations are an important clinical feature of asthma and 
exacerbation frequency is increasingly measured as an important 
outcome variable in many Clinical trials (24). 
In the Formoterol and Corticosteroids Establishing Therapy (FACET) 
study (17), (which was designed to evaluate the benefits of adding a 
long-acting ~ 2 2 agonist to different doses of inhaled corticosteroid), a 
severe exacerbation was defined as an episode "requiring treatment 
with oral corticosteroids", as judged by the investigator, or a "decrease 
of more that 30% below baseline value in the morning peak flow on two 
consecutive days" (the baseline value was established during a run in 
period) (12). Mild exacerbations were defined as 20% decrease in peak 
flow from baseline on two consecutive days, nocturnal awakening or 
three additional inhalations of terbutaline when compared to the study 
run in period. Approximately 850 patients were entered into the study 
and were randomised into one of four groups. The total number of 
severe exacerbations was 425 over a 12-month period, giving an 
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overall exacerbation rate of 0.5 exacerbations/patient/year. The total 
number of mild exacerbations was 16,463 (17). 
In the Gaining Optimal Asthma Control study (GOAL) (27) the 
combination of salmeterol/fluticasone (as S e r e t i d e ~ ~ was compared to 
fluticasone alone in three different groups of patients over the course or 
one year; an exacerbation was defined as hospitalisation or as requiring 
antibiotics or oral corticosteroids. The baseline demographics revealed 
that 3416 patients experienced 1832 exacerbations, giving an 
exacerbation rate of 0.54 exacerbations/patient/year prior to the study 
(27). These figures demonstrate that severe asthma exacerbations are 
common and that the addition of a long-acting ~ 2 2 agonist reduces 
asthma exacerbations. The FACET study also revealed that higher 
dose inhaled corticosteroids have a marked beneficial effect of 
exacerbation frequency but less effect on symptoms and peak 
expiratory flow, whereas with the addition of long-acting ~ 2 2 agonists the 
opposite was shown to be true (12). This indicates that exacerbation 
frequency does not relate closely to symptoms and measures of 
disordered airway function, suggesting that the mechanisms 
responsible for these particular features of asthma are different (28). 
This demonstrates that different strategies are needed to reduce 
asthma exacerbations, as well as optimise asthma control. 
Studies have consistently shown that poorly controlled asthma and 
asthma exacerbations cost a great deal more than well-controlled 
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asthma; Hoskins et al. (2000) (7) found the average cost per patient 
was 3.5 times higher for a patient having an asthma exacerbation, 
compared to a patient who did not (7). Similar figures have been 
published by Van Ganse et al. (2002) (8). Barnes et al. (1996) (6) 
suggested that there was significant scope for cost reduction by 
improving disease control, as one third of the direct cost of asthma was 
related to accident and emergency admission, hospitalisations and 
death (6). 
Prevention of asthma exacerbations: 
The current strategy recommended by the British Thoracic Society / 
Scottish Intercollegiate Group Network suggests a stepwise approach 
to the control of asthma symptoms and exacerbations (2). However, 
patients who appear clinically well-controlled on inhaled corticosteroid 
can still have evidence of airway inflammation and airway 
hyperresponsiveness (22) and vulnerable to exacerbations, airway 
remodelling and possibly fixed airways obstruction (13). These findings 
have important implications for the management of asthma particularly 
in primary care. This will be discussed further in Chapter 1.10. 
Self management plans advocate doubling the dose of inhaled 
corticosteroid if the peak flow drops below a pre-determined baseline 
value. This approach has been questioned, and Harrison et al. (2004) 
(5) found that doubling the dose of inhaled corticosteroid therapy, based 
on a fall in peak flow of >15% from baseline or an increase in the 
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asthma symptom score from baseline, did not prevent the need for oral 
corticosteroids (5). The authors concluded that a higher dose of inhaled 
corticosteroid medication might be needed in order to prevent asthma 
exacerbation. Foresi et al. (2000) (29) demonstrated that quadrupling 
the inhaled corticosteroid dose at the onset of an asthma exacerbation 
had a beneficial clinical effect and reduced the requirement for oral 
corticosteroids compared to placebo (29). This suggests that once peak 
flow or symptoms begin to deteriorate an asthma exacerbation may still 
be prevented. New treatment regimes have been suggested to improve 
asthma control and prevent asthma exacerbations. O'8yrne et al. (2005) 
(30) evaluated the use of budesonide and formoterol ( S y m b i c o r t ~ ~ as 
both maintenance and reliever medication (SMART® plan) (30), and 
compared it to budesonide/formoterol fixed dose therapy and high dose 
budesonide in patients with moderate persistent asthma and poor 
symptom control despite inhaled corticosteroid therapy. Overall 
SMART® reduced the number of exacerbations when compared to fixed 
dose therapy. However this approach may lead to over or under-
treatment of asthma so caution is needed when using SMART® outside 
of the study environment (31). Exacerbations are frightening and 
debilitating for the sufferer and expensive for the NHS. Preventing 
exacerbations is one of the ultimate aims of asthma management, 
however, this proves difficult in many patients with asthma as it is 
difficult to predict when these exacerbations may occur and why. 
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1.5 - The heterogeneity of asthma - Introduction: 
There are four important features of asthma: airway inflammation, 
airway hyperresponsiveness, variable airway obstruction and 
associated symptoms (1). Within asthma these features are often seen 
to overlap, occur independently or change over time. This can be in 
response to medication or other factors including infection and allergen 
exposure. The other common problem, which is seen in clinical practice, 
is that some of these features also occur in other airway diseases such 
as eosinophilic bronchitis (32) and COPD (33). This often leads to 
diagnostic difficulties and treatment uncertainties. The four features 
mentioned above will be discussed individually to present the 
importance of each feature in the asthma phenotype. 
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1.5.1 - Airway inflammation in asthma: 
It is widely hypothesised that airway inflammation causes airway 
hyperresponsiveness which subsequently causes variable airway 
obstruction and asthma symptoms. If left untreated, airway inflammation 
may eventually cause airway smooth muscle remodelling. This 
hypothesis is firmly set in both research and clinical settings and it has 
even become central to guideline definitions of asthma (2) . However, 
large cross-sectional and longitudinal studies of airway inflammation 
using sputum induction (in larger populations with a diverse range of 
asthma presentations) demonstrate disparity between airway 
inflammation and other measures of airway function, suggesting that 
this hypothesis may require modification. 
The pathophysiology of airway inflammation in asthma: 
The role of eosinophilic airway inflammation in the pathogenesis of 
asthma has been researched by bronchoscopy studies performed over 
the last 20 years (34). These studies were largely limited to young 
volunteers with mild airway inflammation. The development of a non-
invasive technique (sputum induction) to measure airway inflammation 
has made it possible to assess the presence of airway inflammation and 
relate it to measures of airway dysfunction in larger and more 
heterogeneous populations than was possible with invasive 
bronchoscopy studies. In general these studies have contradicted 
findings in the earlier bronchoscopy studies and they have not found a 
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correlation between sputum eosinophil levels and various markers of 
airway dysfunction, such as spirometry (28,35-37). 
Encouragingly the results of the research presented in this thesis show 
similar correlations between airway inflammation and airway 
dysfunction. The results of this research can be found in Chapters 4 
and 5. 
One observation has been that subset of patients with symptomatic 
asthma do not have sputum evidence of eosinophilic airway 
inflammation (38-40). Many patients present with sputum neutrophilia. 
This sputum profile is evident in corticosteroid-na"ive (39) as well as 
corticosteroid treated patients with asthma (37, 41,42) suggesting this 
profile is not always related to treatment. It has been noticed that 
patients with non-eosinophilic asthma respond less well to inhaled 
corticosteroid therapy than those with a more typically eosinophilic 
sputum profile (36). Similar sputum findings have been reported in more 
severe patients with asthma also (37, 38, 41, 42) and have identified a 
sub-group of patients with refractory asthma who have bronchoscopic 
evidence of neutrophilic airway inflammation, normal eosinophil counts 
and a normal basement membrane thickness. These findings suggest 
the presence of a distinct asthma phenotype characterised by a 
predominantly neutrophilic airway inflammatory response and relative 
corticosteroid resistance. However, these findings are based on single 
observations, and in a disease as variable as asthma there is a distinct 
need to establish a clearer understanding of whether a neutrophilic 
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asthma phenotype is persistent and whether relative corticosteroid 
resistance of these individuals is long-term. If this is the case, there is 
little point in exposing these patients to corticosteroid medication. As 
such the evidence now suggests that airway dysfunction and 
eosinophilic airway inflammation appear to be independent of one 
another. Further detail on the importance of sputum phenotypes and 
treatment decisions can be found in Chapter S.4. 
There is however a relationship between the change in airway function 
and eosinophilic airway inflammation following intervention with allergen 
challenge (43) or corticosteroid treatment (40) suggesting that there 
may be a within patient association with changes in these markers 
rather than a between patient association. The question as to whether 
changes in eosinophilic airway inflammation are linked to changes in 
airway function has been questioned by Leckie et al. (2000) (44). One 
study has shown that the humanised monoclonal antibodies to IL-S 
cause a profound and long lasting reduction in blood and sputum 
eosinophilia, but they had no effect on airway responsiveness, lung 
function or symptoms pre and post allergen challenge (4S). In another 
study there was no evidence of improvement in traditional markers of 
asthma control in a cohort of patients with more severe asthma who 
were symptomatic and had disordered airway function despite 
treatment with high doses of inhaled corticosteroids (46). One problem 
in interpreting these studies is that the anti-IL-S antibody only partially 
reduced the tissue eosinophilia (4S) although the effects seen were 
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significant. One view is that the findings of anti-IL-5 monoclonal 
antibodies suggest that changes in airway function and eosinophilic 
airway inflammation are independent and that the abnormalities of 
airway function seen in asthma are causally linked to other aspects of 
the inflammatory response which, although closely linked to airway 
inflammation, can be disassociated from it (47). 
80th eosinophilic bronchitis and asthma are associated with cough and 
it is possible that eosinophilic airway inflammation is directly responsible 
for this aspect of the asthmatic process. The previous demonstration of 
a significant correlation between the improvement in cough reflex 
sensitivity and fall in induced sputum eosinophil count following 
treatment of subjects with eosinophilic bronchitis with inhaled 
corticosteroids would be consistent with a causal association (48). 
Other reports suggest an increased rate of decline in FEV 1 with the 
development of fixed airflow obstruction in eosinophilic bronchitis (49); it 
is possible that this complication of chronic asthma is also related to 
eosinophilic airway inflammation. This section highlights the importance 
in understanding the overlap of clinical features between asthma and 
other respiratory diseases. The diagnosis and management of asthma 
can therefore be exceptionally difficult especially in centres where only 
tests of airflow obstruction are available. The problem this poses to the 
diagnosis and management of asthma in primary care will be discussed 
in further detail in Chapter 1.10. 
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Inflammatory phenotypes and the stability of airway inflammation 
in asthma: 
Asthma has been recognised as a heterogeneous disease for many 
years. However, in recent years there has been interest surrounding the 
identification of asthma phenotypes based upon the highly variable 
patterns of airway inflammation in asthma. Asthma airway inflammation 
is not a stable entity and the levels of airway inflammation fluctuate over 
time. The need to assess asthma as a continuum of variable symptoms 
over time, rather than at one fixed time point has become more 
apparent in recent years. 
The introduction of induced sputum as a non-invasive "measure" of 
airway inflammation has facilitated knowledge of asthma phenotypes: 
eosinophilic and non-eosinophilic. It has become popular to 
characterise patients with asthma in this way as these two particular 
phenotypes appear to determine the likelihood of response to treatment, 
particularly with inhaled corticosteroids, which has been shown to differ 
according to the pattern and extent of airway inflammation. The concept 
of differing phenotypes has lead to researchers considering the 
possibility of individualised asthma treatment and management based 
upon the phenotype of airway inflammation which patients personally 
express. 
Numerous studies have been undertaken to attempt to refine and 
explain the phenotypic diversity which is seen in asthma. Adult studies 
which have employed induced sputum, have consistently identified 
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distinct eosinophilic and non-eosinophilic subgroups of asthma. In 
addition inhaled corticosteroids, which are used to suppress airway 
inflammation and sputum eosinophilia, are known to be a significant 
cofounder in such studies. Normal sputum eosinophil counts have been 
reported in up to 25% of adult patients with untreated symptomatic 
asthma (36) and for over 50% of adult patients treated with high dose 
inhaled corticosteroids (38). 
In a study by Simpson et al. (2006) (50) it was suggested that airway 
inflammation in adult asthma could be categorised into four 
inflammatory subtypes based upon the sputum profile: Neutrophilic 
asthma (Neutrophils >61 %), eosinophilic asthma (eosinophils >3%), 
paucigranulocytic asthma (neutrophils <61 % and eosinophils <3%) and 
mixed granulocytic asthma (neutrophils >61% and eosinophils >3%) 
(50). In stable adult asthma, where inhaled corticosteroids are the most 
prevalent treatment, paucigranulocytic asthma is seen to be the most 
common inflammatory phenotype followed by neutrophilic asthma (51, 
52). In a study which examined adults during the stable phase of 
asthma, many clinical features were consistent across the four 
inflammatory phenotypes. Although the presence of the inflammatory 
phenotype appeared to predict a greater likelihood of future 
exacerbation (39) and non-eosinophilic patients were more likely to be 
female subjects and non-atopic than the remaining population (36). 
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Adults with an acute severe exacerbation of asthma are more likely to 
present with neutrophilic or paucigranulocytic sputum (51). The 
evidence is mounting to suggest that a "one size fits all" approach to 
asthma management is neither effective nor acceptable. Researchers 
are now searching for individualised phenotype-specific targeted 
treatment regimes. These different inflammatory profiles may also 
dictate treatment response, and as such, more accurate initial 
investigation of the inflammatory phenotype in individuals may prevent 
incorrect and "trial and error" treatment protocols. 
However, a continuous problem which arises in most studies which use 
sputum profiles to define asthma phenotypes, guide treatment regimes 
or predict exacerbation, is that they confine their analyses to cross-
sectional data measured at a single time point thus assuming temporal 
phenotypic stability. This is potentially a significant limitation of these 
studies given that asthma by definition is a variable disease (2). 
Simpson et al. (2010) (53) showed that the absence of a sputum 
eosinophilia was a consistent finding four weeks and five months after it 
was first demonstrated (53) and identified a subgroup of patients with 
predominantly non-eosinophilic sputum on repeated observations made 
over 12 months (39). 
In a study by Jayaram et al. (2006) (54) the pattern of sputum 
inflammation was similar at baseline and during exacerbation in adults 
with asthma studied longitudinally over two years, indicating that 
patients with non-eosinophilic asthma were far less likely to have 
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eosinophilic exacerbations (54). In a prospective, double-blind, placebo-
controlled trial of inhaled corticosteroids in non-eosinophilic patients 
with asthma a bronchoscopy at baseline was performed and then 
patients underwent repeated induced sputum six times over six months. 
None of the eleven patients studied demonstrated an airway 
eosinophilia at any point and at bronchoscopy all had normal basement 
membrane thickness (55). This supports the hypothesis that the non-
eosinophilic phenotype is stable in adults since increased basement 
membrane thickness has been shown to be a long-term marker of 
eosinophilic airway inflammation (56). 
The fact that inflammometry using induced sputum has been shown to 
be a successful strategy to prevent asthma exacerbations in adults (39, 
54) may also support the theory that the stability or significance of 
inflammatory markers change over time. PhenotypiC analysiS using 
induced sputum does appear to have clinical value, not least as an 
inflammometer to guide inhaled corticosteroid treatment in adults with 
refractory disease, but uncertainties remain. It is now believed that 
variability over time is important in asthma management and that simple 
classifications of asthma based upon characteristics such as airway 
inflammation at a single time point represents over-simplification. Even 
studies which have included multiple factors and mathematical 
modelling techniques (57, 58) have not yet included variability over time. 
In a study by Anderson et al. (2008) (59) it was suggested that research 
should focus on searching for stable subgroups defined by unique and 
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specific genetic and molecular characteristics rather than "phenotypes" 
which can lead to uncertainty. However the other alternative is to 
develop a biomarker of inflammation which can distinguish between 
different inflammatory phenotypes, but which is safe, cost-effective and 
simple enough to be performed on a regular basis to assess changes in 
inflammation accurately and easily over time. 
Sputum induction is not a feasible option as a long-term regular 
biomarker in primary care and patient's homes, it is expensive, time-
consuming and a highly involved technique requiring specialist input. 
Exhaled nitric oxide using the Aerocrine ™ NIOX MINO® portable 
analyser, is a quick and cost-effective technique. It is similar to an 
alcohol breathalyser in that the test only requires the patient to be able 
to perform one breath, unlike sputum analysis. Exhaled nitric oxide has 
been shown to correlate well with sputum eosinophilia in moderate to 
severe patients with asthma, and can distinguish between eosinophilic 
sputum and non-eosinophilic sputum in this selected population. 
Encouragingly the research performed in this thesis yielded similar 
results showing that FeNO can differentiate eosinophilic inflammation 
from both neutrophilic and paucigranulocytic asthma. The results can 
be found in Chapter 5.4. 
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1.5.2 - Airway hyperresponsiveness in asthma: 
Airway hyperresponsiveness is considered to be one of the 
characteristic clinical features of asthma (60). Airway 
hyperresponsiveness is defined as an "increased sensitivity to an 
inhaled constrictor agonist and a steeper slope of the dose response 
curve". Two main forms of bronchoconstrictor stimuli exist; direct stimuli 
and indirect stimuli. Direct bronchoconstrictors consist of agents such 
as histamine and methacholine. These stimulate receptors on the 
airway smooth muscle and as such case direct bronchoconstriction. 
Indirect bronchoconstrictors cause bronchoconstriction via the release 
of secondary bronchoconstrictor mediators from mast cells. For 
example; inhaled adenosine monophosphate or inhaled sodium 
metabisulphate. 
Airway responsiveness is usually measured as the provocation dose I 
concentration of methacholine causing a 20% fall in FEV1 by linear 
interpolation of the log dose / concentration response curve (PD201PC2o). 
In the general population the distribution of airway hyperresponsiveness 
follows a continuous unimodal log-normal distribution, with asthma 
sufferers representing the hyperresponsive part of the log-normal 
distribution curve. A PC20 is not usually measureable in normal healthy 
individual, this suggests that there is a large difference in the airway 
responsiveness between normal healthy individuals and patients with 
asthma. The cut-off used to identify asthma is normally taken to be a 
methacholine concentration of <Bmg/ml. This value had a sensitivity of 
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100%, a specificity of 93% and a negative predictive value of 100% in a 
study on a population of 500 college students with a diagnosis of 
current and symptomatic asthma. Cockcroft et al. (1992) (61) 
concluded that a PC20 of greater than Bmg/ml ruled out presence of 
current asthma and that a PC20 value of less than 1 mg/ml was almost 
certainly a positive diagnosis of current asthma. The values of 
responsiveness between 1 mg/ml and Bmg/ml were regarded as 
intermediate (61). In patients with asthma the presence of airway 
hyperresponsiveness is highly variable. In many patients airway 
responsiveness remains stable over long periods of time but can 
increase during exacerbations of allergen exposure (60). Airway 
responsiveness may occasionally normalise after withdrawal from the 
allergen exposure or after corticosteroid therapy, but is seen to persist 
in the majority of patients even after appropriate treatment (62). 
The use of methacholine PC20 to diagnose asthma has been evaluated: 
Hunter et al. (2002) (1B) demonstrated that when asthma was defined 
as "consistent symptoms with objective evidence of abnormal variable 
airflow obstruction". A positive methacholine challenge was more 
sensitive than peak flow percentage mean and acute bronchodilator 
response (reversibility) in diagnosis (1B). 
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The pathophysiology of airway hyperresponsiveness in asthma: 
Various mechanisms are involved in development of airway 
hyperresponsiveness in asthma. Airway wall thickening is implicated: 
patients with asthma demonstrate subepithelial thickening (63) and 
exudation of plasma (64). This leads onto airway wall thickening, as the 
airway luminal resistance induced by a certain degree of airway smooth 
muscle shortening is then enhanced (65). Secondly, epithelial damage 
may allow greater exposure of bronchial smooth muscle to 
bronchoconstrictor mediators and decrease the amount of 
bronchodilating mediators released (66). Other possible mechanisms 
include both loss of sympathetic innervation to the lung (67), and loss of 
the bronchoprotective effect of deep inspiration in asthma (68). 
Airway hyperresponsiveness and eosinophilic airway 
inflammation in asthma: 
The relationship between eosinophilic airway inflammation and airway 
hyperresponsiveness is complex. Crimi et al. (1998) (35) performed 
measurements of airway hyperresponsiveness and eosinophilic airway 
inflammation (using bronchial waSh, bronchoalveolar lavage and 
induced sputum) in 71 subjects. They found no significant correlations 
between eosinophilic airway inflammation and airway 
hyperresponsiveness (35). Some studies investigating patients with 
atopic asthma have found weak correlations between eosinophilic 
airway inflammation and airway hyperresponsiveness. There was a 
weak inverse correlation (r=-OA) in a study involving 35 patients with 
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mild asthma (69). Similar relationships have been described in patients 
receiving inhaled corticosteroid medication (70, 71). The current view is 
that although interrelated, eosinophilic airway inflammation and airway 
hyperresponsiveness are, to a large degree, independently regulated. 
Support for this view comes from a factor analysis of 99 patients with 
mild asthma (28), and from the recognition that eosinophilic airway 
inflammation can occur without airway hyperresponsiveness in patients 
without functional airway abnormalities seen in asthma, but with a 
corticosteroid responsive cough and associated eosinophilic airway 
inflammation (32). 
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1.5.3 - Variable airflow obstruction in asthma: 
Variable airflow obstruction has long since been considered the 
hallmark of asthma (72, 73). Airflow obstruction and its reversibility to 
treatment, or variability in response to stimuli, are incorporated in all the 
asthma guidelines (1,2, 74). Although variable airflow obstruction forms 
only part of the asthma phenotype, due to its ease of measurement it 
predominates in the diagnosis and assessment of asthma especially in 
primary care settings. Both peak flow and spirometry accurately reflect 
changes in large airway calibre and can be easily measured. Variable 
airflow obstruction, defined as a 200ml or 12% improvement in FEV1 
either spontaneously, or following administration of a bronchodilator or 
glucocorticoid (reversibility), is considered diagnostic of asthma and is 
currently the most commonly used diagnostic test (75), 
The pathophysiology of variable airflow obstruction in asthma: 
Airflow obstruction is normally induced by a variety of stimuli including 
allergen exposure, exercise, cold air and dust. Four mechanisms which 
are believed to relate to underlying airway inflammation have been 
implicated. Firstly, allergen exposure leads to an IgE-dependent release 
of mediators from airway mast cells, including histamine and 
prostaglandins, leading to the early phase asthmatic response. Other 
stimuli cause combinations of direct contraction of smooth muscle, 
mediator release from cytokine "primed" inflammatory cells, and 
stimulation of local and central neural reflexes. All of these responses 
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lead to contraction of the airway wall smooth muscle and consequently 
airflow obstruction (76). 
Secondly, airway wall oedema can independently cause airflow 
obstruction. An increase in microvascular permeability and leakage 
leads to mucosal thickening and swelling of the airway wall outside the 
smooth muscle. This swelling of the airway wall and loss of elastic recoil 
pressure contribute to an increased resistance to airflow within the 
airway. This component of asthma is referred to as the late phase 
asthmatic response and is similar to the reduction in airway calibre that 
is characteristically seen 6 to 24 hours post allergen challenge (76). 
Thirdly, increased exudation of serum protein and cell debris combined 
with mucus production lead to the plugging of the small bronchi with a 
subsequent increase in airflow obstruction (77). Lastly, chronic 
inflammation can cause long-term structural changes if left untreated in 
the airway wall matrix. This is known as airway wall remodelling (78, 79). 
Variable airflow obstruction and eosinophilic airway Inflammation 
in asthma: 
A relationship between FEV1 and sputum eosinophils has been 
demonstrated: Woodruff et al. (2001) (80) used multivariate analysis of 
data collected during screening and enrolment of 205 adults with 
asthma (80). After controlling for confounding factors, their analysiS 
demonstrated that the induced sputum differential eosinophil count was 
independently associated with a lower FEV 1 and a lower PC20; an 
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increased sputum neutrophil percentage was independently associated 
with lower FEV 1 but not with the PC20. These results suggest that both 
eosinophilic inflammation and neutrophilic inflammation independently 
contribute to abnormalities in FEV1 in asthma. Ten Brinke et al. (2001) 
(81) found that the only independent factor associated with persistent 
airflow limitation was a sputum eosinophilia. Other factors examined 
included; age at onset, smoking history, atopic status, bronchodilator 
reversibility, PC20 with histamine, exhaled nitric oxide, blood eosinophils 
and blood IgE. This was a smaller homogeneous population with a 
more limited analysis of dichotomous variable; 132 non-smoking 
patients with asthma receiving high dose inhaled corticosteroids were 
studied and persistent airflow limitation was defined as a post 
bronchodilator FEV 1 or FEV 1/FVC ratio of less that 75% predicted. The 
association was not apparent in the sub-group receiving oral 
corticosteroid therapy (82). Balzano et al. (1999) (83) had previously 
examined 46 patients who were diagnosed with a mixture of different 
airways diseases; there was a significant inverse correlation between 
both FEV1 and sputum neutrophils, eosinophils and eosinophilic 
cationic protein. There was also a significant correlation between 
FEV1/FVC and the same sputum markers of airway inflammation (83). 
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1.5.4 - Asthma symptoms: 
One of the biggest difficulties faced by physicians diagnosing asthma is 
the variability of symptoms. Asthma control and severity is covered in 
detail in Chapter 1.3. This section focuses on the disassociation 
between asthma symptoms and airway inflammation. A correct 
diagnosis of asthma is essential if appropriate drug therapies are to be 
administered. Asthma symptoms may be intermittent and their 
significance may be overlooked by patients and physicians, or, because 
symptoms are regularly "non-specific" may result in misdiagnosis (e.g. 
wheezy bronchitis and COPD which present with similar symptoms) 
(25). 
A clinical diagnosis of asthma is often prompted by symptoms such as 
episodic breathlessness, wheezing, cough and chest tightness (25). 
Episodic symptoms after allergen exposure, seasonal variability of 
symptoms, a family history of asthma and other atopic disease are also 
helpful in diagnosis. Asthma associated with rhinitis may occur 
intermittently, with patients being entirely asymptomatic between 
seasons or it may involve some seasonal worsening of asthma 
symptoms or a background of persistent asthma (25). The effective 
management of asthma relies on monitoring lung function and 
symptoms. There are a number of asthma symptom questionnaires 
which have been validated to assess the presence and severity of 
asthma symptoms in patients (e.g. Juniper Asthma Control 
Questionnaire (84)). 
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The Juniper Asthma Control Questionnaire (ACQ) (84) was developed 
by Juniper and coworkers for assessing asthma control in clinical trials 
and clinical practice. Questions are based on recalling asthma 
symptoms from the previous 7 days and comprise breathlessness, 
nocturnal waking, symptoms on waking, activity limitation, wheeze, 
frequency of short-acting 132 agonist use, and pre-bronchodilator FEV1% 
predicted. All seven items are scored on a 7-point scale without 
weighting (0 = good control, 6 = poor control) and the overall score 
(range, 0-6) is the mean of the responses (20, 84). 
The ACQ has been validated against quality of life and physician 
assessment (84-88) and the minimum clinically important difference is 
0.5 (86). The optimal cut-point for "well-controlled" using the Gaining 
Optimal Asthma Control (GOAL) study classification was less than or 
equal to 0.75, and a value of greater than or equal to 1.50 confirms "not 
well-controlled" asthma (88). Shortened versions, with omission of 
short-acting 132 agonist use and/or FEV1, perform almost as well as the 
7-item version (86, 88) and are likely to be suitable for completion in 
primary care (89). Wording of the validated ACQ is slightly different 
from the originally published version (20, 84). 
A shortcoming of the ACO is the observation that most patients' scores 
are less than or equal to 2.5, with scores of greater than or equal to 4 
only occurring with severe exacerbations. This suggests that the range 
and intervals for individual item scores could be improved. Also. the 
response scales may be more complex and time-consuming than is 
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necessary, and its acceptance for use in primary care needs to be 
demonstrated. Although ACO includes pre-bronchodilator FEV1 (a 
predictor of risk of exacerbations), change in this component may be 
outweighed by the remaining six symptom/reliever components, as was 
seen in a study by Jenkins et a/. (2005) (90) of long-acting J32 agonist 
monotherapy (90). 
(A copy of the Juniper Asthma Control Questionnaire can be found in 
appendix section 3). 
Questionnaires which assess symptoms are subjective and many 
patients with asthma suffer from symptoms but have normal lung 
function and no evidence of airway inflammation (21), conversely there 
are also patients with asthma who have very low symptom scores but 
suffer with airway inflammation (69). Clinical decisions are typically 
based upon the presence or absence of symptoms despite the fact that 
inhaled corticosteroid medications are used to reduce airway 
inflammation (69). 
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1.5.5 - Summary of asthma heterogeneity: 
The clinical evidence today suggests that asthma is not a single 
disease, rather it is a collection of related diseases with different 
phenotypic characteristics. This makes assessment of asthma-related 
symptoms difficult. Currently there are no diagnostic tests which are 
sufficiently sensitive to rule out asthma completely (18). Whilst all the 
tests mentioned in this chapter contribute to providing additional 
valuable clinical information, none of them provide the "gold standard" 
in asthma diagnosis. Despite the fact that these tests cannot give a 
conclusive diagnosis of asthma, in combination, they provide evidence 
to suggest a diagnosis of asthma. However, these tests are not readily 
available in all settings and this has serious implications for the 
diagnosis and management of asthma in primary care. 
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1.6 - Exhaled nitric oxide: 
Nitric oxide (NO) is an important signalling molecule involved in many 
physiological and pathological processes and its presence can be both 
beneficial and detrimental (2). NO is required in appropriate levels for 
the protection of organs such as the liver from ischaemic damage, 
However increased levels can cause vascular collapse associated with 
septic shock and chronic production has been linked with various 
carcinomas and inflammatory conditions, including asthma (16). NO is a 
highly reactive molecule which displays important functions in the 
respiratory system (91-96). It was previously known as "endothelial 
derived relaxing factor" (15, 97) and promotes vascular and bronchial 
dilatation in the lungs (91-96). 
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1.6.1 - Formation of nitric oxide: 
The synthesis of NO is mediated by NO synthases (NOS). Two forms 
exist: constitutive (cNOS) and inducible (iNOS). The constitutive forms 
exist as endothelial (eNOS) and neural (nNOS). iNOS has been shown 
in bronchial epithelial cells, alveolar macrophages (98-101), nasal 
vascular endothelial cells (102) and nasal ciliated epithelial cells (102, 
103). iNOS can produce much greater amounts of NO than cNOS 
(nanomolar concentrations) and increased iNOS is found in airway 
epithelial cells and in asthma. Guo et al. (2000) (104) demonstrated that 
patients with asthma exhibit increased expression of iNOS mRNA in the 
airways compared with healthy controls (104), and that patients using 
ICS had decreased expression of iNOS protein and mRNA compared 
with those not receiving ICS. 
Each of the three NOS isoforms is present in the airways and can 
contribute to the formation of NO. In a study on healthy, atopic and 
children with asthma NOS2 (iNOS) mRNA was detected in bronchial 
epithelial cells from all groups, whereas NOS1 (nNOS) mRNA was not 
detectable and NOS3 (eNOS) mRNA was found in only 36 of the 43 
samples obtained. The levels of iNOS correlated with the fractional 
concentration of NO in exhaled breath (FeNO) measured at a flow of 
200mls/sec, adding evidence that the raised NO in the airways is due to 
iNOS production (105). 
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Other factors may be important in the formation of NO in the airways. At 
least two other mechanisms for the formation of NO have been 
postulated, including the release of NO from S-nitrosothiols, (this may 
account for approximately 80% of NO release) (106) and nitrite 
protonation to form nitrous acid which releases NO gas with 
acidification (107). 
Genetic factors are known to affect the production of NO. van's 
Gravesande ef al. (2003) (108) demonstrated a strong relationship 
between a known functional NOS3 mis-sense sequence variant in the 
endothelial NO gene (G894T) and NO level in a cohort of subjects with 
asthma (108). NOS1 polymorphisms also appear to be associated with 
asthma symptoms and IgE levels (109); further work has shown the 
number of AAT repeats in intron 20 of this gene correlate with NO levels, 
with a higher number of repeats correlating with lower NO levels (110). 
In general, it has been shown that eNOS is predominantly found in 
endothelial cells within the bronchial circulation. However, there is some 
evidence to suggest that eNOS is expressed in the epithelial cells also 
(111). Similarly, nNOS has been reported in epithelial cells (112) even 
though it is generally localised to the cholinergic airway nerves (113). 
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1.6.2 - Function of nitric oxide: 
NO is a free radical with one unpaired electron and a short half life of 1-
5 seconds. NO is also a ubiquitous messenger molecule that is involved 
in the homeostasis of multiple biological functions. As well as these 
functions, NO also serves as a pro-inflammatory molecule in the lung. It 
is produced by alveolar macrophages in response to stimulation by 
endotoxins and cytokines (114, 115). NO also has a toxic effect in the 
lung where it is oxidised to peroxynitrite, a potent epithelial toxin found 
in asthmatic airways after allergen exposure. NO has other important 
functions in the respiratory system, including promoting vascular and 
bronchial dilatation, mediating ciliary beat frequency, promoting mucus 
secretion and acting as a neurotransmitter for non-adrenergic, non-
cholinergic neurons (91, 92, 94-96, 116). Other roles for NO include 
promoting Th2 lymphocyte proliferation (117) and acting as a potent 
mediator of neurogenic oedema in animal models (92, 118). The 
balance of NO activity is controlled by uptake by antioxidant molecules 
such as haemoglobin and glutathione. 
It is apparent that NO has many effects on airway function, however, 
the effects of endogenous NO are strongly dependent upon the site of 
NO production and the amount which is being produced (119). NO and 
NO-donor compounds relax the smooth muscle of human airways in 
vitro by activating guanylyl cyclase and increasing cyclic GMP (120, 
121). In guinea pigs it has been shown that inhaling high concentrations 
of NO causes bronchodilation and protects against cholinergic 
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bronchoconstriction (122). In human subjects however, inhalation of 
high concentrations of NO (above 80ppb) has been shown to have no 
effect on lung function in normal participants and causes only weak and 
varied bronchodilation in participants with asthma (119, 123, 124). It 
may be the case that NO is the major neurotransmitter of bronchodilator 
nerves in the human airways. In the proximal human airways there is a 
prominent inhibitory non-adrenergic, non-cholinergic (iNANe) 
bronchodilator neural mechanism, which has particular functional 
importance as it is the only endogenous bronchodilator pathway present 
in the human airways (96). It has been determined that NO is the 
neurotransmitter of the iNANC pathway in human airways as studies 
have shown that NOS inhibitors almost completely abolish the neural 
response (96, 125, 126). In addition to this, iNANC stimulation of human 
airways causes an increase in cyclic GMP without any increase in cyclic 
AMP occurring (120). 
In terms of vascular effects, NO is a potent vasodilator in the bronchial 
circulation and is also thought to have an important role in airway blood 
flow regulation (127-130). It is believed that endogenous NO may 
increase plasma exudation by increasing the blood flow to leaky post-
capillary venules. This subsequently causes an increase in airway 
oedema (118). However, in a study by Erjefalt et al. (1994) (131) it was 
shown that when iNOS inhibitors were applied to the surface of the 
airways, there was an increase in plasma exudation. This suggests that 
the basal release of NO has an inhibitory effect on microvascular 
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leakage (131). In relation to airway secretions, L-NAME has been 
shown to increase baseline airway mucus secretions. This suggests 
that eNOS derived NO typically inhibits mucus secretion (132). 
Conversely, NO donors have been shown to increase mucus secretion 
in human airways in vitro (133). 
In terms of the inflammatory effects of NO, there is evidence to suggest 
that high concentrations of NO may have effects on the immune system 
and the subsequent inflammatory response. With regard to the 
production of NO in asthmatic airways, previously it has been 
demonstrated that there is evidence for an increase in the expression of 
iNOS in these subjects (primarily from epithelial cells and macrophages) 
(119, 134). It is believed that this trend arises due to pro-inflammatory 
cytokines, oxidants and various other inflammatory mediators. Since 
NO is a gas, it diffuses readily into the airway lumen and thus is 
detectable in exhaled air (135). There is an increase in the level of 
FeNO in asthmatic patients (136, 137), which is understood to be, in the 
most part, derived from the lower airways (138, 139). This increase in 
FeNO in subjects with asthma is correlated to airway inflammation (140), 
is increased during the late phase response to allergen (141), during 
asthma exacerbation (142) and has also been shown to be 
subsequently reduced after treatment with ICS (143). 
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1.6.3 - Measurement of exhaled nitric oxide: 
The fraction of FeNO present in exhaled breath (Fe NO) can be 
measured by chemiluminescence. This is the most sensitive method 
and uses ozone to react with NO and produce nitrogen dioxide. This 
reaction emits photons in a stoichiometric relationship correlating with 
the amount of NO present. This allows measurements down to 1 part 
per billion (ppb) (144). FeNO can be measured either "offline" or 
"online". (Offline measurements are rarely used now). Online 
measurement involves the inhalation of NO free air immediately 
followed by exhalation at a steady flow directly into the measuring 
apparatus. FeNO measurements are influenced by a number of 
variables. The most crucial is the exhaled flow. As NO is produced 
continuously in the airways, the concentration of NO measured at the 
mouth will vary with the flow of exhaled air. Various models describing 
the relationship between flow and NO concentration have been 
proposed. A trumpet shaped model of NO production has now replaced 
a two-compartmental model (145, 146). These studies incorporate axial 
diffusion into a one dimensional model of NO gas exchange in the lungs 
and predict a significant back diffusion of NO from the airways into the 
alveolar region, resulting in loss of NO that would therefore not appear 
in exhaled breath; this may cause an underestimation of both the 
maximum airway flux and the airway diffusing capacity for NO. This 
outcome depends upon on a significant proportion of NO being 
produced by the small airways (147). 
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The joint American Thoracic Society/ European Respiratory Journal 
guidelines 2005 recommend measuring FeNO at a flow of 50ml/sec 
(148). Prior to this joint statement, the two organisations recommended 
different flows, making study comparisons difficult (148); some of the 
larger original studies comparing differential sputum eosinophil counts 
and FeNO measurements were performed at a flow of 250ml/sec. 
Comparison between the two flows and different models have been 
performed with varying results (149, 150). In general the values 
obtained correlate, but the relationship is dependent upon both 
exhalation pressure and flow. 
The technique for measuring FeNO is simple and well within the scope 
of most patients in primary care, including children as young as five 
years of age. FeNO is best measured before other spirometric 
manoeuvres and nasal clips should not be worn. In summary, a patient 
inhales NO free air to total lung capacity and then exhales at a rate of 
50 ml/sec maintained within +/- 10% for> six seconds, and with an oral 
pressure of 5-20cmH20 to ensure velum closure. A disposable filter is 
required, and normally the mean of three measurements is used. The 
test is quick and results instantaneous; three measurements can be 
completed in approximately three minutes. 
Page 70 of 260 
1.6.4 - Reference values for exhaled nitric oxide: 
Reference values for FeNO have been determined from small adult and 
paediatric populations. Values for normal healthy adults range between 
Sppb and 3Sppb and between Sppb and 25ppb in children. 97% of 
healthy individuals have levels of <35ppb; this drops to <22.4ppb if 
outliers and subjects with evidence of atopy are removed (1S1). 
The between subject standard deviation is 2Sppb in asthma and 8ppb in 
normal healthy controls (152) 
Table 1.1: 
Distribution of normal FeNO values (153). 
Exhaled Nitric Oxide according to classes of height and age 
among 1131 healthy never-smoking subjects 
Height (cm) Age (years) 
25-34 35-44 45-54 55-64 65-75 
<160 24.0 24.S 28.8 31.S 34.1 
160-169 27.4 29.7 32.8 35.9 38.9 
170-179 31.2 34.1 37.3 40.9 44.3 
180-189 35.S 38.9 42.S 46.S SO.4 
>190 40.4 44.3 48.4 53.0 57.4 
Data are presented as the 95% upper limit of FeND (in ppb) calculated as mid-class 
values. 
Table is adapted from research published by Olm et al. (2007) (153). 
There is still controversy over FeNO reference values. Current research 
aims to refine these reference values and produce clearer baseline 
figures and guidelines. However, previous research has produced 
reference values which are currently being used in the clinical setting to 
assess airway inflammation. NIOX FlexFlow@ (Aerocrine TM, Sweden) is 
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one such device which measures the level of FeNO in the breath. It 
takes measurements at five different flow rates (10ml/sec, 30ml/sec, 
SOml/sec, 100ml/sec and 200ml/sec) it then uses the slope and 
intercept of the line-graph produced from the five values to ascertain the 
alveolar and bronchial NO levels respectively. Currently it is the 
SOml/sec measurement which is deemed to be the most important value 
(single flow NIOX MINO® machines only measure at 50ml/sec). Figure 
11.1 shows the Aerocrine ™ FeNO reference values for "normal" 
patients based on their sex, height, smoking status, allergy status and 
infection status. Normal values for individuals range from 9ppb 
(50ml/sec) to 50ppb (50ml/sec), therefore it is important that these 
normal values are taken into account when an individual is performing 
the test. It is generally accepted that a mean cut-off value for "normality" 
is around 25-27ppb (50ml/sec), but it should not automatically be 
assumed that all subjects with higher NO levels than this have asthma. 
Their demographics, atopic status and other confounding factors may 
account for the higher measurements. See chapter 1.6.5 for further 
information. 
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Figure 1.1: 
Guideline values for FeNO using the Aerocrine ™ NIOX FlexFlow® 
system (154). 
NIOX® reference va lues 
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Figure is taken from an educational brochure produced by Aerocrine ™ 
for clinicians and researchers using exhaled nitric oxide (154). The 
original research was performed by Dressel et al. (2008). This figure is 
adapted from the original work. 
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1.6.5 - Confounding factors in exhaled nitric oxide reference 
values: 
The effect of atopy on FeNO levels is controversial. Some authors 
argue that there is no influence; Gratziou et al. (1999) (155) found no 
difference in FeNO levels between atopic and non-atopic individuals 
(155). This study was corroborated by a further study from Berlyne et al. 
(2000) (156). However there is a large body of evidence that atopy is 
associated with high FeNO levels, and that the relationship is such that 
in trials using FeNO as a marker of airway inflammation in asthma, the 
influence of atopy can be difficult to exclude (157). Various studies have 
shown that patients with atopic asthma have FeNO levels which are 
higher than matched controls with non-atopic asthma (158-161). There 
is also evidence that atopic individuals without asthma have higher 
FeNO levels than non-atopic individuals without asthma (162); this also 
applies in children. FeNO levels are also higher in children sensitised to 
various aeroallergens, including house dust mite (161, 163) and grass 
pollen. The relationship between atopy and FeNO may just be due to 
exposure; Olin et al. (2004), (2007) (153, 164) found that FeNO levels 
rose in atopic patients after exposure to the relevant antigen, and that 
atopic individuals who had never been exposed to the relevant antigen 
or who had never experienced asthma had normal FeNO levels (153, 
164). This issue is complicated by the influence of rhinitis with both 
asthma and atopy. Levels of FeNO generated in the nose are much 
greater than those generated in the lower airway (165), and nasal 
contamination could theoretically cause difficulties with measurement. 
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In general FeNO is thought to reflect lower airway inflammation rather 
than upper airway inflammation (caused by atopy or allergic rhinitis) as 
the flow used when performing FeNO measurements generates an 
excess pressure in the oral cavity; this is assumed to close the velum 
and prevent contamination from NO produced in the para-nasal sinuses 
(166,167). 
Other factors are known to affect FeNO readings. Causes of lung 
inflammation which increase FeNO levels include bronchiectasis, viral 
infection, fibrosing alveolitis, allergic rhinitis, pulmonary tuberculosis, 
COPD and pulmonary sarcoidosis. However pneumonia (167) and 
cystic fibrosis (168) have both been shown to reduce FeNO levels. 
Caffeine ingestion and smoking (169, 170) both reduce FeNO levels, 
and a nitrate- rich diet increases them (171). Interestingly, Horvath et al. 
(2003) (162) demonstrated that FeNO levels were higher in smokers 
with asthma than in smokers with no asthma (162), however Shaw et al. 
(2007) (172) found that the relationship between FeNO and sputum 
eosinophil counts was much weaker in smokers with asthma 
(172).There has also been debate about diurnal variation in FeNO 
levels, but this aspect is now thought to be minimal (173). More 
importantly measures of lung function and airway hyperresponsiveness 
have both been shown to reduce FeNO levels (174, 175). This has 
practical implications; and as mentioned previously, measurements of 
FeNO should always be performed before any other airway manoeuvre. 
Page 75 of 260 
Virally-induced upper respiratory tract infections have been shown to 
cause a rise in FeNO levels, it has been suggested that this may be as 
a result of the expression of iNOS in response to NF-KB activation by 
the rhinovirus (176). In bronchiectasis there may also be elevated 
FeNO and in the first instance it is believed to be related to the extent of 
lung involvement (173). Conversely, FeNO is reduced in cystic fibrosis 
(177) and the theory is that this is due to the level of intense neutrophilic 
inflammation and the NO is converted into peroxynitrite by the 
superoxide anions. Similarly, FeNO is much lower in COPO also, 
despite the fact that there is active inflammation present (178). A loose 
prediction is that this may be related to the effects of smoking, which 
lowers FeNO levels however, this is not definitive (179), alternatively it 
may be due to neutrophilic inflammation. In lung parenchymal 
inflammation FeNO is seen to be elevated as well as in patients with 
active fibrosing alveolitis, however, trends suggest that when fibrosis 
intervenes FeNO levels may begin to fall (180), in this instance FeNO 
could therefore be used as a marker of disease progression and activity. 
This is consistent with histological studies which have demonstrated an 
increase in iNOS expression during the active inflammatory phase of 
the disease, with no iNOS expression in the areas of fibrosis (140). 
FeNO values should always be interpreted with caution paying specific 
attention to the patient's history and confounding factors. 
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1.6.6 - Relationship between exhaled nitric oxide and eosinophilic 
airway inflammation in asthma: 
When studying the relationship between eosinophilia and airway 
inflammation it becomes apparent that variations exist depending upon 
the populations being investigated. The use of FeND tests have been 
conducted most extensively within populations of children as the test 
serves as a non-invasive alternative to traditional airways tests, such as 
the methacholine challenge, which would be likely to cause distress in 
young children. Payne ef al. (2001) (177) studied the possible 
correlation between eosinophilia and FeND levels in endobronchial 
biopsies. The study included 31 children with difficult-to-control asthma 
and 7 children acting as controls. FeND and eosinophilia were 
measured before and after a two week course of oral prednisolone. 
From the study it was demonstrated that, in children, FeNO levels 
correlate with eosinophilia score (177). This relationship between 
eosinophilia and FeNO level has also been demonstrated in 
bronchoalveolar lavage fluid (178) and induced sputum in children with 
asthma (179, 180). In adults with mild asthma it has been demonstrated 
that sputum eosinophil counts also correlate with FeND levels (140). 
There was no evidence that this was influenced by gender, age, atopic 
status or lung function. However, smoking status did affect the 
relationship (as mentioned previously smokers tend to have a low 
FeND typically 2-10ppb despite inflammation possibly being present). A 
significant but weak correlation between FeND levels and eosinophil 
differential counts was demonstrated by 8erlyne ef al. (2000) (156) in 
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subjects with steroid-na"lve asthma, in subjects with eosinophilic 
bronchitis without asthma and also in healthy atopic subjects. In 
subjects who were taking steroids, FeNO levels were seen to be 
significantly lower than the levels in those participants who were not. 
This trend was seen despite there being no difference in the sputum cell 
counts between the two groups of participants (156). The conclusion 
drawn was that FeNO measurements have limited utility as a surrogate 
biomarker of inflammation in the airways except for in those participants 
which are steroid-na"ive (156, 181). 
A study by Silkoff et al. (2005) (182) which was developed using FeND 
to predict persistent eosinophilia in severe refractory asthma 
demonstrated that FeND levels which exceed 72.9ppb were associated 
with a sensitivity of 0.56 and specificity of 1.0 for identifying persistent 
eosinophilia, as measured by endobronchial biopsy or bronchoalveolar 
lavage. It was also determined that FeND levels were correlated with 
tissue eosinophil level (182). Despite these studies, there have been 
complications in the relationship between FeND and airway eosinophils 
in bronchial biopsies as two trials discovered there to be no significant 
correlation between the two (183, 184). A further complication arose in 
a study examining the potential use of interleukin-5 in subjects with 
asthma. Mepolizumab (anti-IL5) was trialled on 29 patients with a 
diagnosis of refractory asthma. The results showed that exacerbation 
frequency and differential sputum eosinophil counts were reduced in 
those subjects taking the active mepolizumab when compared to 
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placebo. However, there was no significant decrease in the FeNO 
levels in subjects taking the active medication compared to those taking 
the placebo medication. This trend in FeNO levels was seen despite the 
fact that sputum eosinophil count in subjects taking Mepolizumab had 
been reduced to <1 % (185). These results question the biological 
associations thought to be active between FeNO and sputum 
eosinophils. However, predictions have been made which may make it 
plausible that FeNO may in fact be involved in an alternative 
inflammatory mechanism possibly associated with eosinophil production 
or recruitment. 
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1.6.7 - Relationship between exhaled nitric oxide and asthma 
diagnosis: 
As previously mentioned, FeND has been, and continues to be, used in 
research to determine its efficacy as a surrogate biomarker of airway 
inflammation in asthma. However, despite its prevalence in the 
research and its potential as a useful clinical diagnostic tool, no studies 
to date have conclusively proved that FeND can be used as a clinical 
diagnostic test. In a study by Smith et al. (2004) (186) it was determined 
that a FeND level of 20ppb (at the 50ml/sec flow rate) had 88% 
sensitivity for the diagnosis of asthma in steroid-na"ive subjects with 
symptoms suggestive of asthma (186). The results obtained from the 
study showed that there was a strong positive correlation between 
FeND and sputum eosinophils (r=0.67, p<0.001) and a strong negative 
association between FeND and airway hyperresponsiveness (r=0.56, 
p<0.001). In a separate study by Dupont et al. (2003) (187), it was 
found that a FeND level greater than 16ppb at the 50ml/sec flow rate 
had a sensitivity of 90% and a specificity of >90% with regard to 
diagnosing asthma (187). Henriksen et al. (2000) (159) performed a 
large study with 8571 adolescents and combined FeND level results 
with the results of methacholine challenge tests. In 75% of the 
suspected patients with asthma, airway hyperresponsiveness was 
confirmed versus 25% of the control subjects. Whereas 52% versus 
20% respectively had elevated levels of FeND (>8ppb at 250ml/sec 
flow rate); the combination of airway hyperresponsiveness and elevated 
Page 80 of 260 
FeND levels appeared to be a specific finding for allergic asthma in this 
population survey (159). 
Measuring FeND levels in conjunction with traditional airways tests 
such as spirometry and methacholine challenge test can be used by 
clinicians to aid in the differential diagnosis of eosinophilic bronchial 
asthma, thus reducing patient exposure to inappropriate or ineffective 
medications. It was concluded by Smith et al. (2004) (186) that 
measuring FeND levels offers the clinician "correct asthma diagnosis in 
over 80% of patients aged 8-75 years using a cut-off score of 20ppb at 
the 50ml/sec flow rate (186)". "FeND offers a higher degree of 
diagnostic accuracy for asthma (sensitivity 88% at a cut-off of 20ppb) 
than tests based on lung function. The diagnosis of asthma was 
ascertained by a positive response to bronchodilator and/or positive 
bronchial hyperresponsiveness in accordance with ATS guidelines" 
(186). In a study by Malmberg et al. (2003) (188) concluded that 
"correct asthma diagnosis in nearly 80% of children aged 4-8 years 
using a cut-off score of 10ppb at the 50ml/sec flow rate (188)." 
Another benefit of FeND measurement is that it offers rapid 
identification of non-compliant patients (189) and is therefore a good 
non-invasive tool for monitoring adherence to steroid treatment (190). If 
FeND levels remain elevated in patients taking maintenance doses of 
steroids it essentially means one of two things clinically. Either the 
patient is not being prescribed enough anti-inflammatory therapy or the 
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patient is not adhering to the medication which has been prescribed to 
them. In most instances, FeNO levels fall in patients receiving anti-
inflammatory treatment. However, some patients display elevated 
FeND levels despite taking anti-inflammatory steroid medication. The 
most common cause of such an occurrence is non-compliance on the 
part of the patient. However, it may also arise from poor inhaler 
technique, inadequate steroid dose, chronic exposure to allergen or 
non-eosinophilic airway inflammation as the cause of the asthma (191). 
Only in very few cases will a patient with asthma be totally steroid-
resistant (192). 
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1.6.8 - Relationship between exhaled nitric oxide and asthma 
treatment: 
Despite its prevalence in research, as yet only two studies have been 
undertaken which have successfully used FeNO measurements to 
titrate inhaled corticosteroid dosage in subjects with asthma (193, 194). 
The first of these studies was performed by Smith et al. (2005) (252) 
and used FeNO measurements (at the 250ml/sec flow rate) to down-
titrate ICS in 92 subjects with asthma (193, 194). The trial was a single-
blind study and the participants involved were either treated according 
to their FeNO results or according to current guidelines. All participants 
were subject to a run-in period (ranging between 3 and 12 months). 
During this time all subjects were prescribed 750 micrograms of inhaled 
corticosteroid, after the run-in period the steroid dose was reduced in 
the FeNO group if the FeNO level measured <15ppb (193). 
Steroid reduction in the control group was based on current asthma 
management guidelines and only occurred when, over the course of the 
previous week, subjects achieved the following: 
• Less than 2 night-time awakenings due to asthma. 
• A mean peak-flow amplitude of <20%. 
• Bronchodilator use <4 times on 1 or 2 days. 
• Minimal asthma symptoms. 
• FEV1 >90% predicted. 
If a patient did not fulfil all these criteria, an episode of loss of control 
was counted. Within the FeNO group, the optimal dose was one dose 
above the dose at which the subjects FeNO level was >15ppb (193). In 
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the control group the optimal dose was one dose above the dose at 
which a loss of control had occurred. These figures subsequently 
became the optimal doses at which subjects entered the final year-long 
phase of the study. During this stage, the steroid dose was increased in 
the FeNO group if the measured FeNO level exceeded 15ppb. Within 
the control group the optimal dose was increased if a loss of control 
(defined as for the dose optimisation period) occurred. The steroid dose 
was reduced on predetermined criteria in both groups, but never below 
the optimal starting dose (193). Although it was noted that there were 
fewer exacerbations in the FeNO group, it was not great enough to 
demonstrate significance statistically. However, it was determined over 
the course of the study that participants in the FeNO group used 45% 
less inhaled corticosteroid when compared to the control group. There 
was a significant difference in the distribution of doses of inhaled 
fluticasone at the end of the study. The mean dose was 370 
micrograms per day in the FeNO group and 641 micrograms per day in 
the control group. At the end of the study, the control of asthma in the 
FeNO group was not significantly better (193). The results of the FeNO 
differences looked impressive, however, it must be noted that the 
dosage difference was likely to be accounted for by the fact that there 
was a dose increase of steroids in the control group of participants (and 
some participants were on LABA medication also) (195). The study 
does however, confirm that a management plan based on tracking 
changes in FeNO level offers a safe and practical method of asthma 
management and may allow steroid reduction without a concomitant 
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increase in asthma exacerbations. This outcome was also 
demonstrated by Green et al. (2002) (39) who showed that "titrating 
steroid dose to match the severity of airway inflammation results in a 
healthier patient with fewer emergency room visits and significantly 
fewer exacerbations (39)." This not only reduces the amount of 
treatment a patient is exposed to, but also reduces cost to the individual 
and the NHS. 
In a second study Pijnenburg et al. (2005) (194) compared a FeNO 
algorithm to a symptom based algorithm to titrate inhaled corticosteroid 
doses in 39 and 45 children respectively. Subsequently, at a one year 
follow up there was no difference in the symptom scores, lung function, 
inhaled corticosteroid doses or exacerbation rates between the two 
groups, but there was a significant improvement in the methacholine 
PD20 in the FeNO group compared with the control group (194). 
Aerocrine ™ used the results of these three studies to confirm that 
"routine monitoring of the FeNO level as a marker for inflammation 
makes it possible to titrate the steroid dose according to the patient's 
specific needs (193,194)." 
In summary, research has determined that the use of FeNO 
measurements can significantly reduce maintenance doses of inhaled 
steroids without compromising asthma control (193). In those patients 
who already take steroids, the dose can be gradually reduced to the 
point at which the FeNO level starts to increase again. At this point the 
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steroid dose should be raised, but only by the minimum amount 
required to maintain the FeNO measurement at a stable level. This 
method may, in the future, allow personalised asthma treatment plans 
to be initiated, through FeNO level measurement tracking. This method, 
compared to conventional treatment guidelines improves asthma 
prognosis (as measured by improving hyperresponsiveness and 
reduced inflammation) (194). 
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1.6.9 - Using exhaled nitric oxide to predict treatment response in 
asthma: 
As previously mentioned, some studies have been using FeNO 
measurements to track changed in the inflammation levels and increase 
or decrease inhaled corticosteroid treatment accordingly. Other studies 
have used FeNO measurements as a baseline for predicting treatment 
response. 
Wilson et al. (2006) (196) studied the effect of ciclesonide in low doses 
in mild to moderate patients with asthma to determine whether it 
exhibited significant anti-inflammatory effects after 4 weeks of 160 
micrograms per day of treatment. The FeNO level (along with other lung 
function tests) was measured after the 4 weeks of ciclesonide treatment 
and again after a subsequent drug wash-out period. It was established 
that there was no significant difference between the run-in period, 
wash-out period or placebo for any of the end points that were 
measured (196). However, the difference between ciclesonide and 
placebo was significant for the FeNO results [47(95% CI: 15-81) ppb). 
The authors acknowledged that FeNO is particularly sensitive to the 
effects of inhaled corticosteroid (197) and other studies have shown 
significant suppression of inflammation at low to moderate doses. Lee 
et al. (2005) (198) demonstrated significant suppression of inflammation 
using high-doses of ciclesonide (1280 micrograms per day) (198), but 
not using moderate doses (320 micrograms per day) (199). Conversely, 
Kanniess et al. (2001) (200) showed significant suppression of airways 
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inflammation with 320 micrograms per day. The evidence either way is 
inconclusive as different studies obtained opposing results. 
In a second study using FeND to predict treatment response, Jones et 
al. (2002) (201) performed a trial to evaluate the usefulness of FeND in 
investigating the dose response relationship for inhaled 
beclomethasone dipropionate (BOP), and to compare FeND levels with 
other markers of airways inflammation (201). 65 participants were 
withdrawn from their inhaled corticosteroid therapy and were entered 
into a double-blind, parallel-group, placebo-controlled trial involving 50, 
100, 200 micrograms BOP per day for 8 weeks. The relationship 
between the dose of inhaled corticosteroid and change in FeND 
showed a dose-response curve which appears to be linear, at least up 
to a dose of 500 micrograms BOP equivalent (201). In this study Jones 
et al. (2002) (201) have shown that FeND measurements have been 
used to predict deteriorating asthma conditions and control, and 
potentially may reflect underlying changes in the inflammation of the 
airways (201). The findings from the Jones' study along with results 
from similar trials, offer further evidence that repeating FeND 
measurements may serve as a useful guide for the adjustment of 
inhaled corticosteroid dosage in patients with persistent asthma (201). It 
was established by Kharitonov et al. (2002) (202), that the recovery of 
FeND back to baseline following withdrawal of inhaled corticosteroid 
therapy is rapid but also dose-dependent (202). 
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In a similar study, Silkoff et al. (2001) (203) demonstrated the dose 
response and the reproducibility of the FeNG measurements fell 
following inhaled BOP therapy in non steroid-treated patients. From the 
results of the study the general model showed that the test for treatment 
differences in FeNG was highly significant. There was no significant 
difference between FeNG at baseline and after one week of placebo 
inhaler treatment. A progressive fall in FeNG was seen as BOP dose 
was increased, and all doses of BOP were associated with significant 
change in the FeND levels from baseline and placebo values. The level 
of FeNG in subjects taking 100 micrograms BOP was significantly 
different from those taking 800 micrograms BOP. However, there was 
no significant difference between the 100 micrograms and 400 
micrograms doses or between the 400 micrograms and 800 
micrograms doses (203). 
In summary, the authors concluded that FeND was "superior to both 
FEV 1 and PC20 in establishing a dose response for 100 micrograms per 
day and 800 micrograms per day BOP, but was unable to distinguish 
between the interim doses." It was again suggested that FeND 
monitoring may be useful in determining minimal effective doses of ICS. 
However, they believed it may only be useful in patients with raised 
baseline FeND values which could be used to compare the potencies of 
anti-inflammatory medications (203). 
Dther studies which have used FeND to predict treatment response 
have focussed on the time it takes for FeND levels to rise or fall before 
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or after inhaled corticosteroid therapy is administered respectively. In 
one such study investigations into whether systemic glucocorticoid 
therapy (like inhaled corticosteroid therapy) could reduce FeND levels 
in a given individual. All participants who underwent emergency 
treatment for asthma with systemic corticosteroids had their FeND 
levels monitored repeatedly. FeND levels were shown to fall as the time 
since treatment increased. At the same time, relief from airway 
obstruction was also shown to improve (142). The decrease in FeND 
levels was evident from around 48 hours post-therapy. This study 
provides further evidence that using FeND levels to track changes in 
patient airway inflammation can aid recovery through the use of patient-
specific treatment plans (142). 
The fall in FeND levels was much more rapid in treatment of acute 
asthma in children with a single dose of nebulised budesonide. Tracking 
the FeND changes showed a decrease in 6 hours, as FeND decreased 
this was correlated with in a increase in peak expiratory flow rate (204). 
These studies not only offer evidence into the efficacy of FeND as a 
traceable biomarker, but also offer insight into the most effective 
medication types available. In summary, using FeND measurements to 
predict treatment response firstly offers insight into systemic steroid and 
les efficacy. FeND responds faster than any other marker to changes 
in steroid intake (142, 204). There is a clear dose-dependent 
relationship between the inhaled steroid dose and the fall in FeND level 
(203). A reduction in FeND of at least 20% in unstable patients 
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indicates efficacy of the anti-inflammatory treatment (205). The 
implications for clinical practice are that monitoring a patient's FeND 
levels before and during anti-inflammatory therapy is now "a simple, 
quick and patient-friendly way of checking that steroid therapy is having 
the desired effect on airway inflammation levels" (203, 205). 
Secondly, FeND measurement offers prediction of steroid response. In 
patients with non-specific symptoms, a FeND value of >47ppb is highly 
indicative of a subsequent corticosteroid response (206). FeND 
measurement correctly identifies the responders better than spirometry 
or PEF variability. In this group of patients with non-specific respiratory 
symptoms, FeND measurement was significantly better than FEV 1 
bronchodilator response in correctly identifying those who will respond 
to inhaled fluticasone (206). FeND as a predictor of response might 
help to identify individual children who achieve a greater improvement 
in asthma control days with an ICS compared with a leukotriene 
receptor antagonist (207). Patients with normal FeND levels who do not 
show any symptomatic response to anti-inflammatory treatment may 
have little or no underlying inflammation, in which case other forms of 
treatment should be considered, and discontinuation of ineffective anti-
inflammatory treatment is likely to be appropriate (207). 
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1.6.10 - Corticosteroid treatment and exhaled nitric oxide in 
asthma: 
Inhaled and oral corticosteroids are used to treat airway inflammation in 
asthma. Exhaled nitric oxide measurements are shown to fluctuate in 
response to changes in corticosteroid medication use. 
In a study performed by Zanconato et al. (2002) (232), 30 children with 
asthma exacerbation were treated with oral prednisolone (systemic 
steroids) for 5 days. FeNO levels were recorded before and after the 
oral corticosteroid therapy. A control group, consisting of healthy, non-
atopic children also had their FeNO levels measured. The results 
determined that FeND values were higher in children with asthma 
(FeNO online, 74.9±0.4ppb; FeND offline, 20.2ppb±1.4ppb) than in the 
control group (FeNO online, 10.1 ±0.8 [p<0.0001]; FeND offline, 
5.9±0.4ppb [p<0.0001]) (176). The conclusions drawn were that there 
was a significant decrease in FeND levels in children with asthma 
exacerbation after a course of oral prednisolone therapy, and that the 
effect of oral corticosteroids is similar to those of ICS but ICS onset is 
much slower (142, 176). 
In a further study by Slats et al. (2006) (208) the effect of combining oral 
corticosteroid therapy with ICS on FeNO levels was investigated. It was 
hypothesised that airway inflammation can persist despite ICS 
treatment and it may be possible to further reduce inflammation by 
prescribing an oral corticosteroid therapy in combination with ICS. 
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FeND was used to measure the level of airways inflammation. From the 
results obtained, two weeks of treatment "did not significantly change 
the level of FeND either within the prednisolone group (mean change, -
14.0[ppb; SD 33.4ppb) or within the placebo-treated group (mean 
change, 9.7ppb; SD 12.8ppb)" (208). 
A common theme for research has been using FeND to assess the 
response of an individual to ICS therapy. Dne such study was 
performed by Smith et al. (2005) (206) and assessed the predictive 
accuracy of FeND to identify steroid response in 52 patients presenting 
with undiagnosed respiratory symptoms in a single-blind, fixed-
sequence, placebo-controlled trial of inhaled fluticasone for four weeks 
(206). In this study, steroid response was defined as a "change in 
symptoms, peak flows, spirometry or airway hyperresponsiveness to 
adenosine, based on guidelines and recommendations" (206). The 
results showed that response to steroid treatment was significantly 
higher in the highest FeND group (>47ppb) for each endpoint. The 
interesting factor is that these results held true irrespective of the 
diagnostic label. In all instances the predictive values for FeND were 
significantly greater for almost all other baseline predictors, with an 
optimum cut-point of 47ppb (206). 
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1.7 - Asthma control and exhaled nitric oxide: 
FeNO measurement offers both the individuals and the clinicians' 
notification of loss of control. The general understanding is that, if a 
patient's FeNO level increases by more than 60% from one visit to the 
next, even in the absence of asthma symptoms, this increase has a 
positive predictive value of over 80% of an imminent deterioration in 
asthma control (209). Loss of control is different to exacerbation. Loss 
of control can be reversed by increasing the les and SABA dose, 
however, exacerbation requires systemic steroids to reduce the 
inflammation. FeNO measurement also offers prediction of asthma 
relapse. In a study by Pijnenburg et al. (2005) (210) when 
asymptomatic children in clinical remission stopped taking steroids, a 
FeNO level of more than 49ppb 2-4weeks later was an effective 
predictor of asthma relapse (210). 
In a study by Szefler et al. (2005) (211) it was investigated whether the 
equivocal role of FeNO in clinical asthma management could be made 
more certain as a reliable biomarker of airway inflammation. The study 
consisted of a randomised, double-blind, parallel-group trial at 10 
centres in the USA. 780 inner-city adolescents with persistent asthma 
were screened. All participants were entered into a three week run-in 
period based on a standard treatment regime. After this time, 546 
participants who demonstrated adherence to the run-in phase of 
treatment were randomly assigned to a programme of either 45 weeks 
of standard treatment on the basis of measurements of FeNO or control 
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group based on conventional asthma management plans. For this study, 
the primary outcome measure was the number of days a participant 
presented with asthma symptoms (211). The results of the study 
showed that the mean number of days with asthma symptoms did not 
differ between the treatment groups in the FeNO monitoring group 
versus the control group. All other measurements including, lung 
function and asthma exacerbation did not differ between the two groups 
(211). 
The conclusions drawn from the study were that conventional asthma 
management plans resulted in good control of symptoms in most 
participants. Using FeND as an additional control measure of asthma 
resulted in higher doses of ICS, without clinically important 
improvements in symptomatic asthma control (211). This is an 
important result as at times research produces results which look 
impressive in terms of statistical significance, however in relation to 
clinical improvement they are insignificant and little or no improvement 
is seen. With regard to the patients in the clinical setting, it is a 
significant improvement in symptoms which is ultimately most important. 
Following the results from the Szefler et al. (2008) (211) study, a similar 
study by de Jongste et al. (2009) (212) based on telemonitoring of 
FeNO levels in 151 children produced similar results. Participants were 
randomly assigned to one of two groups: FeNO plus symptom 
monitoring, or monitoring of symptoms only. All participants were asked 
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to score their asthma symptoms in an electronic diary over 30 weeks; of 
these 77 were given a portable FeND analyser. Data were transmitted 
daily to the coordinating centre. Every three weeks, participants were 
telephoned and steroid dose was adapted according to FeND and 
symptoms, or according to symptoms. The primary endpoint was the 
proportion of symptom-free days in the last 12 weeks of the study. 
The results demonstrated that telemonitoring was feasible with reliable 
FeND data for 86% of days, and valid diary entries for 79% of days 
(212). Both groups showed an increase in symptom-free days, 
improvement of FEV 1 and quality of life, and a reduction in steroid dose. 
None of the changes from baseline differed between groups. The 
difference in symptom-free days over the last 12 weeks was 0.3%. 
There was a trend for fewer exacerbations in the FeND group. These 
trends may purely be representative of patients becoming more 
compliant to their medication regimes due to the fact that they knew 
they were in a clinical trial (212). The conclusions drawn from the study 
were that 30 weeks of daily FeND monitoring and symptom 
telemonitoring was associated with improved asthma control and a 
lower steroid dose. There was no added value of daily FeND monitoring 
compared with daily symptom monitoring alone (212). Both of these 
studies indicate that there is no added benefit to using FeND 
measurements to evaluate asthma control. 
A study by Van Den Toorn et al. (2001) (213) looked at asthma control 
in a different way. It is clear trend that symptoms of atopic asthma often 
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disappear during puberty (213). Significant airway remodelling was 
found in subjects in clinical remission. This study has shown that there 
is ongoing airway inflammation and airway remodelling in adolescents 
in clinical remission of atopic asthma. Subclinical airway inflammation 
may well determine the risk of an asthma relapse later in life. In 
conclusion, FeND levels may reflect airway inflammation and 
remodelling in asymptomatic individuals and this may be able to be 
used on a daily basis to predict potential relapse in the future (213). 
It is clear to see that the evidence from different studies provides 
different conclusions regarding the efficacy of using FeND as a 
predictor of asthma relapse / loss of control. More studies are needed 
before a conclusive answer can be determined. The answer may be 
that FeND is best used to personalise individual treatment regimes and 
management plans based on individual changes from baseline over 
time. Large population studies are needed to assess the efficacy of 
FeND as a management tool in patients who present with widely 
variable asthma phenotype profiles. 
Page 97 of 260 
1.8 - Asthma exacerbation and exhaled nitric oxide: 
In terms of asthma research, an area which shows a distinct lack in the 
number of studies, is looking at the relationship between FeNO and 
asthma exacerbation prediction in adults. Leuppi et al. (2001) (214) 
addressed the issue that it would be helpful to have predictors for failure 
or success of a planned ICS reduction. 50 participants with well-
controlled asthma, taking a median dose of 1000 micrograms per day 
had their ICS dose halved every 8 weeks. Measurements of 
hyperresponsiveness to bronchial challenge test with histamine were 
measured at baseline. Airway hyperresponsiveness to bronchial 
challenge test with mannitol, spirometry, FeND, and, in 31 subjects, 
sputum inflammatory cells were recorded at baseline and at subsequent 
monthly intervals (214). The results were as follows: 39 subjects 
suffered an asthma exacerbation and 7 subjects were completely 
weaned off ICS without any indication of loss-of control or exacerbation. 
Analysis of the Kaplan-Meier survival method indicated that the 
significant predictors of a failure of ICS reduction were being 
hyperresponsive to both histamine and mannitol at baseline (p=O.039), 
and being hyperresponsive to mannitol during the dose-reduction phase 
of the study (p=0.02). It was also indicated that subjects who were older 
than 40 years tended to be at greater risk of ICS reduction failure than 
those under 40 years (p=0.059) (214). It was observed that subjects 
over 40 years of age in the study population had a significantly lower 
mean FEV 1 percentage predicted and longer duration of asthma than 
those less than 40 years of age. It is understood that there is some 
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evidence that as an inflammatory state persists overtime, anatomical 
and functional airway changes are more likely to occur (215). Response 
to mannitol and percentage sputum eosinophils were significantly 
greater before a failed ICS reduction, whereas there were no significant 
differences in symptoms, spirometry or FeND. There was also a 
correlation demonstrating that an increase in sputum eosinophilia over 
the course of step-down (but not high levels at baseline) was also a 
significant predictor of failure of ICS reduction. The final set of results 
indicated that lung function and FeND measurements did not have any 
significant value in predicting exacerbation following ICS reduction at 
any time period. The conclusion drawn in relation to FeND was that 
"ICS treatment leads to sustained inhibition of inducible ND synthase 
(214), so that FeND does not necessarily increase during exacerbation 
if ICS medications have been taken recently" (214). However, this 
theory has not been conclusively studied to date and therefore in this 
study the data indicated that FeND is not a significant predictor of 
exacerbation or ICS reduction failure (214). 
A similar study by Deykin et al. (2005) (216) investigated the feasibility 
of using sputum eosinophils, airway hyperresponsiveness and FeND in 
predicting an asthma exacerbation following substitution of ICS for 
either salmeterol or placebo (216). The trial consisted of 164 subjects 
with mild-to-moderate asthma assessed over 16 weeks. As would be 
expected, in comparison with continued ICS use, a switch to salmeterol 
or placebo was associated with increased rates of asthma deterioration 
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over the 16 week period (9.3% versus 24.1% and 37.5% respectively; 
p=0.04 and p<0.001 respectively) (216). The results obtained for FeNO 
were similar to those gained in the study by Leuppi et al. (2001) (214). 
FeNO was not a significant predictor of subsequent asthma control in 
subjects who discontinued ICS (216). However, unlike Leuppi et al. 
(2001) (214) Oeykin et al. (2005) (216) also found that bronchial 
challenge test with methacholine PC20 was not a significant predictor 
either (216). Like Leuppi et al. (2001) (214), however, both induced 
sputum counts measured at 2 weeks after a switch from ICS to placebo 
and changes in sputum eosinophil counts from before ICS cessation to 
after a switch to placebo predicted subsequent asthma deterioration 
(area under the ROC curve 0.771 [p<0.001] and 0.825 [p<0.001], 
respectively (216). The conclusion in relation to FeNO is that it 
demonstrates limited utility as a predictive marker of exacerbation. Yet 
on the basis of a model treatment strategy, the study estimates that 
allocating patients to ICS therapy on the basis of changes in sputum 
eosinophil counts after a trial discontinuation could allow 48% of 
subjects with mild-to-moderate asthma to discontinue ICS therapy 
without an increased risk of asthma deterioration over a period of at 
least 14 weeks (216). 
With two studies demonstrating the significant efficacy of sputum 
eosinophil cell counts as a predictive marker of ability to stop ICS 
therapy and future exacerbation, the discussion is underway as to 
whether sputum analysis should become routine in all asthma testing. It 
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is not currently included in the guidelines for routine use within clinical 
practice, however, the evidence suggests that it may in fact be a valid 
and useful test (216) and could provide a rationale for more widespread 
evaluation of sputum eosinophil counts for the optimal management of 
asthma (216). 
In another study by Shaw et al. (2007) (172) FeNO was investigated for 
its utility as a predictive measure of asthma exacerbation, in a similar 
manner to the two studies mentioned previously. The aim of this study 
was to assess whether titrating ICS dose using FeNO results in a 
reduction in the number of asthma exacerbations and thus whether 
FeNO measurements could result in more efficient use of ICS in 
comparison to traditional asthma management regimes (172). 118 
participants who were previously diagnosed with asthma in the primary 
care setting (Le. by traditional spirometry diagnostic methods) were 
randomised to a single-blind trial of ICS therapy based on either FeNO 
measurements (n=58) or BTS guidelines (n=60). All participants were 
assessed monthly over a 4 month period and subsequently every 2 
months for a further 8 months. The primary outcome measure was 
defined as the number of severe asthma exacerbations (172). The 
results of this study were as follows: the estimated mean exacerbation 
frequency was 0.33 (S.O 0.69) per patient per year in the FeNO group 
and 0.42 (S.O 0.79) in the control group treated in line with BTS 
guidelines. Overall, the participants being treated in the FeNO group 
used 11% more ICS (95% CI, -17 to 42%; p=0.40), although the final 
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daily dose of ICS was lower in the FeND group (557 versus 895 
micrograms; mean difference, 338 micrograms; 95% GI, -640 to -37; 
p=0.028) (172). The use of FeND measurements to determine 
treatment decisions in asthma did not result in lower exacerbation 
frequency or in a lower maintenance dose of ICS when compared with 
traditional BTS guidelines asthma management. However, participants 
in the FeND group completed the study on lower ICS doses than the 
control group, but the use of ICS over the entire 12 months of the study 
did not differ between either group (172). Both groups experienced 
fewer exacerbations overall when compared to the previous year, 
however, this may attributed to more intensive monitoring in the study 
setting and increase in patient compliance due to being in a trial. These 
results are consistent with findings from the two studies mentioned 
previously by Leuppi et al. (2001) (273) and Deykin et al. (2005) (214, 
216). 
The three previous studies (Leuppi et al. (2001) (273); Deykin et al. 
(2005) (214, 216) and Shaw et al. (2007) (172» have all looked at 
absolute FeND values and cut-off figures. There is no significant 
evidence to state that a specific FeND cut-off value at a specific flow 
rate should be used alone as a determining measure of airway 
inflammation and future exacerbation. There is some evidence to 
suggest that percentage changes in FeND and individually tailored 
FeND values may provide more useful information on underlying 
changes in airway inflammation in comparison to set cut-off values 
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based on demographic data. For example, a patient may have low 
FeNO values and still suffer an asthma exacerbation. The individual 
change in FeNO may be an important factor as opposed to absolute 
figures. 
A study by Michils et al. (2008) (217) examined FeNO measurements 
using this change in FeNO approach. ACO and FeNO values were 
recorded in 341 unselected patients with asthma. The whole population 
and subgroups were considered, i.e. both ICS-na·ive and low or high-to-
medium (S or > 500 micrograms BOP equivalents per day) ICS groups. 
The study concluded that a fall in FeNO by more than 40% from 
baseline had a positive predictive value of 83% for predicting optimal 
asthma control (217). The authors concluded that measuring changes 
in FeNO overtime in individuals is more useful than using single cut-off 
points in predicting and diagnosing loss of asthma control (217). 
In conclusion, there have been a few studies which have investigated 
the use of FeNO as a predictor of exacerbation and the results are 
mainly insignificant. However, looking at changes in FeNO overtime as 
opposed to whole-population cut-off figures has yielded better results. 
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1.9 - Summary: 
Exhaled nitric oxide as a biomarker: 
A biomarker is a surrogate marker which can be utilised clinically to 
understand, characterise and quantify an underlying disease process 
(218, 219). In many respiratory diseases confirmation of the pathology 
can be sought using tissue biopsy, however the cost to benefit ratio is 
too high to make biopsy a routine monitoring tool. Imaging is also 
available to assess anatomical physiology and respiratory 
measurements can identify some changes in lung function (e.g. 
spirometry). However, both imaging and lung function testing are limited. 
They do not easily track the variability of asthma, they are costly, time 
consuming and imaging services are largely unavailable in primary care 
(220). 
Exhaled nitric oxide is a non-invasive biomarker of airway inflammation. 
It is produced by airway wall cells (including epithelial cells), and levels 
are increased in patients with atopic asthma and rhinitis. Exhaled nitric 
oxide has been used in studies to predict les response and track 
deterioration on discontinuation of therapy (221). 
The performance of exhaled nitric oxide as a biomarker: 
The success with which a biomarker operates in diagnostic decision 
making ultimately depends upon its performance. A sensitive test 
identifies most patients with a specific condition or disease but can also 
pick up some patients without the disease. A sensitive test can also rule 
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out a condition when the result is strongly negative. It is said to have a 
high negative predictive value or a low negative likelihood ratio. A 
specific test is a test which identifies people who have a positive test as 
having a condition or a disease, but some affected patients may be 
missed. A specific test can rule a condition in when the result is positive. 
It is said to have a high positive predictive value or a strong likelihood 
ratio. The severity and presentation of the disease or condition being 
tested by the biomarker would determine whether it would be best to 
use a highly sensitive or highly specific diagnostic tool. 
An example would be a D-Dimer assay. A normal D-Dimer has a high 
negative predictive value for venous thromboembolism (VTE >95%) 
and helps to accurately rule out VTE. However, D-Dimer is associated 
with only modest positive predictive values and cannot be used 
therefore as a positive predictor clinical tool (it is not a specific test). 
Therefore when a D-Dimer is normal clinicians know there is a less than 
5% chance that the patient has a VTE. This means that D-Dimer is a 
sensitive test, this is important because in VTE it is important not to 
miss patients. When D-Dimer is raised, the clinicians cannot associate 
the raised value with a definitive diagnosis of VTE and therefore further 
tests are employed to confirm or deny the diagnosis (222, 223). 
The ideas for FeND use may be similar to that of D-Dimer. 
In a study by Dupont et al. (2003) (224) the pre-test probability of 
diagnosis asthma was 67%. The positive predictive value of exhaled 
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nitric oxide for diagnosing asthma was 90% and the negative predictive 
value was 90%. In a study by Smith et al. (2004) (225) the pre-test 
probability was lower than Dupont et al. (2003) (224) at 36%; the 
positive predictive value for diagnosing asthma with exhaled nitric oxide 
was 70% but the negative predictive value was higher at 92%. These 
and other data by Pedrosa et al. (2010) (226) indicate that exhaled nitric 
oxide values (like D-Dimer), provide more reliable clinical information 
when the value is low. This however, does not preclude using high 
values in clinical decision making, but the weight of a high value needs 
to be appropriately modified to reflect the differing performance 
characteristics of exhaled nitric oxide as a biomarker (221). 
Clinical decisions are generally based on whether an individual result is 
greater or less than a chosen cut-point for the biomarker. Low/normal 
values generally indicate the absence of underlying disease activity, 
and high/abnormal values indicate its presence (227). However, cut-
pOints tend to differ between studies depending on the nature of the trial. 
For example different studies investigating exhaled nitric oxide may use 
one, two or even three different cut-points. 
The table below examines three different studies which employ FeND 
as a tool for monitoring ICS treatment and the cut-points associated 
with the different trial designs. 
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Table 1.2: 
FeNO cut-off values chosen for different FeNO based intervention 
studies. 
Summary of studies investigating exhaled nitric oxide as 8 tool for monitoring ICS treatment In 
asthma 
Smith (228) Pilnenbura (194) Shaw(172l 
Design Single blind Single blind Single blind Parallel group Parallel group Parallel group 
97 adults 85 children 118 adults Population Mild-moderate asthma Atopic asthma Primary care diagnosis 
of asthma 
Duration 12 months 12 months 12 months 
Control: Conventional Control: Control of symptoms Control: Control of 
Intervention measures of asthma control Intervention: Control of symptoms Intervention: FeNO <15ppb symptoms and FeNO Intervention: FeNO 
(250mUs flow rate) <30ppb <26ppb 
Symptoms s 2days/week Symptom score> 14 (over Night symptoms s 1/week 
132 S four times/week and S two weeks) ACO> 1.57 Symptoms 2days/week Symptoms S for the first time ACO <1.57 x 2 visits 
PEF variation S 20% Symptom score S for the 
FEV, ~ ~ 90% of baseline second time 
FeNO >30ppb = increase FeNO > 26ppb = Controlled if FeNO < 15ppb ICS 
FeNO and 250mUS (35ppb at 50mUs) FeNO S 30ppb and Double ICS 
treatment = decrease one dose step if symptom >14 = ICS no FeNO < 16ppb = 
steps controlled change Halve ICS 
Uncontrolled ~ ~ 15ppb FeNO S 30ppb and symptom FeNO < 16ppb + 
s 14 = decrease ICS ACO >1.57 = +LABA 
Decreased exacerbations Improved AHR and AI Decreased Outcomes Decreased ICS dose Non significant change in exacerbations ICS dose or exacerbations Increased ICS dose 
In these studies the FeNO cut-points were chosen based upon the 
upper limits of normal exhaled nitric oxide values derived from a healthy 
control population (212, 229, 230) or from patients with stable asthma 
(228). In a study by Shaw et al. (2007) (172), a low cut-point, validated 
against corresponding sputum eosinophil counts, was used to 
determine the likely absence of underlying disease activity (low exhaled 
nitric oxide and high negative predictive value for inflammation, and 
therefore the ICS was reduced). In contrast Hewitt et al. (2009) (231) 
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used a high cut-point related to likely steroid responsiveness (high 
exhaled nitric oxide and moderate positive predictive value for steroid 
response, and therefore the ICS dose was increased). The differences 
between these two studies highlight the difficulties in standardising 
exhaled nitric oxide as a clinical biomarker. 
Exhaled nitric oxide and improving clinical outcomes: 
Current asthma guidelines (2, 25) recommend treatment decisions are 
made based upon the assessment of asthma control using a 
combination of symptoms and lung function (2,25). 
However, studies which employ biomarkers differ in that they seek 
improved outcomes by basing treatment decisions upon the biomarkers 
in question (e.g. airway hyperresponsiveness (232), sputum eosinophils 
(39, 233), eosinophilic cationic protein (ECP) (234) and exhaled nitric 
oxide (172, 228-230, 235, 236). All such studies use calculations which 
provide recommendations for up and down-titration of asthma treatment 
based upon inflammatory biomarkers. These types of studies are 
important for improving patient care as research indicates that asthma 
control remains suboptimal despite the extensive clinical guidelines and 
effective asthma treatments (237). There is also evidence to suggest 
that over-treatment of asthma with inhaled corticosteroids is also 
occurring due to poor compliance with step-down guidelines (238), and 
further evidence that a different subset of patients remain under-treated 
(239,240) and that medication compliance needs to improve (241,242). 
Simple biomarker tests may improve the treatment and compliance 
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regimes in asthma management. Biomarker studies have the potential 
to improve asthma pharmacotherapy by individualising treatments and 
adjusting doses based upon personal response, as well as increasing 
patient participation in pharmacotherapy, thus enhancing compliance 
and adherence and improving monitoring and subsequent control of 
asthma. The use of clinical biomarkers can lead to improved asthma 
outcomes at a similar or lower cost. 
The use of sputum eosinophils as a biomarker to guide asthma therapy 
has reported a high significant reduction in the likelihood of asthma 
exacerbation by 50% (233). Such studies could be considered the 
closest studies to a "gold standard" in the use of biomarkers to 
determine inhaled corticosteroid dose in asthma. The problem with 
sputum induction is that it is not available in primary care and requires 
specialist equipment and staff to process the samples. Additionally, 
although the test is considered relatively safe, it is not feasible to use it 
as a regular test and many patients with mild to moderate asthma are 
unable to produce sputum. 
Exhaled nitric oxide, which is more accessible and simpler to measure 
has been used as a surrogate biomarker for sputum eosinophils in five 
recent studies (172, 194, 228, 229, 236) However, unlike sputum 
eosinophil studies, exhaled nitric oxide based studies are less 
successful (172, 194, 228, 229, 235, 236), and unlike sputum 
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eosinophils, exhaled nitric oxide shows now significant reduction in 
asthma exacerbation rates to date. 
The results of these studies are disconcordant and only one study by 
Smith et al. (2005) (228) has shown a positive effect of reduced 
maintenance inhaled corticosteroid dose with exhaled nitric oxide 
guided therapy. Key points in exhaled nitric oxide studies are the 
assessment of improved selection of active treatments based upon 
individual response, and improved titration of treatment using exhaled 
nitric oxide related treatment outcomes. In asthma, inhaled 
corticosteroids are the treatment of choice to reduce airway 
inflammation; but guidelines recommend that treatment decisions are 
based upon a combination of symptoms and spirometry (2,25) despite 
the fact that these variables demonstrate poor correlation with airway 
inflammation (243). Consequently, these studies have been performed 
to seek and evaluate the efficacy of treatment and dose adjustment 
using exhaled nitric oxide as a marker of eosinophilic airway 
inflammation. 
Exhaled nitric oxide responsiveness: 
A clinical biomarker needs to be responsive to changes in treatment, 
responsive to changes in the clinical condition, and sensitive to detect 
changes early enough. Exhaled nitric oxide has been confirmed as 
highly responsive to inhaled corticosteroid dosing changes. A strong 
linear dose-relationship is seen for sputum eosinophils and changes in 
exhaled nitric oxide also correlate significantly with changes in sputum 
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eosinophilia (244). As part of this thesis additional data analysis 
examined the same relationship between exhaled nitric oxide and 
sputum eosinophil count, the results of this analysis can be found in 
Chapter 5.2. Encouragingly the results obtained in the studies in this 
thesis correlated well with the findings of previous studies. 
In a study by Silkoff et al. (2001) (245) exhaled nitric oxide was shown 
to be able to detect a dose effect between 100 and 800 micrograms bdp, 
whereas FEV1 was not able to detect the same changes (245). 
FeNO is considered to be a responsive biomarker, however, the best 
use for this simple clinical tool needs to be confirmed through further 
research. 
Exhaled nitric oxide reproducibility: 
A biomarker needs to be highly reproducible in order to produce 
accurate and clinically relevant results. Measuring exhaled nitric oxide 
using chemoiluminescence has been shown to be highly reproducible 
by Taylor et al. (2006) (244) and Gabbay et al. (1998) (246). 
There are some issues with confounding factors when measuring 
exhaled nitric oxide. While it have been shown that exhaled nitric oxide 
values are reduced when inhaled corticosteroid is started for treatment 
of eosinophilic airway inflammation, exhaled nitric oxide is also 
influenced by factors other than eosinophilic airway inflammation. 
These include age, atopy, gender, smoking, 8MI and genetic variation. 
This can have the effect of leading to a false negative or false positive 
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exhaled nitric oxide result when compared to the "gold standard". In a 
study by Shaw et al. (2007) (172), the relationship between exhaled 
nitric oxide and sputum eosinophilia was imperfect, resulting in many 
false-positives when an exhaled nitric oxide cut-point of 26ppb was 
used. 
This limitation surrounding exhaled nitric oxide cut-points can be 
partially improved by using exhaled nitric oxide in combination with 
other tests to produce composite markers. Using exhaled nitric oxide in 
combination with spirometry (247) or airway hyperresponsiveness (248) 
may improve the prediction of future exacerbation risk. In a different 
study by Gelb et al. (2006) (247), using FEV1 in combination with 
exhaled nitric oxide improved the predictive value for asthma 
exacerbations. A raised exhaled nitric oxide in combination with a 
reduced FEV1 percent predicted had a likelihood ratio of 5.94 for 
predicting subsequent asthma exacerbation. 
Biomarker studies are also concerned with determining methods to 
individualise the marker by investigating individual change from 
baseline. In a study by Michils et al. (2008) (217) change in individual 
exhaled nitric oxide from baseline had a better predictive value for 
future loss of control than using "whole-population" fixed cut-points. 
The measurement interval of exhaled nitric oxide: 
Some clinical markers such as blood glucose level change rapidly over 
a few hours, whereas others for example HbA 1 C change more slowly 
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over a period of weeks or months (249). Exhaled nitric oxide has been 
shown to rapidly reduce in response to dose-dependent inhaled 
corticosteroid therapy in asthma. This reduction occurs in the short-term 
(3-5 days post treatment commencement) (244, 245). Similarly the 
opposite effect is also true and exhaled nitric oxide levels rise rapidly 
during the first 3-5 days post cessation of inhaled corticosteroid therapy. 
There is however, a limiting factor with exhaled nitric oxide 
measurement and that is the presence of patients who present with a 
persistently high exhaled nitric oxide which is not reduced by inhaled 
corticosteroid medication but may still have elevated sputum 
eosinophils. This phenomenon has been identified and studied by 
Pijenenburg et al. (2005) (250) and seems to affect a small percentage 
of the asthmatic and non-asthmatic population. Shaw et al. (2007) (172) 
also addressed this occurrence (which was seen in approximately 15% 
of study subjects), by using sputum eosinophils in combination with 
exhaled nitric oxide to identify these individuals. 
A more recent trial involving exhaled nitric oxide, referred to as the 
BASALT trial (3), compared "as-needed, symptom-based inhaled 
corticosteroid use", as well as exhaled nitric oxide based dosing, with 
traditional daily inhaled corticosteroid use with dosing determined by a 
physician. The trial addresses the potential utility of measuring exhaled 
nitric oxide as a biomarker to guide adjustment of asthma medications 
(3). Although exhaled nitric oxide is associated with allergic 
inflammation and the risk of asthma exacerbation, prior studies have 
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not provided sufficient evidence for the justification of monitoring 
exhaled nitric oxide as part of routine asthma management (211, 251). 
In the BASALT trial, dose adjustment of inhaled corticosteroid therapy 
in response to exhaled nitric oxide monitoring was not shown to be 
better than the physician lead and symptom lead dosing. The results 
are consistent with other studies which do not provide conclusive 
justification for the use of routine exhaled nitric oxide monitoring in 
asthma management. A recent ATS practice guideline (252) 
recommends the use of exhaled nitric oxide measurement in monitoring 
airway inflammation in patients with asthma. However, the results of the 
BASALT study indicate that it is difficult to justify additional healthcare 
expenditure for routine exhaled nitric oxide monitoring in mild to 
moderate adult asthma. 
Exhaled nitric oxide has desirable properties as a biomarker to assess 
airway inflammation and adjust inhaled corticosteroid dosing but 
requires more specific studies to assess its place in clinical practice. 
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1.10 - The diagnosis and management of asthma in primary care: 
In the UK, approximately 9% of the population have a diagnosis of 
asthma. Approximately 80% of all patients with asthma are managed 
solely in primary care (2). The majority of mild to moderate well-
controlled patients with asthma will only visit their GP or practice nurse 
once a year for an annual asthma review consisting of a peak flow 
measurement. For this reason it is important that the diagnosis and 
management of asthma in primary care is adequate and carefully 
monitored to ensure patients receive the appropriate medical care. 
It is important to mention that the definitions, goals and guidelines for 
asthma management and diagnosis are the same for primary care and 
secondary care, however there are often disparities between the 
services due to time and equipment constraints. 
In 2004 The GMS (General Medical Services) Contract introduced a 
"pay for performance" scheme called The Quality and Outcomes 
Framework (QOF). This framework financially rewards GPs who 
achieve targets set over a wide range of clinical indicators. This is to 
encourage accurate diagnosis, maintenance of disease registers and 
proactive care of people who require medical attention for long-term 
conditions but who do not require hospitalisation and secondary care 
(253). Of the 1050 QOF points available, 35 of them are allocated to 
asthma indicators and 30 to COPO indicators with additional points 
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assigned to generic smoking cessation advice. Approximately 20% of 
GP income is related to the achievement of the OOF targets (254). 
(A copy of the OOF indicators for respiratory diseases can be found in 
the appendix section 8). 
Whilst the OOF system makes certain aspects of asthma management 
compulsory, it does not address the issue of diagnosis of asthma in 
primary care. 
The lack of a "gold-standard" test means that conclusive diagnostic 
accuracy cannot always be obtained. In secondary care and research 
environments there is a greater provision of tests to assess lung 
function and airway inflammation but even so these tests do not provide 
definitive diagnoses of asthma. Rather they serve to build up a bigger 
range of valuable clinical data to support a diagnosis of asthma. 
However, these tests are not routinely available in primary care settings. 
This is usually because they are too costly, too time consuming and too 
complex (often requiring specialist input into the processing and 
interpretation of results). As a result asthma diagnosis in primary care 
can be difficult. Before an asthma management plan can be 
implemented, patients firstly need to be accurately diagnosed. 
Guidelines from GINA, ATS, STS and SIGN recommend the 
assessment of symptoms and measurement of lung function in primary 
care (2, 25). However, there is a poor relationship between symptoms 
and lung function and as such asthma is often misdiagnosed. Thus, 
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whilst lung function testing and symptom assessment is of great value, 
over-reliance on these techniques (especially in primary care) can be 
misleading. This has lead to increasing evidence that there is a lack of 
diagnostic rigour in primary care. 
A study by Dennis et al. (2002) (255) in GPs in the UK reported that 
56% of children and 45% of adults received some form of asthma 
treatment before a diagnosis was established (255). 
In addition, lung function results were recorded for <20% of people 
diagnosed with asthma in primary care. The proportion was even lower 
in patients who were immediately prescribed anti-asthma medications. 
The final issue noticed in primary care diagnosis of asthma is the time it 
takes to establish a firm diagnosis. In the majority of patients and 
children it is estimated to be around 18 months. But diagnostic delays of 
up to five years have been reported in some GP surgeries in the UK 
(256). The problem is not restricted to the UK, across Europe and The 
USA studies have identified the same trends (257). 
Once a diagnosis of asthma has been decided upon and an anti-
asthma medication has been prescribed, a future management plan for 
the patient should be implemented. The management of asthma in both 
primary and secondary care should follow the same stepwise approach 
(Figure 1.2). The OOF system ensures that all patients receive an 
asthma review each year, however the subsequent management of 
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patients varies from practice to practice, however there are no OOF 
targets addressing these management issues. 
Figure 1.2: 
Summary of stepwise management of asthma in adults from the British 
Thoracic Society guidelines (2). 
The stepwise approach diagram below was designed by the British 
Thoracic Society, however the initial research into step-down was 
performed by Hawkins et al. (2003) (258). 
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Figure reproduced from the British Thoracic Society Guidelines on the 
Management of asthma (2). 
The BTS guidelines now include a monitoring and management 
statement within the diagnostic section (2). Effective management 
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serves to facilitate the diagnostic process by recording and monitoring 
patient response to treatment thus reinforcing or reducing the 
probability of asthma whilst also providing clinicians and patients with 
information to underpin treatment and or referral decisions. 
Various tools including composite symptom and quality of life scores, 
lung function tests, exacerbations, inhaler technique and compliance 
assessment systems are available for clinicians to use in day to day 
practice (2). Questionnaires such as the Asthma Control TesFM (ACTTM) 
and Asthma Control Questionnaire (ACQ) are particularly useful 
validated questionnaires in primary care (259, 260). 
Guidelines recommend a stepWise management approach to achieving 
asthma control. The stepwise approach (258) is a guideline for the 
management of all asthma in both primary and secondary care. The 
aim of pharmacological treatment remains to achieve and maintain 
control by stepping-up or down as appropriate. As with the international 
GINA guideline (25), the level of treatment is dictated by an assessment 
of control rather than an assessment of severity (which is difficult to 
assess in treated patients). The need to check adherence, inhaler 
technique and trigger factor exposure before initiating new drug therapy 
is stressed as "vital" to primary care GPs. 
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1.10.1 - Over-treatment with inhaled corticosteroids: 
Under-diagnosis and under-treatment are considered to be a major 
problem in the management of asthma and COPD in primary care and 
worries exist about the consequences of under-treatment (261). It is 
stressed to GPs that symptoms indicating asthma have to be 
interpreted more carefully as indicators of disease (262). According to 
international guidelines, a diagnosis should be confirmed by GPs using 
spirometry (263) and consequently correct levels of medication can be 
prescribed, and thus the problem of under-treatment is beginning to 
diminish in primary care. Combined with the growing awareness of 
asthma in the general population this practice has begun to lead to 
over-treatment with inhaled corticosteroids (ICS). When the symptom 
complaints disappear, a healthy person using ICS may be mistaken for 
being well-controlled and thus be advised to continue treatment with 
ICS. This may particularly be the case in patients who may have had 
viral infections. The recent development of diagnostic support services 
in European primary care (264-266) has triggered awareness that over-
treatment is an increaSing problem. These services offer GPs the 
possibility to refer all their patients with respiratory problems for 
diagnosis and advice. These services are not yet available in the UK 
and they still do not overcome the problem of over-treatment. 
In a study by Lucas et al. (2008) (238) the primary care services and 
the diagnostic support services offered to patients with asthma were 
assessed through the use of questionnaires and analysis of patient 
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records. Of the 2271 patients who had their diagnosis reassessed, 36% 
were diagnosed as asthmatic, 19% as COPO, 6% as asthma and 
COPO, 20% as neither asthma nor COPO and 19% as unclear 
diagnosis. Of 1177 taking an ICS medication in 505 patients the use of 
ICS did not match the results of the spirometry or the medical history. 
Of these 505 patients, 133 were able to completely stop their ICS 
medication with no worsening of their symptoms at three months (238). 
This study only looks at the outcome of patients who had their ICS 
medication stopped completely, but in reality the STS guidelines 
suggest a stepwise reduction (2). In a study by Hawkins et al. (2003) 
(258) stepping-down of ICS medication was evaluated in a randomised 
controlled trial. The results showed that 49% of participants in the step-
down group completed the study taking a 50% reduced dose of the ICS 
with good control (258). The study was based on existing evidence 
which states that a stepwise approach to ICS reduction should be 
implemented, evidence shows that a reduction can be achieved in 
patients with mild disease and the clinical implications of stepping-down 
ICS in moderate to severe disease are not conclusive. The results of 
the study (258) show that adopting a step-down approach to the use of 
high dose ICS in patients with stable asthma can lead to a significant 
reduction in the daily dose of ICS without compromising asthma control 
(258). 
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1.11 - Studies assessing the feasibility of exhaled nitric oxide 
monitoring for asthma in UK primary care: 
In a study by Gruffydd-Jones et al. (2007) (267), the feasibility of using 
FeND as an asthma monitoring tool in primary care was assessed. 
In this study, 22 adults and 15 children completed the study which 
involved FeND measurements being performed by the practice nurse at 
two-week intervals over a period of 12 weeks. The primary aim of the 
study was to investigate the feasibility of measuring exhaled nitric oxide 
in children (over six years of age) and adults, during the standard 
asthma review appointment in primary care. The secondary outcome 
was to measure the variability of FeND readings over time and to 
collect comparative data on the relationship between FeND and 
measures of asthma control such as symptoms, exacerbation, 
medication use and asthma-related health status (267). 
The study assessed the stability of FeND measurements in individual 
patients, and the relationship changes between changes in FeND 
readings and changes in other primary care parameters of asthma 
control. Previous hospital-based studies had reported weak cross-
sectional and longitudinal correlations between FeND readings and 
other parameters of asthma control such as lung function, symptomatic 
control, and asthma-related health status. In the study performed by 
Gryffydd-Jones et al. (2007) (267). correlations of a similar magnitude 
were observed and generally failed to reach statistical significance, 
probably due to the small population size. The study found weak and 
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inconclusive relationships between FeND readings and both 
physiological and patient-centred outcome measures after cross-
sectional analysis, there were weak but non-significant relationships 
between FeND and lung function parameters after longitudinal analysis. 
There were however, statistically significant relationships between rising 
FeND and worsening lung function (267). The study concluded that 
FeND monitoring in primary care is feasible with most patients age six 
years and over being able to perform the test successfully. The primary 
care practitioners found the test acceptable and easy to use, but with no 
statistical significance between FeND and lung function the team 
concluded that further studies are needed to investigate the clinical 
effectiveness and cost-effectiveness of such technology in the primary 
care diagnosis and management of asthma (267). 
Hewitt et al. (2008) (268) performed a study to investigate whether 
FeND in primary care can help GPs in the diagnosis of patients who 
present with non-specific respiratory symptoms. The team hypothesised 
that FeND, coupled with spirometry would improve diagnostic and 
therapeutic decision making as well as enhanci ng clinician confidence 
when assessing patients presenting with non-specific respiratory 
symptoms (268). 
55 patients aged from 12 to 80 years presenting with non-specific 
respiratory symptoms were recruited from 14 GP practices into the 
study. The patients were required to have a history of cough, wheeze or 
shortness-of-breath for at least six weeks and with no previous 
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respiratory diagnosis or if their previous diagnosis was deemed as 
uncertain. The results of the study confirmed that FeND measurements 
obtained in primary care offered helpful diagnostic information. The 
primary outcome was to demonstrated that FeND coupled with 
spirometry improves diagnostic accuracy in primary care patients. 
When asked, GPs deemed that FeNO improved diagnostic accuracy in 
94% of cases (268). The results showed that spirometry was normal in 
the majority of cases (88%) and was only considered helpful in aiding 
the diagnosis of non-specific respiratory symptoms in 53% of cases. 
This is, in contrast to FeND which clinicians deemed to be relevant in 
94% of cases of uncertain diagnosis. The reason for this is likely to be 
because FeNO measurements are a surrogate marker for eosinophilic 
airway inflammation (69,269,270), which in turn indicates the likelihood 
of steroid-responsiveness (271, 272). Hence, in patients with non-
specific respiratory symptoms and high FeNO levels, a positive 
response to inhaled corticosteroids may be anticipated (206), thus 
FeND levels may be useful in guiding treatment decisions and 
management. 
Deciding whether or not to prescribe a trial of ICS is often decided 
empirically, and this aspect of management was simplified in the study 
using FeNO. Follow-up evaluation confirmed that 14 out of the 17 
patients with a high FeND level in this study demonstrated a 
satisfactory clinical response when treated with inhaled corticosteroids. 
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The study also showed that both low and high FeNO levels proved to 
be meaningful in the interpretation of non-specific respiratory symptoms 
(271, 273). This is not the case for changes in lung function, where only 
low values are clinically instructive. The study also showed that access 
to FeNO measurements improved diagnostic confidence, the follow-up 
diagnosis at three-month review was different in 10 out of 51 cases 
(20%). In these cases the FeNO level was either intermediate (20-
35ppb) or low «20ppb) at the point of initial diagnosis. Nether FeNO 
measurements nor spirometry could distinguish between GORD, non-
specific cough, post-viral respiratory symptoms and anxiety 
hyperventilation (268). 
The study was not designed to confirm or complement previous studies 
which investigated the overall utility of FeNO measurements (224, 225, 
274). Rather it was used to assess the usefulness of adding FeNO into 
a busy general practice. As with the Gruffyd-Jones study, 2007 (267), 
this study confirmed that FeNO can be successfully implemented in 
general practice but there is further research required to confirm the 
utility of FeNO for diagnostic support in primary care. The feeling is that 
spirometry is limited in the information it can provide (275) and whilst 
the use of FeNO has not been conclusively determined, the test can 
provide complementary data which is useful in the assessment and 
management of respiratory patients in primary care. 
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Hewitt et al. (2009) (231) then performed a second study to investigate 
the use of exhaled nitric oxide specifically in the management of asthma 
in primary care (231). The primary aim of the study was firstly to assess 
whether an open-ended FeNO based protocol could be applied in the 
primary care setting, and the subsequent impact this would have on 
asthma outcomes. The secondary outcome was to evaluate the 
practical issues associated with using and interpreting FeNO levels in 
nurse-led primary care asthma clinics. 78 patients with asthma 
completed the study having attended five visits at three-monthly 
intervals where FeNO, symptom scores and spirometry were recorded 
at each visit. The inhaled corticosteroid treatment was then adjusted in 
response to FeNO levels (231). The treatment algorithm devised for this 
study based on previous research which indicates that FeNO values 
over 47ppb are associated with steroid responsiveness (274) or that the 
potential for relapse in asthma control when inhaled corticosteroid 
therapy is reduced or withdrawn (210) and that the upper limit of 
"normal" for patients with stable asthma is 33ppb (152). Thus 45ppb 
and 30ppb were chosen as cut-offs for the study. 
The results of the study showed that based on the treatment algorithm 
presented for FeNO cut-off values resulted in an overall increase in the 
number of patients with well-controlled asthma (from 40% to 70% 
approximately). The improved asthma control also coincided with a 
progressive reduction in the dose of inhaled corticosteroid medication, 
notably in patients already being prescribed inhaled corticosteroid 
treatment (a 44.6% reduction). The results recorded were similar to 
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those recorded in a randomised controlled trial by Smith et 81. (2005) 
(274). The study team concluded that although achieving asthma 
control in 70% of patients is less than ideal, these results are consistent 
with the GOAL study in which 60-70% of patients achieved well-
controlled asthma involving progressive step-up in inhaled 
corticosteroid dose (27). Therefore, the FeNO algorithm presented in 
this study appear to achieve clinical benefits of the same magnitude as 
other clinical processes. The research concluded that using the FeNO 
algorithm to support decisions surrounding asthma management in 
primary care decreased the proportion of patients with poorly controlled 
asthma as well as a progressive reduction in inhaled corticosteroid dose 
requirements. The outcomes obtained in patients with persistently high 
FeNO levels suggest that fixed cut-points from FeNO are less likely to 
be helpful that individually determined optimum changes (231). 
In conclusion, although the weight of evidence in the literature does not 
support the routine use of FeNO to optimise asthma diagnosis and 
management, measuring FeNO levels enables factors other than airway 
inflammation to be identified in patients with ongoing symptoms and this 
can now be done cheaply and easily in UK primary care (231). 
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Chapter 2 - Hypothesis and aims: 
Previous research has demonstrated that exhaled nitric oxide is a 
simple clinical biomarker which would be feasible for use in UK primary 
care (267). It has been shown to correlate well with measures of 
sputum eosinophilia in the moderate to severe asthma cohort (269), 
and levels change rapidly in response to steroid medication (196, 245, 
276). It has also been used to guide treatment regimes in an attempt to 
reduce exacerbation rates (172, 210, 277). 
However, there have been no exacerbation studies to date which have 
investigated whether exhaled nitric oxide can be used as a clinical 
marker to distinguish between well-controlled patients with asthma who 
can and cannot successfully step-down their inhaled corticosteroid 
medication. 
Overall hypothesis: 
Exhaled nitric oxide can be used as a non-invasive biomarker of airway 
inflammation to predict which patients with mild to moderate asthma 
can successfully step-down their inhaled corticosteroid medication in 
UK primary care. 
The data presented in this thesis aimed to answer five questions: 
1. Can exhaled nitric oxide (either at baseline or change within 
seven days) be used to predict successful step-down of inhaled 
corticosteroid medication in patients with mild to moderate 
asthma in UK primary care? 
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2. Do asthma symptoms (as measured by the Juniper Asthma 
Control Questionnaire) reflect airway inflammation in patients 
with mild to moderate asthma? 
3. Does exhaled nitric oxide reflect airway inflammation in patients 
with mild to moderate asthma? 
4. Can exhaled nitric oxide be used in primary care to predict the 
likelihood of "true" asthma in patients with a suspected diagnosis 
of mild to moderate asthma? 
5. Can exhaled nitric oxide can distinguish between eosinophilic 
and non-eosinophilic sputum in a mixed cohort of patients with 
asthma. 
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Chapter 3 - Methods: 
All procedures were carried out according to ATS/ERS/BTS guidelines 
and followed standard operating procedures outlined within the 
guidelines and the manufacturer's instructions. 
Specific safety measures were in place throughout all the tests in 
accordance with guidelines, University of Nottingham, Nottingham 
University Hospitals NHS Trust and Leicester University Hospitals NHS 
Trust health and safety procedures. 
3.1 - Allergen sensitisation: 
Atopy was assessed by skin prick tests to Dermatophagoides 
pteronyssiunus (house dust mite), cat and dog fur, tree and grass pollen 
and Aspergillus fumigatus with normal saline and histamine controls 
(Alk-Abello TM, Berkshire, UK). A positive response to an allergen on the 
skin prick tests was recorded in the presence of a weal >3mm and more 
than the negative (saline) control. 
Participants were requested not to take any antihistamine medications 
for a minimum of 48 hours prior to the test. 
3.2 - Spirometry: 
Spirometry was performed with a Vitalograph ™ spirometer 
(Vitalograph TM, Buckinghamshire, UK). The spirometer was calibrated 
daily by a qualified lung function technician. Bronchodilator reversibility 
was assessed 15 minutes after administration of 400 micrograms of 
salbutamol inhaled via a Volumatic® spacer. FEV1 was recorded as the 
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best of three successive readings within 100ml or 5%. Percentage 
predicted values were calculated using the ECGS guidelines. 
The same spirometer was used throughout the study. 
3.3 - Airway hyperresponsiveness: 
Using the standard Juniper tidal breathing method, the concentration of 
methacholine causing a 20% fall in FEV 1 was recorded as the PG20 
FEV1 (278). In brief, following the measurement of the baseline FEV1 
subjects inhaled normal saline followed by doubling concentrations of 
methacholine from 0.03mg/ml to 16mg/ml via a Wright's® nebuliser 
(Roxon, Canada) (flow 0.13ml/min driven by dry compressed air). The 
subject was instructed to breath normally (tidal breathing) through the 
two-way valve nebuliser for two minutes with a nose Clip. The FEV 1 was 
then measured 30, 90 and 180 seconds after the two minute 
nebulisation period. If the FEV1 fell less that 20% from baseline the 
procedure was repeated with the next highest concentration. If the FEV 1 
fell more than 20% from baseline (or the highest concentration 16ml/mg 
had been given), no further methacholine was given. Methacholine 
PG20 FEV1 concentration was calculated by linear interpolation of the 
log dose response curve. 
At the end of the bronchial challenge test 400 micrograms of salbutamol 
was administered via a Volumatic® spacer to the subject. 
The same Wright's® nebuliser was used throughout the study. 
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3.3.1 - Calibration for methacholine challenge: 
The output of the Wright's® nebuliser was assessed at baseline by a 
qualified lung function technician using the following protocol: 3ml of 
saline was placed into the nebuliser at room temperature. The solution 
was then weighed and then nebulised at a flow rate of 71/min for two 
minutes. This process was repeated three times for a range of flow 
rates and the average output at each flow rate was calculated. The 
necessary flow rate was determined to give an output of 0.13mllmin. 
The calibration process was repeated at one monthly intervals by the 
same individuals. 
The calibration for the study varied between 4 and 6 Umin. 
3.3.2 - Safety procedures during methacholine challenge: 
As inhaled methacholine is a bronchoconstrictor the process of 
methacholine challenge was carried out in a careful safety first manner. 
Resuscitation equipment and nebulised salbutamol were readily 
available and a doctor nearby at all times. 
3.4 - Sputum Induction: 
The following protocol was used to obtain sputum from patients: 
1. Measure baseline FEV 1 on three occasions. 
2. Give 200 micrograms of salbutamol by MOl (Metered Dose 
Inhaler) and Volumatic® spacer. 
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3. After 20 minutes, measure post bronchodilator FEV1 three times. 
Use the best bronchodilator FEV 1 value to calculate any 
subsequent fall in FEV1 during the procedure. 
NB: Do not proceed if the FEV 1 after inhalation of the short -
acting 132 agonist is less than one litre. 
4. Fill the nebuliser cup with 5ml of 3% pyrogen-free hypertonic 
saline. 
5. Hold the nebuliser upright and do not adjust from the default 
maximum output setting. Ask the patient to breathe tidally, whilst 
taking a slightly deeper breath every minute. Do not use a nose 
clip. Discontinue the procedure if significant symptoms occur or if 
the patient experiences undue discomfort. Use of the Borg 
breathlessness scale allows patients to quantify any symptoms 
they may be experiencing. A discard vessel should always be 
available for the patient to spit out any excessive saliva 
generated during the induction. 
6. After five minutes, ask the patient to rinse their mouth and throat 
with water and blow their nose in order to reduce squamous cell 
contamination and post-nasal drip. 
7. Ask the patient to cough any sputum into a plastic sputum pot 
using a deep cough. Several attempts at coughing should be 
made until the sound of the cough becomes dry and 
unproductive. 
8. Measure FEV1 (three measurements will be made). 
Page 133 of 260 
9. Repeat the above steps on two further occasions with 4% and 
5% pyrogen-free hypertonic saline, respectively, if the FEV1 has 
not fallen by more than 10% or 200ml (whichever is greater) of 
the best post-bronchodilator FEV1 value. If the FEV1 falls by 
more than 10% or 200ml (whichever is greater) but less than 
20% of 400ml (whichever is greater), repeat the steps for the 
same concentration of saline. Patients should not breathe saline 
for more than 15 minutes in total. 
If the FEV 1 falls by more than 20% or 400ml (whichever is 
greater) of the best post-bronchodilator value, or if significant 
symptoms occur, stop nebulisation and administer repeat short-
acting ~ 2 2 agonist. 
10. At the end of any nebulisation 200 micrograms of salbutamol 
was administered via a Volumatic@ spacer. FEV1 is reassessed 
to ensure return to baseline in the case of a fall. 
The same sputum induction nebuliser was used throughout the study 
(NE-U17, Omeron Healthcare™, Milton Keynes, UK). 
3.4.1 - Sputum induction instruction for patients: 
Prior to commencing the induction the procedure is fully explained to 
the patient with the emphasis of the following: 
Instruction on spitting out saliva generated during the inhalation of 
saline into a "discard" vessel. 
Instruction about blowing their nose, rinsing their mouth and swallowing 
the water prior to trying to expectorate sputum. 
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Instruction on how to expectorate effectively. It is necessary to 
demonstrate the technique for coughing up sputum and moving the 
sputum from the back of the throat, forward to the specimen container. 
A reminder not to swallow sputum as it comes up the bronchial tree. 
Guidance on posture: sitting straight upright during nebulisation, and 
leaning forward during expectoration. 
3.4.2 - Calibration for sputum induction: 
The manufacturer performed the initial calibration of the mass median 
diameter and the output. Subsequent calibration checks of the nebuliser 
output were performed by a qualified lung function technician using the 
following protocol: 5ml of 3% hypertonic saline was placed into the 
nebuliser at room temperature. The nebuliser was then weighed and 
the solution nebulised for five minutes. The nebuliser was then 
reweighed and emptied. The process was repeated three times for a 
range of flows and the average output was calculated. The same 
individual repeated the calibration at monthly intervals. 
3.4.3 - Safety procedures during sputum induction: 
As inhaled hypertonic saline is a bronchoconstrictor the process of 
sputum induction was carried out in a careful safety first manner. 
Resuscitation equipment and nebulised salbutamol were readily 
available and a doctor nearby at all times. 
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3.5 - Protocol for sputum processing: 
The following protocol was used to process and count the sputum 
samples. 
Sputum is collected in a sputum sample pot, stored on ice and 
processed at 4°C within two hours of expectoration. 
Select sputum plugs from saliva and transfer to a Petri dish. Transfer 
sputum free from salivary contamination into an empty (pre-weighed) 
polypropylene centrifuge tube (opaque) with a screw top. 
Subtract the weight of the empty centrifuge tube from the weight of the 
centrifuge tube plus sputum to obtain the weight of the sputum portion 
to be processed. 
Add dithiothrietol (DDT) freshly diluted to 0.1 % (from a stock solution of 
1%) using phosphate buffered saline (PBS) using 4 times 
weight/volume (e.g. 4 ml DTT per gram of selected sputum). 
Disperse the sputum by repeated gentle aspiration into a plastic pipette, 
15 seconds vortex and 15 minutes rocking on a bench rocker on ice. 
Add an equal volume of Dulbecco's phosphate buffered saline (D-PBS). 
Vortex for a further 15 seconds, filter the sputum suspension through a 
48mm nylon gauze pre-wet flat with D-PBS, shake off excess and 
centrifuge at 200rpm (790g) for ten minutes. 
Aliquot all of the supernatant in O.Sml portions into 2ml microtubes, 
leaving behind a covering of fluid and the undisturbed pellet. There 
should be sufficient supernatant for 2-4 microtubes of supernatant. 
Resuspend the cell pellet in O.Sml to 1.0ml of D-PBS (depending on the 
size of the cell pellet) and mix gently with a wide bore plastiC pipette. 
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Assess the total cell count and cell viability using a Neubauer™ 
haemocytometer and the trypan blue exclusion method: 
Flood haemocytometer with 10microlitres of cell suspension mixed 
thoroughly with 0.4% trypan blue. 
Count all cells in the centre square and the four 1 mm corner squares of 
chamber one of the haemocytometer. Cells should be classified as 
viable, non-viable and squamous. 
Calculate the mean number of cells per square and the portion of viable 
and squamous cells. 
Calculate the total number of cells and the total cell count (cells/ml 
sputum). 
Total number of cells = mean number of cells/square x 2 x 10,000 x 
volume of cells resuspended in (ml). 
Total cell count (cells/g sputum) = mean number of cells/square x 2 x 
10,000 x volume of cells resuspended in (ml) I weight of selected 
sputum (g). 
Adjust the cell suspension to 0.5-0.75 x 106 cells/ml with D-PBS. 
Use 50microlitres to prepare two cytospins and centrifuge at 450rpm 
(18.1 g) for six minutes using a Shandon III cytocentrifuge TM. 
Air dry four slides for at least 15 minutes at room temperature, then fix 
with methanol for ten minutes. 
Perform a 400 cell count (non-squamous cells) differentiating between 
eosinophils, neutrophils, macrophages, epithelial cells and lymphocytes. 
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The cell counts were all performed by trained laboratory scientists and a 
number of the slides were sent for quality control assessment to 
determine they were accurate and consistent. 
3.5.1 - Cell counting: Romanowski stain preparation: 
1.5g Azure-B-thiocyanate in DMSO was dissolved at 370 e and 0.5g 
Eosin was dissolved in 300ml methanol at room temperature. The 
Azure blue solution was slowly added to the Eosin and stored away 
from light. 
Dilute Romanowski stain: 
62ml 10mM HEPES buffer pH 7.2 
3.5ml DMSO 
4.6ml Romanowski stain 
3.5.2 - Cell counting: Differential cell counts: 
A sputum differential cell count was obtained by counting >400 non-
squamous cells on a Romanowski stained cytospin. Cell counts were 
performed by trained laboratory scientists and a number of the slides 
were sent for quality control assessment to determine they were 
accurate and consistent. 
3.6 - Exhaled nitric oxide: 
Exhaled nitric oxide concentration was measured using an online 
chemiluminescence analyser (NIOX FlexFlow®; Aerocrine™, Tolna, 
Sweden). Air was inhaled via a scrubber to ensure nitric oxide free air, 
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up to tidal volume and then exhaled at constant pressure (>1 OcmH2D) 
to aid closure of the velopharynx. The rate of exhalation was set by a 
standard valve at five different flow rates (10, 30, 50,1 00,200ml/sec) 
and controlled by means of visual feedback. The exhaled nitric oxide 
concentration was recorded as the mean of three recordings of the 
plateau phase. The analyser was calibrated twice weekly against a 
standard gas containing 200ppb of nitric oxide, according to the 
manufacturer's instructions. 
The same machine was used throughout the study. 
Participants were blinded to their FeND values. 
Exhaled nitric oxide was the first clinical test to be performed at every 
visit. 
3.7 - Juniper asthma control questionnaire: 
The Juniper Asthma Control Questionnaire (ACQ) was used to assess 
asthma control. This is a validated questionnaire which was designed in 
consultations with 100 international experts. Each symptom was scored 
for its importance in evaluating asthma control. From the 91 responses, 
the five highest scoring symptoms were selected for the ACQ. In 
addition, one question on short-acting P2 agonist use and one on airway 
calibre were added. The ACQ was tested in a 9-week observational 
study of 50 adults with symptomatic asthma. The ACQ and other 
measures of asthma health status were assessed at baseline, 1,5 and 9 
weeks. In patients whose asthma was stable between clinic visits, 
reliability of the ACQ was high (intraclass correlation coefficient 
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(ICC)=O.90). The questionnaire was very responsive to change in 
asthma control (p<O.0001). Cross-sectional and longitudinal validity 
were supported by correlations between the ACO and other measures 
of asthma health status (84). The questionnaire is self-completed by the 
patient with the exception of question 7 which is completed by the 
researcher. 
See appendix section 3 for copy of the ACQ. 
3.8 - Blood tests: 
Venepuncture was performed to obtain venous blood samples using 
standard NHS protocol. 
5ml of blood was collected in a serum-separating tube (SST" Gold-top 
V a c u t a i n e r ~ ~ to determine serum IgE level using the Phadia-100 
ImmunoCapTM Automated Clinical Chemistry System. 
4ml of blood was collected in an EDTA tube (Lavender-top V a c u t a i n e r ~ ~
to determine full blood count and white cell differential cell counts using 
the Sysmex XE-21 OOTM Automated Haematology System. 
The blood samples were all processed by the NHS pathology 
laboratories at Nottingham City Hospital and Leicester Glenfield 
Hospital. 
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Chapter 4 - Using exhaled nitric oxide to step-down 
inhaled corticosteroid therapy in patients with mild to 
moderate asthma in UK primary care. 
Introduction: 
Inhaled corticosteroids (ICS) are one of the mainstays of treatment in 
asthma and act to reduce airway inflammation. Although generally 
regarded as safe, inhaled corticosteroids are associated with side 
effects including adrenal suppression, bone loss, skin thinning, 
increased cataract formation, metabolic changes and decreased linear 
growth in children (279, 280). 
Although ICS target airway inflammation in asthma, guidelines 
recommend increasing or decreasing ICS dose based on the 
assessment of symptoms (281, 282). Once asthma symptoms and 
exacerbations are controlled, ICS dose reduction is recommended and 
safe (283), but is often not implemented leaving some patients over-
treated (282). There are few studies investigating the most appropriate 
way to reduce ICS dose. A study in adults receiving at least 900 
micrograms per day of ICS found that for patients who are stable it is 
reasonable to halve the dose of ICS every 3 months (258) and this 
study forms the basis for the recommendation in the current British 
Thoracic Society (BTS) and Scottish Intercollegiate Group Network 
(SIGN) guideline (282). 
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Given the poor relationship between symptoms (17), or spirometry 
(284), and airway inflammation in asthma, other strategies using the 
measurement of airway inflammation to increase or decrease steroid 
treatment in asthma have been assessed. The differential induced 
sputum eosinophil count has been successfully used to guide steroid 
therapy and reduce exacerbations (39, 54) in patients with moderate to 
severe asthma, however induced sputum is time consuming, requires 
expertise and is less suited for near patient testing in primary care. 
FeNO (the fraction of nitric oxide in the exhaled breath) is attractive as a 
non-invasive marker of airway inflammation in asthma. The test is 
relatively inexpensive, provides a rapid result, can be used for near 
patient testing and correlates with the degree of eosinophilic airway 
inflammation (69, 269), Although a study has recently been published 
demonstrating that FeNO measurements can be used to up and down 
titrate les dose in pregnant women with asthma (285), and the ATS 
(American Thoracic Society) guidelines currently recommend the use of 
FeNO as a non-invasive biomarker in patients with asthma to provide 
additional clinical information (252), its use is controversial. Other 
studies utilising FeNO measurements to guide treatment decisions, 
(with differing designs and outcome measures) have been less 
successful in guiding les dose (230, 236), reducing exacerbations (172) 
or improving asthma control (3, 229) when compared to routine 
management. These latter studies have been criticised for not using 
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individualised cut-points for FeNO levels, and not assessing change 
from baseline FeNO levels (243). 
Given the evidence of over-treatment from treatment prescription 
surveys (286) and clinical trials (287), and the possible reluctance of 
medical staff to reduce treatment in well-controlled patients (231), we 
set out to explore whether FeNO measurements could be used 
practically to step-down ICS dose whilst addressing some of the 
criticism levelled at previous studies of FeNO in asthma management. 
We performed a single blind cohort study in well-controlled patients with 
asthma recruited from primary care. It was designed to identify whether 
a baseline level or a change in Fe NO levels following inhaled 
corticosteroid dose reduction could be used to step-down treatment, 
and the sample size needed for a definitive randomised placebo-
controlled study. 
Methods: 
Settings and Patients: 
The study was conducted across two sites: Nottingham Respiratory 
Research Unit (Nottingham City Hospital, UK) and Leicester 
Respiratory Biomedical Research Unit (Leicester Glenfield Hospital, 
UK). 
Patients were identified with the help of the Primary Care Research 
Network (PCRN) from registers held in GP surgeries in Nottingham and 
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Leicester, UK. All patients were aged between 18 and 75 at study 
enrolment and had a diagnosis of asthma recorded in their GP medical 
notes. Patients were eligible if they had received at least one 
prescription for any inhaled corticosteroid medication in the previous 12 
months. 
The study was restricted to non-smokers with a past smoking history of 
less than 10 pack years. Patients were also excluded if they were 
considered by their GP to be poorly compliant, had experienced an 
asthma exacerbation requiring oral steroids in the previous 12 weeks, 
or if their Asthma Juniper Control Questionnaire (ACQ) (84) score at 
visit 1 was greater than 1.5 (see below for further details). 
All suitable patients on the register who responded to an invitation from 
their GP to were invited to participate in the study. Ethics approval for 
the study was given by Leicester, Rutland and Northampton REC 2 and 
Nottingham City, Nottinghamshire County, Leicester City and 
Leicestershire County Primary Care Trusts. All patients gave written 
informed consent prior to starting the study. The study was funded by a 
grant from the National Institute for Health Research (RfPB). 
Clinical tests: 
Patients were seen at visit 1 (day zero) and then at visit 2 (day 14), visit 
3 (day 21) and for a final visit 4 (at three months). Each of the visit 
appointments occurred at the same time of day and consisted of ACQ, 
FeNO and Spirometry. ICS reduction occurred after the tests at visit 2 
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had been performed. At visits 1 and 4 sputum induction and 
methacholine challenge were also performed. 
Tests were performed in the order listed in the flow diagram below 
(figure 1). Symptoms were assessed using the Juniper Asthma Control 
Questionnaire (ACQ) (score of <1.5 required to enter the study). Airway 
inflammation was measured using exhaled nitric oxide levels (F eNO) 
measured at flows of 10, 30, 50, 100, 200ml/sec, differential cell counts 
were performed on induced sputum, spirometry, airway 
hyperresponsiveness, skin prick tests, blood tests to determine blood 
differential eosinophil count (x109/L) and blood IgE (kIU/L) were 
performed. Detailed methodology for each test can be found in chapter 
3. See Figure 4.1 for further details of the study regime. 
Figure 4.1: 
Study design 
o days 14 days 19-21 days 110 days 
Baseline Step-down Follow-up 3 Month Follow-up 
Visit 1 Visit 2 Visit 3 Visit 4 GP 
advised of 
successful 
step-down 
of ICS 
ACO, I 50% ICS reduction I ACO, ACO, FeNO, medication. FeNO, I FeNO, FEV1, PC20, 
FEVlI PC20, ACO, FeNO, FEV1 Sputum Sputum, FEV1 Blood, SPT 
Study design. FeNO = fraction of exhaled nitric oxide at five flow rates; 
ACQ = Juniper Asthma Control Questionnaire; PC20 = methacholine 
challenge; Sputum = differential sputum eosinophil count; Blood = Full 
blood count, IgE, eosinophils; SPT = skin prick tests 
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Inhaled corticosteroid step-down: 
Patients were assessed at visit 2; if their ACO score remained <1.5 and 
had not increased by more than 0.5, their ICS dose was reduced by 
50%. Inhaler types were kept the same, by prescribing a smaller dose 
or halving the number of puffs. In the majority of instances we halved 
the dose of the inhaler prescribed and kept the number of puffs the 
same. However, where this was not possible (e.g. Seretide® 125) we 
halved the daily routine (number of puffs) and kept the inhaler dose the 
same (e.g. 2bd to 1 bd). Participants who were taking less than 200 
micrograms bdp equivalent daily were asked to stop their inhaled 
corticosteroids entirely. This was only applicable to participants who 
were taking inhaled corticosteroid inhalers as monotherapy. 
In the case of participants who were taking combination inhalers (e.g. 
Seretide®' Symbicort® and F o s t a i r ~ , , the inhalers were prescribed as 
two separate component inhalers (Seretide® = Flixotide® and Serevent®, 
Symbicort® = Pulmicort® and Oxis®, F o s t a i ~ ~ = Clenil Modulite® and 
Atimos M o d u l i t e ~ . .
The dose of long-acting ~ 2 2 agonist (LABA) was kept the same in all 
participants who were taking them. All participants were told to use their 
short-acting ~ 2 2 agonist (SABA) whenever they required it. 
A 50% reduction in ICS dose was chosen to reflect the BTS/SIGN and 
GINA guidelines, both of which recommend a 50% step-down in 
patients with asthma after three months of good symptom control (288). 
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Patients were asked to take the half dose of ICS for seven days and 
then return for visit 3. When patients returned for visit 3 their ACO score 
was re-measured. If the score had not increased by >0.5 or above 1.5 
and they had not experienced an exacerbation (see definition below) 
they were entered into the final phase of the study, which saw patients 
remain on their half dose inhaled corticosteroid for a period of three 
months until visit 4. 
Safety measures, loss-of-control and exacerbation: 
Patients were given a detailed safety card explaining what to do in the 
event of worsening of their symptoms. All patients who contacted the 
emergency team were assessed by a physician within 24 hours and 
their ACO score was recorded. A physician (blinded to the study data) 
made a decision on how to treat each based on the BTS guidelines. 
Every patient who contacted the emergency team with a worsening of 
their symptoms had their ICS dose increased back to its original level. 
A loss of control was defined as an increase in symptoms with an 
increase in ACO score of greater than 0.5. An exacerbation was defined 
as an episode of increasing asthma symptoms requiring a course of 
antibiotics or oral steroids (17, 172). 
Analysis: 
Power calculation: 
Based on findings from the FACET (17) and from a previous study 
looking at the role of FeNO in asthma we estimated that we needed 154 
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patients to give 80% power to show that a low Fe NO, or persistently low 
FeNO could successfully predict stable control and lack of asthma 
exacerbation following a reduction in inhaled corticosteroid dose. Our 
power calculation was based on the assumption that within the patients 
with a persistently low FeNO (less than 2Sppb at SOml/sec flow rate), 
10% would have a loss of control or exacerbation, compared to 30% in 
the high FeNO group. To counter an expected 10% drop out rate we 
aimed to recruit 200 patients into the study. 
Statistical analyses: 
Predictors of loss of control and exacerbation were sought using 
multiple logistic regression. Correlations were measured using Pearson 
correlation coefficient or Spearman rank correlation. FeNO and PC20 
were log transformed to normality and analysed as geometric means 
with 95% confidence intervals. Pack years, ICS dose, blood IgE, blood 
eosinophils, ACO questionnaire, differential sputum eosinophil and 
sputum neutrophil count were all presented as median and lOR non-
normal data. All analyses were performed using STATA 11. 
In order to assess whether Fe NO measurements could predict which 
patients would remain stable following a SO% reduction in their ICS 
dose from those who would deteriorate (either suffer a loss of control or 
exacerbation) we analysed the data in two ways. Firstly we assessed 
whether a low baseline FeNO could predict successful dose reduction; 
then we evaluated whether change in FeNO could predict a successful 
dose reduction. We assessed whether a change in measurements of 
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FeNO between visit 2 (step-down visit) and visit 3 (7 days post step-
down) could distinguish between those patients who could or could not 
tolerate a 50% ICS dose reduction as defined by a loss of control or 
exacerbation. 
Next we evaluated whether any clinical measures could predict stability. 
We assessed whether other baseline clinical measurements of 
spirometry, methacholine PC2o, blood IgE, blood eosinophil count, ACO 
score, differential sputum eosinophil or sputum neutrophil count could 
distinguish between those patients who could or could not tolerate a 
50% ICS dose reduction at three months. 
We assessed whether a change in spirometry between visit 2 (lCS dose 
reduction) and visit 3 (7 days post ICS reduction) could distinguish 
between those patients who would or would not tolerate a 50% ICS 
dose reduction at three months. 
Lastly we carried out a reanalysis in a pre-specified sub group 
examining the stable, loss of control and exacerbation groups 
separately. 
A p-value of SO.05 was regarded as statistical significance. 
Results: 
A total of 5068 patients with a primary care diagnosis of asthma were 
contacted in writing by their GP to ask if they were interested in 
participating in the study. Of these, 3266 declined screening or failed to 
respond. 350 patients were recruited into the study for a screening 
baseline visit (visit 1), and 200 were entered into the study across the 
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two sites between September 2010 and December 2011. During the 
study 9 patients were not able to complete the study. 191 patients 
completed the study with a complete data set (Figure 4.2). 
There were a total of 128/191 (67%) patients who completed the three 
month study period (post ICS reduction) with no loss of control or 
exacerbation. 63/191 (33%) patients suffered from either a loss of 
control (32 = 17%) or an exacerbation (31 =16%) within the three month 
period following ICS dose reduction. The median and lOR baseline 
(visit 1) ACO was 0.6 (0.2-1 .0) for the stable group and 0.8 (0.2-1.0) for 
the deterioration group (p=0.53). 
Additional graphs for results presented below can be found in appendix 
section 12. 
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Figure 4.2: 
Study consort diagram 
5068 patients with asthma 
contacted via GP registers 
350 patients initially screened for 
the study 
200 patients entered into the study 
191 patients completed the study 
3266 declined 
screening or failed to 
respond 
150 patients failed 
screening due to high 
initial ACO score or 
significant co-
morbidity 
Patients unable to 
complete: 
1 moved away from 
area 
2 dropped out 
1 changed mind 
4 differential 
diagnoses 
1 time constraints 
128 patients 
completed 
step-down 
32 patients 
suffered a loss 
of control 
32 patients 
suffered an 
exacerbation 
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Table 4.1: 
Baseline demographics presented for study population (n=191). 
Data are presented as: • Mean and standard deviation, t Median and 
Interquartile range, * Geometric Mean and 95% confidence intervals. 
VARIABLE RESULT 
Age 
, 
54.15 ± 13.50 
Gender 
Male 83 (43.5%) 
Female 108 (56.5%) 
When Diagnosed 
0-5 Years 16 (8.4%) 
>5 Years 175 (91.6%) 
BTS Stage 
2 57 {29.84%} 
3 111 (58.12%) 
4 23 (12.04%) 
Pack Yearst 0(0-4) 
Height (cm)' 169.24 ±9.89 
Weight (kg)' 81.14±17.31 
BMI (kg/m2)' 28.27 ±5.36 
BOP Equivalent Daily Dose (mcg/day)t 400 {200-1 OOO} 
FEV1(l)' 2.68 ± 0.85 
FEV1 % predicted (%)' 89.85 ±19.15 
FVC (l)' 3.65 ± 1.00 
FVC % predicted (%)' 99.81 ±16.87 
Airway hyperresponsiveness (PC20)* 8.02 (95%CI 6.31-10.17) 
Blood loE (kIU/L)t 91.5 (28.50 - 253.50) 
Blood Eosinophils (X109/l)t 0.20 (0.12-0.32) 
Sputum Eosinophils (%)t 0.80 (0.25-4.75) 
Sputum Neutrophils (%)t 64.75 (42.25-84.00) 
ACQ Questionnaire 1-St 0.60 {0.20-1.00} 
BMI = Body Mass Index 
ACO = Juniper Asthma Control Ouestionnaire. 
BOP Equivalent = Beclomethasone Oipropionate Equivalent 
(OVAR = 2: 1 BOP, Fluticasone = 2:1 BOP, Budesonide = 1:1BOP) 
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Baseline FeNO: 
There were no significant differences in the baseline (visit 1) FeNO 
between the patients who could successfully reduce their ICS dose 
(stable group) compared to those who suffered from a loss of control or 
exacerbation (deterioration group), at any of the five Fe NO flows. At a 
flow of 50ml/sec the stable group had a mean FENo of 18.9ppb (95% CI 
16.8-21.5) and the deterioration group a mean of 19.7ppb (95% CI 
16.4-23.6ppb), (p=0.76). 
Table 4.2 shows the baseline Fe NO for these two groups of patients for 
the other flows studied. 
Table 4.2: 
The difference in baseline Fe NO for successful step-down patients 
versus exacerbation and loss of control patients for all of the NIOX 
FlexFlow® flow rates. 
Exhaled Nitric Stable GrouR: Deterioration Significance 
Oxide {n=128 {67.0%}} GrouR: level: 
Characteristic {n=63 {33.0%}} {T-test} 
FeNO 10ml/sec 59.7 (46.1-77.51 73.7154.1-102.5) p=0.34 
n=43 n=22 
FeNO 30ml/sec 26.6 (23.1-30.9) 32.1 (25.8-40.41 p=0.13 
n=91 n=43 
FeNO SOml/sec 18.9 (16.8-21.51 19.7116.4-23.6) p=0.76 
n=128 n=62 
FeNO 100ml/sec 11.4 (9.9-13.1) 11.5 (9.7-14.01 p=0.95 
n=111 n=53 
6.8 (5.9-7.8) 7.5 (6.4-8.9) 
FeNO 200ml/sec n=108 n=50 p=0.31 
n=101 n=47 
t Data calculated as Geometric Mean with 95% confidence mtervals. 
Presented as anti-log Geometric means and 95% confidence intervals. 
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Change in FeNO: 
There were no significant differences in the change in FeNO (visit 2 to 
visit 3) between stable group and deterioration group, at any of the five 
FeND exhalation rates. The mean absolute change between visit 2 and 
3 was 1.58 ± 11.9ppb for the stable group and 1.03 ± 14.88ppb for the 
deterioration group (p=0.80). In terms of percentage change in FeNO 
values at 50ml/sec the changes were 17.60 ± 69.97% for the stable 
group and 11.01 ± 41.05%, (p=0.54) 
Table 4.3: 
Change in FeND between these two groups of patients for the other 
flow-rates studied. 
Change in FeNO between visit Stable G r o u ~ : : Deterioration Significance 
2 and visit 3 G r o u ~ : : level: 
{T-test} 
10ml/sec flow rate profile n=42 n=16 
Absolute Change in FeNO_(ppbl 5.63 ± 58.24 5.47 ± 54.87 p=0.99 
Percentage Change in FeND (%) 22.31 ± 107.99 6.91 ± 51.46 p=0.59 
Fold Change in FeND 1.22 ± 1.08 1.07 ± 0.51 p=0.59 
30ml/sec flow rate profile n=81 n=33 
Absolute Change in FeND (ppb) 0.06 ± 19.82 0.87 ±25.58 p=0.86 
Percentage Change in FeNO (%) 12.85 ± 66.88 13.39 ± 49.39 p=0.97 
Fold Change in FeND 1.13 ± 0.67 1.13 ± 0.49 p=0.97 
SOml/sec flow rate profile n=124 n=49 
Absolute Change in FeNO (ppb) 1.58 ± 11.9 1.03 ± 14.88 p=0.80 
Percentage Change in FeNO (%) 17.60 ± 69.97 11.01 ± 41.05 p=0.54 
Fold Change in FeNO 1.18±0.70 1.11 ± 0.41 p=0.54 
1 OOml/sec flow rate profile n=103 n=42 
Absolute Change in FeNO (ppb) 0.72 ± 7.42 0.63 ± 8.98 p=0.95 
Percentage Change in FeND (%) 14.38 ± 76.24 11.41 ± 42.80 p=0.81 
Fold Change in FeND 1.14 ± 0.76 1.11 ± 0.43 p=0.81 
200ml/sec flow rate profile n=102 n=42 
Absolute Change in FeNO (ppb) 0.46 ± 4.09 0.35 ± 6.15 p=0.90 
Percentage Change in FeND (%) 13.31 ± 58.79 9.90 ± 52.42 p=0.74 
Fold Change in FeND 1.13 ± 0.59 1.10 ± 0.52 p=0.74 
Data is presented as Mean and Standard Deviation 
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Baseline clinical measurements: 
There were no statistically significant differences in the baseline clinical 
measurements between the patients who could successfully reduce 
their ICS dose (stable group) compared to those who suffered from a 
loss of control or exacerbation (deterioration group). 
Table 4.4: 
Differences in these baseline clinical measurements between the two 
groups studied. 
Baseline Stable Groul2: Deterioration Significance 
Demogral2hic {n=128 {67.0%}} Groul2: level: 
Characteristic {n=63 {33.0%}} {T-test}t 
(Kruskall-
Wallis tesU# 
FEV1 (L) 2.71 ± 0.89 2.61 ± 0.79 p=0.49t 
FEV 1 percent 91.0 ± 19.3 87.5 ± 18.7 p=0.23t predicted (%) 
FVC (L) 3.67 ± 1.03 3.62 ± 0.95 p=0.74t 
FVC percent 100.2 ± 17.3 98.9 ± 16.0 p=0.62t predicted (%) 
FEV1/FVC Ratio (%) 0.72 ± 0.09 0.72 ± 0.10 p=0.21t 
AHR (PC20) doubling 3.14 ± 2.21 2.74 ± 2.49 p=0.28t doses 
Blood IgE * 93.5 (26.0-222.5) 72.9 (30.8-269.0) p=0.66# 
Blood Eosinophils * 0.20 (0.10-0.32) 0.2 (0.14-0.39) p=0.64# 
JAC Questionnaire 0.60 (0.20-1.00) 0.80 (0.20-1.00) p=0.53# 1-5 Score* 
Sputum Eosinophils 0.78 (0.25-4.63) 0.50 (0.00-4.25) p=0.62# (%) * 
Sputum Neutrophils 65.88 (41.38-84.38) 58.00 (46.00-83.00) p=0.51# (%) * 
.. Differences m baselme clinical measurements between the two groups 
studied. Data is presented as mean and standard deviation except 
where variable is marked * here the data is presented as median and 
interquartile range. 
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Change in spirometry: 
There was no significant difference in spirometry between visit 2 and 
visit 3 between the stable group and deterioration group. 
Sub group analysis: 
We split the deterioration group into patients with loss of control (n=32) 
or patients with an exacerbation (n=31). There was no significant 
difference in any of the measurements, at any of the flows for FeND 
either at baseline or between visit 2 and visit 3. 
Table 4.5: 
Difference in baseline FeND for successful step-down patients versus 
exacerbation patients versus loss of control patients for all of the NIDX® 
FlexFlow flow rates. 
Exhaled Nitric Stable Groul2: Exacerbation Loss of Sig level: 
Oxide (n=128 Groue: {n=31 control ANOVA 
Characteristic {67.0%}} {16.0%}} groue: {n=32 {F-test} 
{17.0%1l 
FeNO 10ml/sec 59.7 73.7 73.7 (46.1-77.5) {45.2-126.51 (46.5-122.7) p=0.64 t n=43 n=10 n=12 
FeNO 30ml/sec 26.6 32.5 31.8 (23.1-30.9) 122.0-49.91 {24.3-42.5) p=0.31 t n=91 n=19 n=24 
FeNO 50ml/sec 18.9 19.9 19.0 (16.8-21.5) 115.6-26.31 {15.0-25.0) p=0.92 t n=128 n=31 n=31 
FeNO 100ml/sec 11.4 12.3 10.8 (9.9-13.1) (9.4-16.9) (8.6-14.21 p=0.74 t n=111 n=25 n=28 
FeNO 200ml/sec 6.8 8.0 7.1 J5.9-7.8) (6.2-10.7) 15.8-8.91 p=0.45 t n=108 n=24 n=26 
t Data calculated as Geometric Mean with 95% confidence mterva/s. 
Presented as anti-log Geometric means and 95% confidence intervals. 
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Conclusion: 
We set out to evaluate the use of FENo to guide asthma management in 
primary care, a setting where the technique likely to be particularly 
applicable and where the majority of patients with asthma are managed. 
As there is evidence that clinicians are reluctant to sanction treatment 
reductions (287) we set out to establish whether FENO measurements, 
or other clinical indices, could inform medical professionals and patients 
about timing of ICS dose reduction. We also set out to address 
criticisms of previous studies by attempting to define individualised cut 
points for FENo measurements and by assessing change in baseline 
values. 
We found that neither baseline FENo measurements, nor change at 7 
days following ICS dose reduction, could delineate between stability or 
deterioration in asthma control at 3 months. Our study does confirm 
previous observations (258) that les dose reduction is safe in the 
majority of patients with mild to moderate asthma when well controlled. 
Recruitment for our study was not difficult suggesting that dose 
reduction does not occur despite the recommendations in the asthma 
guidelines and that patients think this is an important topic (see 
appendix section 2 for patient feedback). 
In order for our study to have practical benefits for the future 
management of asthma we used a dose reduction period of 7 days 
between the two FENO measurements. Dose-dependent onset and 
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cessation of action of ICS on FENo levels in patients with mild asthma 
has been demonstrated, with levels rising after one day of treatment 
reduction (289). Moreover if reassessment was left for a longer time 
period it would defeat the object of using FENo, or any other clinical 
measure, to predict dose reduction. Compliance may have improved 
between visit 1 and 2, however there was no significant decrease in 
FENo, or improvement in other clinical measurements, suggesting 
compliance was not an issue. 
We also considered the percentage ICS dose reduction needed to lead 
to an increase in FENo levels. The relationship between sputum 
eosinophilia and FENo levels is strongest between 100-800mcg of ICS 
(BOP) equivalent (245) and most of our patients fell within this range. 
Moreover previous studies have shown that only a small reduction in 
ICS dose is required to observe an increase in FENo levels (243) with 
one study demonstrating a significant increase with a dose reduction of 
200mcg BOP equivalent (290), less than the mean reduction in our 
study. A 50% reduction of ICS dose was also the level at which the 
ethics committee were happiest. 
Our study is the first to investigate whether FENo measurements can be 
used practically to guide ICS dose reduction in an unselected 
population of patients with asthma, and is the first to investigate 
different FENo flows in treatment decisions. There is uncertainty as to 
the use of the different flows rates of FENo measurements in asthma, 
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with lower flows thought to be associated with bronchial rather than 
alveolar inflammation (291). Our study shows there are no differences 
in the results of the different flow rates in predicting successful step-
down. None of the baseline clinical indices measured (baseline AGO, 
spirometry, blood eosinophil count, differential sputum eosinophil count, 
blood IgE, methacholine challenge) could delineate between future 
stability or deterioration in asthma control. This applied even if the 
patients who deteriorated were divided into patients with loss of control 
or exacerbation (24). This has important implications for IGS dose 
reduction and suggests better methods of identification of at risk 
patients are needed. 
The study was deSigned as a pilot study to assess the feasibility of 
recruitment into a dose reduction randomised controlled trial and to 
evaluate FENo cut-points for this trial, consequently our study did not 
require a placebo controlled arm (or a non-dose reduction arm). We 
saw no increase in FENo following IGS withdrawal. Moreover previous 
evidence suggests (258) that the proportion who deteriorated following 
ICS reduction would not have differed from the proportion who would 
have deteriorated with no reduction. Taken together these findings 
suggest that our ICS reduction was not aggressive enough for our 
biomarker to become predictive and that a more aggressive step down 
in ICS dose is safe and needs to be studied in order to fully evaluate the 
added value of FENo in asthma management. 
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Chapter 5 - Additional analyses: 
As part of the main clinical trial a selection of pre-specified additional 
analyses were performed to address aims 2-5 in chapter 2. 
5.1 : 
The correlation between airway inflammation and asthma 
symptoms 
5.2: 
The correlation between eosinophilic airway inflammation and 
exhaled nitric oxide in asthma 
5.3 
The relationship between clinical diagnostic tests and exhaled 
nitric oxide in asthma 
5.4 
The relationship between elevated exhaled nitric oxide and 
eosinophilic inflammation in mixed granulocytic asthma 
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5.1 - The correlation between airway inflammation and asthma 
symptoms: 
Hypothesis: 
Asthma symptoms (as measured by the Juniper Asthma Control 
Questionnaire) reflect airway inflammation in patients with mild to 
moderate asthma. 
Introduction: 
Asthma diagnosis and management in UK primary care is largely based 
upon the assessment of symptoms and occasionally lung function 
(usually peak flow or spirometry). Primary care centres rarely have 
access to tests which measure airway inflammation without referring 
patients into secondary care or research. When patients suffer with 
deteriorating symptoms, asthma medications are typically stepped-up 
(2). Similarly, the BTS guidelines recommend that once a patient has 
experienced three months of good symptom control their medication be 
reduced to ensure optimum control on the lowest possible medication 
doses (2). However, these decisions are based upon symptoms and 
lung function, but there is little evidence to suggest that symptom 
scores accurately reflect the presence or absence of airway 
inflammation. Despite the fact that the guidelines define control as 
"absence of symptoms", many patients will be asymptomatic but still 
have evidence of airway inflammation (2). If airway inflammation is left 
untreated it can ultimately lead to airway remodelling and permanent 
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damage to the airways. Conversely, there are also patients who suffer 
from severe symptoms but have no evidence of airway inflammation. 
These patients may be taking inhaled corticosteroid medication 
unnecessarily, exposing these people to side effects and prescription 
costs which may be avoided. 
Methods: 
The same methodology was used as is previously detailed in chapters 3 
and 4. 
Analysis: 
8T AT A 11 was used to analyse the data. Non-normal data were 
corrected using natural logs where possible. Pearson correlation was 
used to assess the correlations between symptom scores and 
measures of lung function and airway inflammation. A p value of SO.05 
was regarded as statistical significance. 
Results: 
The baseline variables for the participants studied were all within the 
normal clinical range (Table 5.1). 
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Table 5.1: 
Baseline variables for participants studied in a correlation between 
airway inflammation and asthma symptoms. 
Clinical Variable Mean Baseline Score (n=191) 
ACO 1-5 Score* 0.70 (0.63 - 0.78) 
ACO 1-6 Score* 0.64 (0.58 - 0.72) 
ACO 1-7 Score* 0.72 (0.65 - 0.80) 
Blood Eosinophils (mmoIlL)* 0.23 (0.21 - 0.25) 
Sputum Eosinophils (%)* 1.95 (1.14 - 2.71) 
Exhaled Nitric Oxide (ppb)* 20.79 (18.98 - 22.89) 
FEV1 % Predictedt 89.85 ± 19.15 
o,Data presented as Geometric Mean (95% confidence intervals) 
tData presented as mean and standard deviation 
Table 5.2: 
Pearson Correlation Coefficient table to show relationships between 
ACQ score, lung function and airway inflammation. 
ACQ1-5 ACQ 1-6 ACQ 1-7 
R P R P R P 
Coefficient Value Coefficient Value Coefficient Value 
Blood 
Eosinophils 
(mmoVL)* 0.1636 0.0600 0.1444 0.0843 0.1444 0.0731 
Sputum 
Eosinophils 
(%)* 0.2168 0.3028 0.0823 0.4982 0.1034 0.3707 
Exhaled 
Nitric Oxide 
- < p ~ b ) * * 0.0683 0.4060 0.0326 0.6858 0.1358 0.0972 
FEV1 % 
Predicted -0.0505 0.5382 -0.0730 0.3639 -0.4811 0.0000 
* Data calculated as log(variables) 
.. There are no significant correlations between ACQ symptom scores 
and measures of airway inflammation. 
See appendix section 10 for further detailed graphs of these 
correlations. 
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Discussion: 
The study required all participants to have an ACQ score of less than 
1.5 in order to be included. This is reflected in the normal mean 
baseline figures in Table 5.1. 
Table 5.2 shows the correlations between symptom scores and 
measures of airway inflammation. There were no significant correlations 
between log10 symptom score and log10 sputum eosinophil count, 
log10 blood eosinophil count and log1 0 exhaled nitric oxide (50ml/sec). 
There was also no correlation between symptom score and FEV 1 
percent predicted (with the exception of ACQ1-7, but this is expected as 
this form of the ACQ takes FEV1 percent predicted into account). 
This shows that asthma symptom scores alone do not accurately reflect 
the underlying inflammatory disease processes in patients with mild to 
moderate asthma. 
This is important data as GPs make many treatment decisions in 
primary care based solely on the presence or absence of symptoms 
due to a lack of clinical assessment tools available in this setting. This 
can lead to patients being over-treated or mis-treated with inhaled 
corticosteroids when they present with symptoms (but may have no 
evidence of airway inflammation) thus subjecting these patients to 
unnecessary side effects and medication costs. Conversely, there are 
patients who have no symptoms but do not have evidence of airway 
inflammation. Leaving these patients untreated because they are 
asymptomatic may cause airway remodelling and long-term smooth 
muscle and airway damage. This analysis corroborates previous 
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research which highlights the disparities between symptoms and airway 
inflammation. 
Conclusion: 
Inhaled corticosteroids are used to treat airway inflammation in asthma. 
Guidelines recommend that patients whose symptoms are poorly 
controlled have their ICS medication increased and conversely patients 
who demonstrate three months of good symptom control should attempt 
to decrease their ICS dose (2). However we have shown that symptom 
scores do not accurately reflect the levels of underlying airway 
inflammation and therefore cannot be used alone to accurately guide 
management decisions involving anti-inflammatory medications. 
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5.2 - The correlation between eosinophilic airway inflammation and 
exhaled nitric oxide in asthma: 
Hypothesis: 
Exhaled nitric oxide reflects airway inflammation in mild to moderate 
asthma. 
Introduction: 
Exhaled nitric oxide is known to reflect eosinophilic airway inflammation 
in moderate to severe asthma (292). Less is known about the 
relationship between exhaled nitric oxide and other markers of airway 
inflammation and airway dysfunction in patients with a primary care 
diagnosis of mild to moderate asthma. 
Decisions regarding inhaled corticosteroid treatment regimes are largely 
based upon the presence or absence of asthma symptoms. However in 
Chapter 5.1 the results showed that there is no correlation between 
asthma symptoms and airway inflammation in patients with mild to 
moderate asthma. Current tests to assess airway inflammation which 
are available in secondary care and research settings (such as sputum 
induction) are too expensive, time consuming and specialised to 
perform in primary care centres. 
Exhaled nitric oxide is understood to be a non-invasive surrogate 
biomarker of airway inflammation, it also has added benefits in that it is 
portable, cost effective and quick. Therefore a suitable test to use in 
primary care. This is important as in the UK up to 80% of asthma is 
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managed purely in primary care and mild asthma may represent a 
different rather than simply "less severe" phenotype of asthma when 
compared to the moderate to severe spectrum of the disease. There is 
debate as to the role of routine exhaled nitric oxide monitoring in mild 
asthma. 
Methods: 
The same methodology was used as is previously detailed in chapters 3 
and 4. 
Analysis: 
STAT A 11 was used to analyse the data. Non-normal data were 
corrected using natural logs where possible. Pearson correlation was 
used to assess the correlations between exhaled nitric oxide and 
measures airway inflammation. A p value of SO.05 was regarded as 
statistical significance. 
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Results: 
Table 5.3: 
Pearson's Correlation Coefficient between log10 (FeNO 50ml/sec) and 
clinical variables of airway inflammation and airway function. 
Clinical Variable R Value P Value 
ACO Score -0.0040 0.9568 
FEV 1 % Predicted -0.2278 0.0016 
FVC % Predicted -0.1018 0.1621 
FEV1/FVC Ratio (%) -0.3155 <0.0001 
Sputum Eosinop_hils(%)* 0.2283 0.0392 
Blood Eosinophils (mmoI/L)* 0.3543 <0.0001 
Blood IgE (kU/L)* 0.2643 0.0005 
PC20 (mg/ml)* -0.1248 0.0988 
*Data calculated as log values 
There was no significant correlation between baseline log10 (mean 
FeNO 50mllsec) and ACQ, FVC percent predicted and PC20• However 
there was a significant correlation between baseline log10 (mean FeNO 
50ml/sec) and FEV1 percent predicted, FEV1/FVC ratio, log10 sputum 
eosinophils, log10 blood eosinophils and log10 blood IgE. 
See appendix section 9 for further detailed graphs of these correlations. 
Discussion: 
Inhaled corticosteroid medications are used to treat airway inflammation 
in asthma. GPs currently make treatment decisions based upon the 
presence or absence of symptoms because they have limited access to 
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clinical tools which measure airway inflammation in their practices. 
However the research and the analysis performed in Chapter 5.1, 
shows there is no correlation between airway inflammation and asthma 
symptoms in patients with mild to moderate asthma. 
This corroborates previous research which has shown similar findings. 
Exhaled nitric oxide is shown to correlate well with other clinical 
markers of airway inflammation in patients with mild to moderate 
asthma including sputum eosinophils (currently the "gold standard" in 
airway inflammation measurement). 
Although the relationship is relatively weak between sputum eosinophils 
and FeNO (r=O.2283, p=O.0392), we are not considering the use of 
FeNO as a replacement for sputum induction, rather as an additional 
tool for clinicians to have access to which may provide helpful 
information when faced with uncertain diagnosis and treatment 
decisions. 
Further research is needed to find the best use for this biomarker. 
Conclusion: 
Exhaled nitric oxide could be used as a non-invasive surrogate 
biomarker of airway inflammation in primary care to aid treatment and 
management decisions in patients with mild to moderate well-controlled 
asthma. 
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5.3 - The relationship between clinical diagnostic tests and 
exhaled nitric oxide in asthma: 
Hypothesis: 
Exhaled nitric oxide be used in primary care to predict the likelihood of 
"true" asthma in patients with a suspected diagnosis of mild to moderate 
asthma. 
Introduction: 
In primary care, accurate diagnosis of mild to moderate asthma can 
prove difficult due to the lack of clinical tests which are available or 
feasible. 
In secondary care and research centres there are numerous clinical 
tests available which can help to confirm or exclude a diagnosis of 
asthma. The two tests of choice are airway hyperresponsiveness as 
measured by methacholine bronchial challenge test and airway 
inflammation as measured by sputum induction. 
Patients who present with a positive sputum eosinophilia and I or a 
positive methacholine challenge test are more "likely" to have asthma 
which will respond to inhaled corticosteroid medication. 
GPs cannot refer every patient they suspect may have asthma into 
secondary care for additional testing. Therefore it would be useful for 
GPs to have a simple test which they could use to help them make 
quantitative decisions about inhaled corticosteroid treatment regimes, 
and to help determine who may benefit from a referral into secondary 
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care for additional testing. It may also help GPs exclude asthma in 
patients who present with some "asthma-like" symptoms. 
This analysis set out to investigate whether exhaled nitric oxide can be 
used to predict whether patients may have other positive clinical tests 
and thus that a diagnosis of "true" asthma is more likely and would be 
more likely to be responsive inhaled corticosteroid medication. 
Methods: 
The same methodology was used as is previously detailed in chapters 3 
and 4. 
Methacholine challenge result of less than 8mg/ml was defined as a 
positive test. Sputum eosinophils of greater than 3% was chosen as the 
cut-off for predicting likelihood of asthma and future exacerbation risk 
(293). An FEV1 percent predicted of <80% was the chosen cut-off for 
spirometry to reflect reduced lung function. 
Analysis: 
The analysis set out to assess the mean baseline FeND levels for 
participants who had a positive or negative test (spirometry, 
methacholine challenge and sputum eosinophilia). T-test was used to 
determine differences within the clinical test groups. The three clinical 
tests were then combined together and one way ANDVA in STATA 11 
was used to calculate if there was a significant difference in baseline 
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FeNO based upon the number of normal and abnormal clinical tests. 
This was to determine whether FeNO reflects the "likelihood" of having 
other abnormal lung function tests and thus the likelihood of having 
asthma which will respond to inhaled corticosteroid treatment. A p value 
of SO.05 was regarded as statistical significance. 
Results: 
The mean baseline FeNO was significantly higher in participants who 
had a positive PC20 (30.26ppb 50ml/sec) versus a negative PC20 
(23.68ppb 50ml/sec) (p=0.0279). 
The mean baseline FeNO was significantly higher in participants who 
had a positive sputum eosinophilia (40.92ppb 50ml/sec) versus a 
negative sputum eosinophilia (23.06ppb 50mllsec) (p<0.0001). 
The mean baseline FeNO was significantly higher in participants who 
had an FEV1 percent predicted <80% (35.02ppb 50ml/sec) versus FEV1 
percent predicted >80% (22.66ppb 50ml/sec) (p=0.0001). These results 
are shown in table 5.4 and illustrated graphically in Figure 5.1. 
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Table 5.4: 
The relationship between exhaled nitric oxide and variables of airway 
inflammation and lung function. 
Mean Baseline Exhaled Nitric Oxide {FeNO} and Baseline Variable of Airwall 
Inflammation and Function 
Clinical Variable Mean FeNO (ppb) Mean FeNO (ppb) for P Value 
for a positive a negative clinical (T-Test) 
clinical test test 
Airway Hyperresponsiveness: 
30.26 (24.77 - 35.76) 23.68 (20.55 - 26.82) 0.0279 (PC20 - mg/ml) 
(+ test <8mglml, - test >8mglml) 
Sputum Eosinophils: 
40.92 (30.62 - 51 .21) 23.06 (19.76 - 25.69) <0.0001 (%) 
(+ test >3%, - test <3%) 
FEV 1 Percent Predicted: 
35.02 (28.40 - 41 .64) 22.66 (19.97 - 25.35) 0.0001 (%) 
(+ test <80%, - test >80%) 
Data were calculated using Log mean values, the values presented in the table above are geometric means and 95% 
confidence intervals 
Figure 5.1: 
Bar chart to illustrate the difference in Mean Baseline FeND values 
associated with clinical tests measuring airway inflammation and lung 
function. 
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There was a significant difference in mean baseline FeNO associated 
with no positive variables (18.7Sppb SOml/sec), 1 positive variable 
(28.44ppb SOml/sec), 2 positive variables (3S.0Sppb SOml/sec) and 3 
positive variables (S1.6Sppb SOml/sec). ANOVA (p=O.0004). These 
results are presented in table S.S and illustrated graphically in Figure 
S.2. 
Table 5.5: 
Mean Baseline FeNO associated with number of positive clinical 
variables. 
Baseline Mean FeNO according to number of ~ o s i t i v e e clinical variables 
Mean Baseline FeNO (ppb) P Value (ANOVA) 
Number of Positive 
Clinical Variables 
0 18.75 (14.39 - 23.11) 
1 28.44 (22.41 - 34.46) 0.0004 
2 35.05 (24.64 - 4 5 . 4 ~ ~
3 51.65 (18.96 - 84.34) 
Data calculated as log Mean FeNO, data presented as geometric means and 95% 
confidence intervals 
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Figure 5.2: 
Bar chart to illustrate the difference in Mean Baseline FeNO values 
associated with the number of positive clinical tests. 
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See appendix section 11 for further detailed graphs of these 
correlations. 
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Discussion: 
GPs do not have access to detailed clinical lung function tests which 
measure airway hyperresponsiveness and airway inflammation in 
primary care. As such, it can be difficult for GPs to diagnose mild to 
moderate asthma and decisions to treat with inhaled corticosteroids are 
usually made based upon symptoms rather than evidence of airway 
inflammation. The results shows that an elevated exhaled FeND 
(>25ppb) is associated with having more positive clinical tests for 
asthma and therefore asthma is a more "likely" diagnosis. Patients with 
a persistently low FeND are "unlikely" to have a positive PC20, sputum 
eosinophilia and reduced lung function. Symptoms in these patients 
may be attributed to other conditions, it is unlikely that inhaled 
corticosteroids would be useful in these individuals. This is also 
corroborated in Chapter 5.4 where it is shown that a high FeND can 
distinguish between eosinophilic and neutrophilic airway inflammation 
and the likelihood of a response to steroids. Further investigations may 
be required in order to accurately determine the cause of the symptoms. 
Conversely a patient who presents with a persistently high FeND and 
symptoms of asthma is more "likely" to have a positive PC20, sputum 
eosinophilia and reduced lung function. In these instances inhaled 
corticosteroid medications are likely to be useful in reducing airway 
inflammation. Patients who present to their GP with symptoms of 
asthma and an elevated FeND are more "likely" to have additional 
evidence of asthma (should these tests be performed). GPs could 
initiate an inhaled corticosteroid trial in these patients before referring 
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into secondary care. The patients who present with an intermediate 
level FeNO may prove more problematic. Despite the mean baseline 
FeNO for one positive clinical test (28.44ppb) and two positive clinical 
tests (35.15ppb) being elevated the confidence intervals for the two 
groups range from 22.41-45.49ppb. One positive clinical test may not 
be enough to accurately diagnose asthma. For example a reduced 
FEV1 percent predicted alone may not be a reliable indicator of asthma. 
Using FeNO in primary care may help GPs to determine whether to 
prescribe an inhaled corticosteroid and whether to refer into secondary 
care. 
Conclusion: 
Exhaled nitric oxide is a non-invasive biomarker of airway inflammation. 
It is a quick and Simple test which is feasible in primary care. When 
patients present to their GP with symptoms of asthma, using FeND 
could provide important additional clinical information in primary care 
centres. FeNO is likely to be most useful in patients where it is 
persistently high or persistently low to help GPs determine whether a 
patient is "likely" to have other positive clinical tests (in the case of a 
high FeND), or "unlikely" to have other evidence of asthma (in the case 
of a persistently low FeNO). This could help prevent unnecessary 
inhaled corticosteroid treatment and help guide referrals into secondary 
care more accurately. Thus saving NHS prescription and referral costs 
and preventing unnecessary exposure to inhaled corticosteroids and 
their side effects. 
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5.4 - The relationship between elevated exhaled nitric oxide and 
eosinophilic inflammation in mixed granulocytic asthma: 
Hypothesis: 
Exhaled nitric oxide can distinguish between eosinophilic and non-
eosinophilic sputum in a mixed cohort of patients with asthma. 
Introduction: 
This section refers to a separate analysis and study population. We 
were interested in determining whether FeND measurements could 
distinguish between eosinophilic and non-eosinophilic sputum in a large 
mixed cohort of patients with asthma. In order to do this analysis we 
combined three separate study populations together into one data set. 
Population one was the mild to moderate study population described in 
chapter 4. Population 2 was taken from a study looking at asthma 
patients who were taking SABA medication and/or ICS medication only 
(no LABA). Population 3 was taken from a study looking at patients with 
severe asthma taking high dose les and/or oral steroids. 
The sputum and FeND from all the patients was combined and 
analysed as a separate data set (n=191). 
Exhaled nitric oxide (FeND) and induced sputum differential cell counts 
can be used to classify the heterogeneous airway inflammation 
observed in asthma. Airway eosinophilia is associated with elevated 
FeND, while neutrophilic inflammation is associated with a reduction in 
FeND. Because neutrophils produce superoxide which can reduce nitric 
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oxide, we hypothesised that FeNO would be reduced in mixed 
granulocytic inflammation when compared to pure eosinophilic 
inflammation. This may be clinically relevant as the detection of 
eosinophilia by FeNO alone may be impaired by the presence of airway 
neutrophi lia. 
Methods: 
We performed a retrospective, cross-sectional study of 191 subjects 
with asthma recruited to our respiratory research database between 
August 2009 and October 2011. Subjects with a clinical diagnosis of 
asthma, aged 18-80 years, prescribed as-required bronchodilators, 
long-acting 132 agonists, 0-4000 micrograms inhaled beclomethasone 
dipropionate equivalent or maintenance oral steroids (0-20mg 
Prednisolone) were selected. 
Detailed methodology of the techniques used can be found in chapter 3. 
Current smokers were excluded. Spirometry, FeNO 50ml/sec flow, 
sputum induction and Asthma Control Questionnaire (ACQ) were 
recorded. 
Analysis: 
Groups were based on differential cell counts and classified as 
neutrophilic (neutrophils ~ 6 1 % ) , , eosinophilic (eosinophils ~ 3 % ) , , mixed 
granulocytic (neutrophils ~ 6 1 1% and eosinophils ~ 3 % ) ) and 
paucigranulocytic (eosinophils <3% and neutrophils < 61 %). SPSS 
v16.0 was used to log transform FeNO 50ml/sec for one way ANOVA 
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with Tukey post-hoc test and Kruskal Wallis used for non-normal data. 
A p-value of SO.05 was regarded as statistical significance. 
Results: 
One way ANOVA demonstrated there was a statistically significant 
difference in mean log10 FeNO between the four sputum groups (F 
[3,187] =14.61=p<0.001). Post hoc analysis revealed this was not due 
to differences in the log10 FeNO between the eosinophilic and mixed 
granulocytic groups (41.11 ppb versus 35.47ppb, p=0.84) or differences 
in the log10 FeNO 50 between the paucigranulocytic and neutrophilic 
groups (17.46ppb versus 22.10ppb, p=0.26). 
The significant differences in the log10 FeNO occurred between 
eosinophilic and neutrophilic groups (41.11 ppb versus 22.10ppb, 
p=<0.001) and between the eosinophilic and paucigranulocytic groups 
(41.11ppb versus 17.46ppb p<0.001). This was replicated between the 
mixed and neutrophilic groups (35.47ppb versus 22.10 ppb, p=O.02) 
and between the mixed and paucigranulocytic groups (35.47ppb versus 
17.46ppb, p<0.001). 
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Table 5.6: 
Baseline demographics for study population classified by sputum 
phenotype 
Neutrophilic Mixed Eosinophilic Paucl- Between 
granulocytic granulocytic Group 
difference 
p value 
Number % 69(36%) 25 (13%) 42 (22%) 55 (29%) . 
Age yrs' 58.61 (13.56) 55.28 (12.17) 51.59 (13.23) 55 (14.61) 0.072 
Sex M/F (%) 34/35 11/14 19/23 33122 -(49.3%/50.7%) (44%/56%) (45.2%/54.8%) (60%/40%) 
BMI' 29.12 (6.39) 28.59 (4.15) 27.71 (4.02) 29.22 (4.57) 0.700 
Smoking historY 0(0-20) 0(0-15) 0(0-10) 0(0-19) 0.069 
(pack years) 
BOP equivalene 400 (0-3000) 800 (0-2200) 800 (0-3200) 400 (0-2000) 0.020 
mcg 
Oral prednisoloneOl 0(0-15) O( 0-10) 0(0-10) 0(0-15) 0.079 
(mg) 
FEV,' (L) 2.22 (0.70) 2.15 (0.85) 2.24 (0.74) 2.47 (0.92) 0.666 
FVC'(L) 3.2 (0.90) 3.18 (1.10) 3.45 (0.85) 3.50 (1.24) 0.944 
FeNO 50 (ppb)3 22.10 (18.88- 35.47 (25.18- 41.11 (31.77- 17.46 (14.83- <0.001 
25.69) 49.97) 53.19) 20.56) 
Sputum 0.64 (0.51- 7.76 (5.58- 13.87 (9.36- 0.89 (0.64- <0.001 
eoslnophlls3(%) 0.81) 10.79) 20.55) 1.25) 
Sputum 83.75 (46.00- 72.00 (62.00- 38.05 (7.00- 47.00 (3.00- <0.001 
neutrophlls2(%) 99.50) 88.50) 56.50) 60.00) 
Blood 0.21 (0.18- 0.47 (0.35- 0.41 (0.33- 0.19 (0.15- <0.001 
eosinophils3(x1091L) 0.26) 0.61) 0.51) 0.24) 
ACQ2 1.14 (0-4) 2.29 (0-5) 1.5 (0-5) 1.14 (0-4) 0.020' 
" 
0 Notes. Mean (Standard DevIatIon). MedIan (Range). GeometrIC Mean (9S% ConfIdence Interval). 
'Significant at O.OSlevel 
The baseline demographic data for the four groups is summarised in 
Table 5.6. There were no significant differences overall between 
Page 181 of 260 
sputum groups for age (p=O.072), 8MI (p=O.67), FEV1 (p=O.53), FVC 
(p=O.94) or smoking history (p=O.056). 
Discussion: 
The data presented show that in a mixed, un-selected cohort of patients 
with asthma exhaled nitric oxide can be used to differentiate between 
different sputum inflammatory phenotypes. 
Patients with sputum eosinophilia (eosinophilic asthma) are more likely 
to be steroid responsive than patients with sputum neutrophilia 
(neutrophilic asthma) (294). 
In primary care sputum analysis is not routinely available due to time 
and cost constraints. However, exhaled nitric oxide is a clinical test 
which we know to be feasible in primary care settings. 
If GPs could use exhaled nitric oxide to distinguish between eosinophilic 
and neutrophilic asthma in without sputum induction, they would be 
better placed to make informed decisions about which patients to treat 
with inhaled and oral steroids and which patients to refer into secondary 
care for additional testing. 
Conclusion: 
Our data suggests FeND can differentiate eosinophilic inflammation 
from both neutrophilic and paucigranulocytic asthma. Significantly, 
FeNO can detect eosinophilic inflammation even in the presence of the 
coexisting neutrophilic inflammation observed in mixed granulocytic 
asthma. 
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Chapter 6 - Overall discussion and conclusions: 
In order to establish whether exhaled nitric oxide can be used as a non-
invasive surrogate biomarker of airway inflammation to predict which 
patients with mild to moderate asthma could reduce their inhaled 
corticosteroid medication without suffering from a loss of control or 
exacerbation, certain assumptions were made. 
Firstly, it must be assumed that FeNO measurements reflect an 
important aspect of the asthma disease process acting either directly or 
as a surrogate marker, secondly that FeNO is modifiable and responds 
to changes in treatment regime, and thirdly that FeNO measurements 
provide clinically important information that cannot be discerned by 
simpler methods. The background introduction to this thesis explores 
the previous research which quantifies these assumptions. 
The research to determine the model for using FeNO measurements as 
a biomarker of airway inflammation was induced sputum differential 
eosinophil counts (the current "gold-standard" in non-invasive 
quantifying of airway inflammation). 
Exhaled nitric oxide has been shown to be a good predictor of airway 
inflammation in moderate to severe patients with asthma (295), but the 
research is less robust for the mild to moderate asthma cohort (296). 
Exhaled nitric oxide has been shown to respond to changes in inhaled 
corticosteroid medication dose and act as a biomarker with which to 
titrate medication in patients with asthma (172, 230). This is an 
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important feature of exhaled nitric oxide as asthma is a highly variable 
disease and treatment requirements are likely to change over time. 
Clinical decisions are largely based around the presence or absence of 
asthma symptoms; however, inhaled corticosteroids are used to treat 
airway inflammation. The research presented in Chapter 5.1 found no 
correlation between symptoms and airway inflammation in the analyses 
performed. These results corroborate similar previous research which 
also concludes that there is no evidence of a correlation between 
airway inflammation and asthma symptoms. All patients were recruited 
into the clinical trial on the basis that they were mild-to-moderate, well-
controlled patients with asthma (as defined by a Juniper Asthma Control 
Questionnaire symptom score <1.5). 
However, despite the overall well-controlled, asymptomatic nature of 
the study population. there was great disparity in the levels of airway 
inflammation present. There were no significant correlations between 
measures of inflammation (Blood eosinophils (r=0.1636, p=0.06). 
Sputum eosinophils (r=0.2168. p=0.3028). exhaled nitric oxide 
(r=0.0683. p=0.4060) and symptoms. 
Participants who suffered from a loss of control (as defined by an 
increase in asthma symptoms of >0.5 according to the Juniper Asthma 
Control Questionnaire) did not show a corresponding significant 
increase in levels of airway inflammation. 
Patients who suffered from an exacerbation showed an increase in 
FeNO and sputum eosinophilia however there were only three sputum 
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samples and five FeNO readings at the time of exacerbation from the 
31 (17%) patients who suffered from an exacerbation. The low numbers 
of exacerbation samples mean that accurate conclusions are difficult to 
draw and thus these results are difficult to interpret. 
Despite the fact that symptoms have been repeatedly shown to not 
correlate with measures of airway inflammation, primary care centres 
still continue to make ICS treatment decisions based on the presence or 
absence of symptoms. This is likely to be due to the lack of clinical tools 
which are available, affordable and feasible in primary care. GPs need 
a test which can be quickly performed with ease and produce an instant 
result to quantify levels of airway inflammation in a 3-5 minute 
consultation. Exhaled nitric oxide is a clinical tool which fulfils these 
criteria and whist it has been shown to have positive correlations with 
other measures of airway inflammation (sputum eosinophils) in 
moderate to severe patients with asthma, the results in the mild to 
moderate population remain debated. 
An analysiS assessing the relationship between measures of airway 
inflammation and FeNO (Chapter 5.2), determined that there were 
significant correlations between FeNO and sputum eosinophils 
(r=O.2283, p=O.0392), blood eosinophils (r=O.3543, p<O.001) and blood 
IgE (r=O.2643, p=O.0005). 
The results show that in patients with mild to moderate asthma FeNO 
does reflect airway inflammation and could therefore potentially be used 
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as a simple measureable biomarker in primary care to add quantitative 
clinical data to the subjective assessment of symptoms. 
An additional analysis (chapter 5.3) also assessed whether exhaled 
nitric oxide levels change in patients depending on the number of other 
tests of airway (dys)function which indicate asthma each patient may 
have. Thus whether FeNO alone can help GPs decide which patients 
may need to be referred into secondary care or research centres for 
additional testing. 
The three tests of airway function which were used in the model were: 
airway hyperresponsiveness (PC20: positive indicator test <8mg/ml), 
sputum eosinophil count (Eosinophils: positive indicator test >3%) and 
FEV1 percent predicted (% predicted: positive indicator test <80%). 
The analysis concluded that participants who had no positive indicator 
tests had a mean baseline FeNO (SOml/sec) of 18.7Sppb (normal cut-off 
for the Aerocrine ™ FlexFlow® = <2Sppb = normal/not raised). 
Participants who had all three positive indicator tests had a mean 
baseline FeNO (SOml/sec) of S1.65ppb (normal cut-off for the 
Aerocrine ™ FlexFlow® = >SOppb = high/raised). 
The four groups (0,1,2,3 positive indicator tests) were significantly 
different by ANDVA analysis (p=0.0004). 
This relationship may help GPs decide how treatment regimes should 
be changedlimplemented in their patients with asthma. For example if a 
patient presents with a perSistently low FeND and "symptoms of 
asthma" which do not change/improve despite medication, the GP may 
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wish to refer this patient for further investigation. The patient may have 
neutrophilic asthma which is typically unresponsive to inhaled 
corticosteroid medication and presents with a lower FeNO value or they 
may have a different medical condition. In the abstract presented in 
Chapter 5.4 the results show that FeNO can distinguish between 
eosinophilic and neutrophilic airway inflammation, which further 
supports the use of FeNO to help guide treatment and referral decisions. 
Using FeNO in primary care could provide important additional clinical 
information in addition to airway function (where performed) and 
symptom assessment. 
The analyses concluded that FeNO does correlate with airway 
inflammation, does not correlate with symptoms and can potentially 
provide important information on underlying disease pathophysiology 
and likelihood of having other positive indicator tests of asthma. Despite 
this, unfortunately the results of the pilot study showed that FeNO 
cannot be used to predict which well-controlled patients with asthma 
can step-down their inhaled corticosteroid medication without suffering 
from a loss of control or exacerbation. Despite 67% of the study 
population achieving a successful 50% ICS step-down, FeNO cannot 
help predict who these patients from their baseline measurements. 
An important part of good asthma management is ensuring that 
symptom control is maintained on the lowest doses of inhaled 
corticosteroid medication possible (2). In well-controlled patients with 
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asthma inhaled corticosteroid step-down is recommended after three 
months of good control. However, this generally does not routinely 
happen in primary care. This is likely to be for three reasons: firstly; 
GPs do not have access to any clinical measurements to quantify a 
step-down decision. Secondly; GPs fear they may provoke an 
exacerbation in the patients who step-down. Thirdly; patients can be 
reluctant to step-down. This means that many patients with asthma 
remain over-treated with inhaled corticosteroids and thus they are 
exposed to unnecessary side effects and prescription costs. 
Exhaled nitric oxide has been shown to be a simple measure which is 
feasible in primary care. Whilst FeNO has been shown to have positive 
uses, this study concluded that it cannot be used to predict successful 
step-down of inhaled corticosteroids in well-controlled patients with 
asthma. 
Step-down was achieved in the majority of patients (67%) and the 
exacerbation rate was no higher than in background control groups in 
the literature (17, 277). This indicates that step-down in the mild to 
moderate asthma population is safe and worthwhile. However there are 
no clinical measures of airway (dys)function or inflammation which can 
be used to predict successful step-down. This lack of a quantitative 
clinical tool may mean that GPs remain reluctant to step-down ICS 
therapy in patients with mild to moderate well-controlled asthma. 
However the study results should give confidence to GPs and patients 
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who do with to trial ICS step-down, that it is possible even without a 
quantitative monitoring tool. 
Many of the patients who participated in the ICS step-down study 
indicated that they wanted to step-down their ICS dose in a "controlled" 
environment as they were unsure if they were taking the correct dose of 
ICS while others were concerned with the side-effects and the "bad 
press" associated with taking steroids. Despite the fact that the study 
concluded that there were no tests which can predict successful step-
down, the study was exceptionally well received and easy to recruit. 
14% of the partiCipants who remained well-controlled at three months 
attempted to decrease their ICS dose further after the study (appendix 
section 1). In the appendix section 2 I have included some of the 
feedback questionnaires from the study which clearly indicate that step-
down is wanted by the patients. 
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6.1 - Study weaknesses: 
This study was designed as a pilot study to determine the FeNO cut-off 
values and sample size required for a randomised placebo-controlled 
trial. As such the study did not require a placebo (non-step-down) arm. 
The study also suffers from the same problem as other pragmatic 
clinical asthma studies; asthma is a heterogeneous disease and 
because of that the possible GP "asthma" diagnosis may not have been 
correct in some patients. In this study population 106/191 (55%) had a 
normal PC20 at baseline (>8mg/ml). 
It could be argued that the 7 day duration of step-down was not long 
enough. However, this decision was made for two reasons: Firstly, it is 
a practical time period to perform two FeNO measurements (without 
losing patients to drop-out). Secondly, it has been demonstrated that 
FeNO levels rise after one day of treatment reduction (289). 
Another problem may be that the step-down of 50% was not big enough 
to see a response in the 7 day time period in patients with mild to 
moderate well-controlled asthma. Previous studies have shown that 
only a small reduction in inhaled corticosteroid dose leads to an 
increase in FeNO (243). Also a 50% step-down is the recommended 
dose reduction in the ATS/BTS/SIGN/GINA guidelines and was also the 
maximum reduction in dose which the regional ethics committee would 
approve. 
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The exacerbation rate in the study was low and consequently the study 
was completed being under-powered. This is not necessarily a 
weakness as this was a pilot study and the study was designed to 
assess the level of exacerbation to determine a sample size for a full 
randomised controlled trial. Many other exacerbation studies are 12 
months in durations (this study was only 3 months) to allow for seasonal 
variation. The reason for choosing a 3 month study was for practical 
purposes in primary care and also to follow BTS guidelines which 
recommend a three month follow-up (2). A questionnaire was sent to all 
patients in the study after 12 months of step-down. There were only an 
additional four patients who suffered from a loss of control or an 
exacerbation in this time period. The completed results of the 
questionnaire can be found in appendix section1. 
The fact that the exacerbation rate was so low could be due to the fact 
that the exacerbations which did take place may have been "chance" 
exacerbations. Exacerbation frequency is typically around 0.5 
exacerbations / patient / year (17, 277) (in the well-controlled, mild to 
moderate control cohort) and the low number of exacerbations recorded 
in this study could have been "routine" exacerbations rather than step-
down driven. 
The low levels of exacerbation could also be attributed to an 
improvement in medication compliance due to being in a research study. 
Compliance is difficult to assess but measures were put in place to 
ensure compliance monitoring where possible. GP surgeries were 
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contacted to ensure all patients had been collecting their inhaled 
corticosteroid prescriptions at regular intervals for the previous year. 
Devices with counters (Seretide® and S y m b i c o r t ~ ~ were also checked to 
ensure compliance across the four visits. This was not possible for 
inhalers without counters. However, the FeNO and spirometry values 
did not change between visit one and visit two indicating that 
compliance did not change. 
The final problems which need to be addressed when planning studies 
of this nature are the recurrent problems experienced with the 
Aerocrine ™ N lOX FlexFlow® equipment. These problems have recently 
been raised by Gibson (2009) in a review article (243). The Aerocrine ™ 
NIOX MINO® system appears to be much more robust than the 
Aerocrine ™ NIOX FlexFlow®. Primary care centres would be most likely 
to use the Aerocrine ™ NIOX MINO® system whereas secondary care 
and research centres are more likely to use the Aerocrine TM NIOX 
FlexFlow@ system. Technical difficulties need to be addressed if more 
research is to be performed. 
The other technical issue experienced was that well-controlled 
partiCipants found it difficult to produce sputum. This should be taken 
into account when designing studies which require sputum results. This 
study obtained 105 viable sputum samples at baseline from a total of 
191 patients (55%). 
Despite these weaknesses, the study has significant strengths as 
discussed below. 
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6.2 - Study strengths: 
The study was designed well to maximise recruitment and ease of 
collecting clinical data. The data collected was complete and accurate 
and served to produce robust statistical analysis. 
The study confirmed previous observations (258) that step-down is safe 
in the majority of mild to moderate, well-controlled patients with asthma, 
The study completed with a 67% successful step-down rate. 
Recruitment was straight forward; GPs were supportive of the study as 
were the participants. Initially there was a concern that participants may 
be worried that stepping-down would lead to a loss of control. However, 
the feedback received from the participants was positive. Even the 
patients who could not successfully step-down were reassured to know 
that they were taking the correct dose of medication as many had never 
attempted a step-down. The participants and GPs all wanted this study 
and it was welcomed with ease in Nottingham and Leicester. 
The study was the first collaboration study to recruit 191 patients into a 
study to assess the feasibility of using FeNO to predict step-down in 
primary care. It was also the first study to assess all five flow rates of 
exhaled nitric oxide but this study showed no differences in the results 
of different flow rates in predicting successful step-down. 
The study was also designed to reinforce previous research which 
shows there is no relationship between airway inflammation and 
symptoms in asthma and investment is needed into research for tools 
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which GPs can use to improve clinical outcomes in primary care 
patients with asthma. The study confirmed the relationship between 
FeNO and sputum eosinophils which was previously shown in moderate 
to severe patients with asthma. The study also showed that FeNO is 
higher in patients who have multiple positive indicator clinical tests. 
Finally, many participants may not have had a "true diagnosis" of 
asthma, but the cohort represents the primary care asthma population 
accurately. It also highlights the need to educate GPs to increase the 
rate of step-down in well-controlled patients to prevent unnecessary 
exposure to side effects and to save NHS costs. 
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6.3 - Unanswered questions: 
Using exhaled nitric oxide to guide step-down of inhaled corticosteroid 
medication was no worse than using the clinical guidelines. In all 
instances there is no clinical tool or biomarker which can be used to 
determine who can successfully step-down their inhaled corticosteroid 
medication. It remains a "trial and error" process, however, the study 
reaffirmed, that despite the lack of backing by a clinical test, step-down 
is successful in the majority of well-controlled primary care patients with 
asthma, and therefore step-down should be attempted. It may become 
more routinely implemented if step-down became part of the primary 
care aDF scheme. 
The first question is whether FeND is an individual value in diagnosis, 
treatment decisions, exacerbation risk and adherence? It is possible to 
generate a FeND for each patient and rather than using "whole-
population" cut-off values, individual change around a personal value 
and variability over time may better reflect underlying changes in airway 
inflammation. Would it be possible to give people individualised 
treatment plans based upon their weekly/daily FeND values? 
Whilst the study did examine whether a change in FeND over 7 days 
could predict step-down, personalised FeND asthma management 
plans were not examined and they may be useful in order to track 
deterioration (e.g. seasonal variation). 
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The second question is whether using Fe NO to step-up/step-down 
inhaled corticosteroid treatment is the best use of the tool? 
FeNO may have a better place in using a low value as a negative 
predictive tool (as with a D-Dimer assay for VTE). 
Thirdly, should we make the same assumptions across all patients with 
asthma? Mild asthma may actually represent a "different" disease to 
severe asthma rather than varying severities of the same disease. 
Treatment and management may need to be completely different. 
Finally, a significant number of patients with the diagnostic "label" of 
asthma have no clinical evidence of the disease, yet these patients are 
receiving ICS treatment. This may suggest that earlier and more 
intensive assessment of airway physiology may prevent unnecessary 
treatment. More intensive work is required to answer these questions, 
but non-invasive assessment of airway inflammation serves to provide 
more clinical information into asthma and the diseases processes. 
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6.4 - Overall Conclusion: 
Despite the fact that asthma affects 9% of the UK population and is a 
highly prevalent disease worldwide, we still know relatively little about 
the phenotypic variation which exists between and within patients with 
different severities and clinical presentations of the disease. 
The majority of patients with asthma in the UK are managed solely in 
primary care and with the shift in medical services from secondary care 
and primary care and community increasing rapidly, the role of asthma 
diagnosis and management in primary care is set to become even more 
important. 
Providing GPs with the clinical tools they need to manage asthma more 
effectively is difficult, expensive and time consuming. 
This thesis has explored the possibility of using exhaled nitric oxide as a 
biomarker of airway inflammation to improve asthma diagnosis and 
management in primary care. The results of the studies in this thesis 
confirm the findings of previous research that asthma symptoms do not 
correlate with airway inflammation and that in a mild to moderate 
population FeNO correlates with other measures of airway inflammation. 
However, this research concludes that FeNO cannot be used to predict 
successful step-down of inhaled corticosteroid medication in patients 
with well-controlled mild to moderate asthma. 
There is no doubt that FeNO can provide beneficial additional clinical 
information but the best use for this biomarker is yet to be determined. 
Further research is needed into the underlying cell biology of asthma 
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and FeNO to understand more fully the potential uses for FeNO is 
asthma management. 
In the mean time, good relationships between primary care, secondary 
care and research need to be developed and fostered to support and 
improve shared patient care, research progression and the treatment of 
asthma in the community. A detailed step-down guideline needs to be 
implemented in primary care to reduce unnecessary side effects in 
patients who are over-treated and to reduce NHS and prescription costs. 
Future research into asthma needs to focus on improving primary care 
diagnosis, management and medication review over time (step-down 
and step-up) and improvement of the annual review process. 
The focus of future research should ultimately provide better 
understanding, successful diagnostic accuracy, improved patient 
outcomes and lower costs. 
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Chapter 7 - Suggestions for future work: 
The data presented in this thesis and previous research studies have 
shown that exhaled nitric oxide correlates with airway inflammation in 
asthma, It has also been shown to successfully distinguish between 
different types of airway inflammation (neutrophilic and eosinophilic) in 
asthma, However, it is a poor predictor of exacerbation risk and 
outcome; as such the use of exhaled nitric oxide to predict future 
exacerbation risk is probably not the right use for this biomarker at this 
time, 
This thesis has also presented the importance of step-down of inhaled 
corticosteroid medication, Despite step-down being safe in the majority 
of patients it does not routinely occur in primary care asthma 
management regimes, 
From the background information and the novel research presented in 
this thesis ideas for that future research into exhaled nitric oxide in 
asthma and primary care asthma management may focus upon the 
following areas: 
1. FeNO as an aid to diagnosis and management of asthma in 
steroid-na'ive patients. 
FeNO has been shown to change in relation to inhaled 
corticosteroid medication dose, However, steroids could be 
masking the true nature and use of FeNO, It may be more 
accurate to measure FeNO in steroid-na'ive individuals, who are 
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suspected of having asthma, as an aid to diagnosis. This would 
prevent steroid use being a confounding factor in the 
measurement of FeNO values. It may also be beneficial in 
helping GPs to determine which patients need inhaled 
corticosteroids and which patients need referring into secondary 
care for additional diagnostic support. 
2. FeNO as a tool to exclude asthma. 
FeNO may be best used as a tool to exclude asthma rather than 
as a diagnostic tool. In a similar way to D-Dimer being used to 
"rule-out" VTE rather than confirm it. This would require a large 
population cohort study to determine the lower limit cut-off values 
of FeNO to accurately exclude a diagnosis of asthma. 
3. FeNO as a tool to monitor long-term medication response. 
FeNO has been shown to fluctuate in response to changed in 
inhaled corticosteroid medication doses. Use of FeNO in a 
monitoring capacity could prove useful in patients who are non-
compliant and also in patients who are over-treated. Regular 
monitoring may prove difficult unless a portable, low-cost "home" 
version of the exhaled nitric oxide analyser was introduced into 
the market. GPs would not have time to see all their patients with 
asthma in their surgery for routine FeNO monitoring. 
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4. The importance of "personalised" FeNO values as an 
alternative to whole-population cut-off values. 
Further research is needed into the role and importance of 
personalised FeNO values. The fluctuation in an individual's 
baseline FeNO value may be more important in diagnosis, 
management and outcome than using whole population values. 
A certain percentage change in FeNO from baseline may be 
more important in assessing exacerbation risk than an initially 
high or low FeNO. Whilst our research did analyse whether a 
change in FeNO from baseline was useful in predicting 
exacerbation risk, the number of exacerbations was too low to 
detect a signal in change in FeNO. A large population study may 
help answer these questions. 
5. The importance of FeNO variability over time. 
It has become widely understood that asthma is a highly variable 
disease both between patients but also within patients. It is 
known that the disease presentation and severity can change in 
patients with asthma over time. This variability can range from 
short-term seasonal variation to long-term change in disease 
characteristics. Monitoring a highly variable disease only once a 
year and being treated continuously with the same medication 
may not be the best approach. 
FeNO may prove to be a useful tool in personalising asthma 
treatment over time. For example: a patient could measure their 
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FeNO at home on a daily basis and then take a pre-determined 
dose of their inhaled corticosteroid medication based on the 
FeNO result. This could potentially prevent over-treatment during 
well-controlled periods and increase inhaled corticosteroid dose 
intake in response to a rise in FeNO / inflammation thus 
potentially preventing an exacerbation in the future. 
6. The design of a model which includes FeNO, spirometry and 
symptoms. 
It may be possible to incorporate FeNO into a multi-factorial 
model along with spirometry and symptoms. 
The study demonstrated that participants were more likely to 
have a positive PC20 and sputum eosinophilia (therefore more 
likely to have asthma) if their FEV1 percent predicted was 
reduced and their FeNO was high. The Juniper Asthma Control 
Questionnaire incorporates symptoms, FEV 1 percent predicted 
and short-acting ~ 2 2 agonist use. If a model was developed which 
incorporated FeNO also, more clinical benefit may be 
ascertained in a short GP consultation. 
7. To improve the understanding of underlying cell biology in 
asthma and FeNO production. 
Another important aspect of future research is to try and fully 
understand the underlying cell biology of asthma, airway 
inflammation and FeNO production. It seems more likely that 
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there may be different forms I variants of the disease rather than 
just varying severities of the disease. 
For example: Rheumatoid Arthritis (like asthma) is characterised 
as being an inflammatory disease. In Rheumatoid Arthritis (at the 
time of first presentation with jOint stiffness) 60% of patients will 
have a normal Erthythrocyte Sedimentation Rate (ESR) and C-
Reactive Protein (CRP), over 60% will be seronegative for 
Rheumatoid Factor (RF) and 70% will have normal radiographs 
(297). However, these are the tests used to "diagnose" 
Rheumatoid Arthritis, thus negative test results cannot always 
reliably exclude the diagnosis. The disease is "relatively" slow 
onset and routine monitoring of these patients is vital in order to 
establish a correct diagnosis as early as possible. Other patients 
with Rheumatoid Arthritis present with positive tests from onset. 
A similar phenomenon may be likely in asthma. There may be 
some presentation of symptoms but all biochemical and lung 
function tests are normal. Further assessment and monitoring of 
the symptoms should occur before excluding the diagnosis of 
asthma. Further research into these underlying processes is vital 
if asthma presentation and progression is to be fully understood. 
8. To determine whether there is a genetic component to 
asthma and FeNO production levels. 
There could be a genetic component to FeNO production which 
has not yet been determined and could alter treatment response 
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in these patients. There may be patients with asthma who are 
genetically "high FeNO" producers. 
For example: There are two reasons why a person may have a 
high cholesterol, they may have a poor diet and lifestyle 
(smoking, alcohol consumption and lack of exercise) or they may 
have a genetic disorder known as Familial Hypercholestrolaemia 
(FH) which means they lack a receptor which removes 
cholesterol from the bloodstream. However, the "lifestyle" 
induced patients with high cholesterol have a much better 
response to statins (cholesterol lowering medication) than the 
patients with FH. This could be the same in asthma; there may 
be genetiC and non-genetic variations of FeNO production and 
inflammation which respond differently to the same treatments. 
9. To introduce a standardised step-down guideline into 
primary care. 
Future research should also begin to focus on why GPs are not 
routinely stepping-down inhaled corticosteroid dose in their well-
controlled patients with asthma. More support for GPs and 
patients may be needed in addition to a standardised step-down 
guideline (rather than just a recommendation). Step-down should 
ideally be introduced into primary care aOF guidelines in order 
to maximise compliance. 
Research also needs to focus upon developing tools and 
methods of assessing step-down, however, the evidence 
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suggests that step-down is safe in the majority of well-controlled 
patients with asthma even without these tools. Guideline 
changes could have the most immediate impact in preventing 
unnecessary exposure to side effects and reducing NHS 
prescription costs. Both are valuable reasons to promote 
research into step-down. 
10. To better educate GPs and patients about asthma through 
the use of digital media and mobile technology. 
Developing new drugs and new assessment tests is useless if 
GPs and patients are not educated effectively about the basic 
topics such as medication compliance and inhaler technique. 
There have been recent ideas with regard to introducing more 
asthma education tools into digital media and mobile technology. 
Some centres already use electronic feedback (such as blood 
sugar levels in patients with diabetes) to monitor their patients 
more regularly without the need for face-to-face appointments. 
This not only gives the clinicians regular daily diaries of clinical 
information, but also encourages the patients to take more 
responsibility for their own condition as they know the GP has 
access to the data at anytime and not just at the annual review 
appointment. Similar systems may be feasible in asthma to 
encourage compliance but also to monitor medication responses, 
step-down and disease progression remotely. 
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Appendix: 
Appendix Section 1 : 
Results of 12 month follow-up questionnaire: 
This questionnaire was posted to the 128 patients who completed the 
three month step-down successfully, to assess their symptoms and 
medication after 12 months. 121 questionnaires were returned. The 
results are included. 
1. Since completing the study how would you describe your 
asthma symptoms? 
Better: 25% 
Worse: 4% 
The same: 71 % 
2. Since completing the study have you needed to increase 
your ICS medication? 
No: 84% 
Yes Temporarily: 14% 
Yes Permanently: 2% 
3. Since completing the study has your ICS medication 
changed? 
Yes Increase: 2% 
Yes Decrease: 14% 
Yes Change: 3% 
No: 81% 
4. Since completing the study have you needed any oral 
steroids? 
Yes: 2% 
No: 98% 
5. Since completing the study have you been involved in any 
other research studies? 
Yes: 26% 
No: 74% 
6. Since completing the study have you had any difficulty in 
obtaining your new ICS prescription from your GP? 
Yes: 8% 
No: 92% 
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Appendix Section 2: 
Step-down study patient feedback: 
Below are the comments which were received from the patient 
feedback questionnaire. 
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Appendix Section 3: 
Juniper Asthma Control Questionnaire: 
Question 1: 
On average, during the past week, how often were you woken by your 
asthma during the night? 
O. Never 
1. Hardly ever 
2. A few times 
3. Several times 
4. Many times 
5. A great many times 
6. Unable to sleep because of asthma 
Question 2: 
On average, during the past week, how bad were your asthma 
symptoms when you woke up in the morning? 
O. No symptoms 
1. Very mild symptoms 
2. Mild symptoms 
3. Moderate symptoms 
4. Quite severe symptoms 
5. Severe symptoms 
6. Very severe symptoms 
Question 3: 
In general, during the past week, how limited were you in your activities 
because of your asthma? 
O. Not limited at all 
1. Very slightly limited 
2. Slightly limited 
3. Moderately limited 
4. Very limited 
5. Extremely limited 
6. Totally limited 
Question 4: 
In general, during the past week, how much shortness of breath did you 
experience because of your asthma? 
O. None 
1. A very little 
2. A little 
3. A moderate amount 
4. Quite a lot 
5. A great deal 
6. A very great deal 
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Question 5: 
In general, during the past week, how much of the time did you wheeze? 
O. Not at all 
1. Hardly any of the time 
2. A little of the time 
3. A moderate amount of the time 
4. A lot of the time 
5. Most of the time 
6. All of the time 
Question 6: 
On average, during the past period, how many puffs of short-acting 
bronchodilator (e.g. V e n t o l i n ~ ~ have you used each day? 
o. None 
1. 1-2 puffs most days 
2. 3-4 puffs most days 
3. 5-8 puffs most days 
4. 9-12 puffs most days 
5. 13-16 puffs most days 
6. More than 16 puffs most days 
Question 7: 
FEV1 pre-bronchodilator (L) 
FEV1 predicted (L) 
FEV1 % predicted (%) 
o. >95% predicted 
1. 95-90% predicted 
2. 89-80% predicted 
3. 79-70% predicted 
4. 69-60% predicted 
5. 59-50% predicted 
6. <50% predicted 
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Appendix Section 4: 
Letter of invitation: 
Dear patient, 
I am writing to ask if you would be interested in 
participating in an Asthma trial of a new method of monitoring asthma 
run by a research group based at Nottingham Respiratory Biomedical 
Research Unit (based at Nottingham City Hospital). Please find 
enclosed some more information about this trial. If you decide to 
participate your asthma care will be taken over by the team at 
Nottingham City Hospital for the next 3 months, and I will be informed of 
your progress throughout. I must emphasise that this trial is not looking 
at a new treatment for asthma, but is investigating whether a new 
method of monitoring the disease results in an improved outcome and 
reduced medication doses. The team at Nottingham City Hospital / 
Leicester Glenfield Hospital will make every effort to fit in with you, and 
endeavour to make it easy for you to park. They will also meet 
reasonable travel expenses. If you are interested please contact them 
or return the pre-paid envelope with the form inside to them. 
Thank you for your time, 
Yours sincerely, 
Practice Manager 
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Appendix Section 5: 
Consent form: 
CONSENT FORM 
(Final version 1: 25.01.2010) 
Title of Study: Using exhaled nitric oxide to step-down inhaled 
corticosteroid therapy in asthma 
REC ref: 10/H0402/11 
Name of Researcher: Dr. Dominick Shaw (P.I) and Miss Emma Wilson 
(PhD student) 
Name of Participant: Please initial box 
1. 
2. 
3. 
4. 
5. 
6. 
I confirm that I have read and understand the information D 
sheet version number 2dated 07.03.2010 for the above 
study and have had the opportunity to ask questions. 
I understand that my participation is voluntary and that I D 
am free to withdraw at any time, without giving any reason, 
and without my medical care or legal rights being affected. 
I understand that should I withdraw then the information 
collected so far cannot be erased and that this information 
may still be used in the project analysis. 
I understand that relevant sections of my medical notes D 
and data collected in the study may be looked at by 
authorised individuals from the University of Nottingham, 
the research group and regulatory authorities where it is 
relevant to my taking part in this study. I give permission 
for these individuals to have access to these records and 
to collect, store, analyse and publish information obtained 
from my participation in this study. I understand that my 
personal details will be kept confidential. 
I understand and agree that a blood sample will be taken D 
for analysis of IgE antibodies and eosinophils and a 
sputum sample will be taken for cell counts. 
I agree to my GP being informed of my participation in this D 
study. 
I agree to take part in the above study. D 
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Name of Participant Signature Date 
Name of Person taking consent Signature Date 
Principle Investigator Signature Date 
3 copies: 1 for participant, 1 for the project notes and 1 for the medical 
notes 
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Appendix Section 6: 
Patient Information Sheet: 
PATIENT INFORMATION SHEET 
"Using exhaled nitric oxide to step-down inhaled corticosteroid 
therapy in asthma" 
Research Student: Emma Wilson 
Chief Investigator: Dr Dominick Shaw 
Introduction 
You are being invited to take part in a research study. Before you 
decide, it is important for you to understand why the research is being 
done and what it will involve. Please take the time to read the following 
information carefully and discuss it with others if you wish. Please feel 
free to ask us if there is anything that is not clear or if you require any 
further information. You may keep this information for future reference. 
Purpose of the study 
In asthma the breathing tubes become very congested and inflamed; 
this can lead to shortness of breath and wheeze or exacerbations. 
Inflammation in the lower breathing tubes can be measured by 
monitoring a gas present in your breath called nitric oxide. This 
research study proposes to evaluate whether tailoring long-term asthma 
therapy based on exhaled nitric oxide values is better than conventional 
care, in which therapy is based on symptoms and the results of lung 
function tests. 
Why have I been chosen? 
You have been chosen because you have been diagnosed with asthma 
and are receiving inhaler medications on prescription or because you 
have responded to our advertisement and expressed an interest in this 
research project 
Do I have to take part? 
It is entirely up to you whether or not you decide to take part. If you do 
decide to take part you will be given this information sheet to keep and 
be asked to sign a consent form (you will be given a copy of this as 
well). If you decide to take part you are still free to withdraw at any time 
and without giving a reason. You will also be asked to sign a consent 
form which allows us to store your details on our secure BRU database; 
this is for the purposes of inviting you back for further studies and 
continuing our research. This is optional and it is entirely your choice 
whether we store your details or not. A decision to withdraw, or a 
decision not to take part, will not affect the standard of care you already 
receive. 
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What will happen to me if I take part? 
If after reading this information sheet and talking to a member of the 
research team, you would like to take part in this study, you will be seen 
by a respiratory researcher at Nottingham City Hospital, where you will 
be asked to sign a consent form and fill out a questionnaire. At this 
point you will undergo a screening visit; however, you may not be 
eligible to continue in this study depending on the outcome of this visit. 
You would also undergo a variety of breathing tests, which include the 
following: 
1. Spirometry; which will measure the amount (volume) and/or speed 
(flow) of air that can be inhaled and exhaled. You will be asked to 
blow into a tube which is connected to a recording device and repeat 
this three times. Please be aware that if your spirometry results are 
slightly lower than normal you will not have a methacholine 
challenge test (see test 2). 
2. Methacholine Challenge Test; this measures how reactive your 
airways are and involves inhaling increasing concentrations of a 
substance called methacholine, after which your spirometry 
breathing tests are repeated. It is a simple and safe test widely used 
in the assessment of asthma. 
3. Sputum Induction; this test measures the amount of inflammation 
in the breathing tubes. By taking a sample of sputum we are able to 
measure the inflammatory cells present in that sputum. If you cannot 
produce sputum readily we can 'induce sputum' by asking you to 
inhale increasing concentrations of a salt solution called hypertonic 
saline. The methacholine challenge test and the sputum induction 
can sometimes make you feel a bit tight chested but this can be 
rapidly reversed with an inhaler or nebuliser 
4. Skin Prick Test; this simple test is used to diagnose any allergies 
(e.g. grass pollen). A tiny scratch will be made on your forearm and 
the degree of redness and swelling will be measured. 
5. Exhaled Nitric Oxide Test; this simple test measures the amount of 
inflammation in the breathing tubes by measuring the concentration 
of exhaled nitric oxide. It involves breathing into a tube connected to 
an analyser for a few seconds at various flow rates. 
6. Blood Test; a standard blood sample will be taken and analysed for 
inflammatory cells (eosinophils) and levels of antibody (lgE). Blood 
samples will not be stored for further use. 
After this visit you will be asked to re-attend at 14 (visit 2) and 21 (visit 3) 
days, at which times we will perform another exhaled nitric oxide and 
spirometry test and ask you to complete another questionnaire (this 
questionnaire will be the same as the one completed at visit one). 
Finally, one further visit is planned at 3 months (visit 4) at which time we 
will perform further spirometry, induced sputum, questionnaires, 
methacholine challenge tests, and exhaled nitric oxide tests. Please be 
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aware these visits will be brief and at your own convenience as far as 
possible. 
We will ask you if you would be willing to have your details added to our 
Respiratory database, this means that we can contact you if we have 
any further studies which we believe you may be interested in. You will 
sign a separate consent form if you agree to this, but it is completely 
optional. 
What do I have to do? 
In this study you will have your asthma steroid treatment reduced by 
50% this may involve you stopping your steroid treatment if you are on 
initially low doses. You should carry on as normal; this study should not 
affect your lifestyle and you should continue to take any other 
medication as normal. We also ask that you attend the scheduled study 
visits although there is some flexibility in terms of the days and times 
when these occur. 
What is the procedure being tested? 
This research study proposes to evaluate whether tailoring long-term 
asthma therapy based on exhaled nitric oxide values is better than 
conventional care, in which therapy is based on symptoms and the 
results of lung function tests. 
What are the possible disadvantages of taking part? 
The methacholine challenge test and the sputum induction can 
sometimes make you feel a bit tight chested but this can be rapidly 
reversed with an inhaler or nebuliser. 
There is the risk that you will experience an asthma exacerbation, 
however, 24hour help will be available from our physicians should you 
require any assistance. You will be provided with emergency contact 
details for this service. Your GP will also be aware of your involvement 
in the trial and you may seek advice from them also. 
Will any genetic tests be carried out? 
No. 
What will happen to any samples I give? 
A sputum sample will be analysed for the level of inflammatory cells. 
This gives us a good idea about what type of asthma you may be 
suffering from and also whether you have a chest infection. The results 
of the sputum induction will be recorded but the sample will not be 
stored or kept for future use. 
A blood sample will be tested for blood inflammatory cells and IgE 
(antibodies). The results of the sample will be recorded but the sample 
will not be stored or kept for future use. 
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What are the possible benefits of taking part? 
We cannot promise the study will help you, but it is hoped that we will 
be able to assess and control asthma symptoms more accurately and 
sensitively. This will hopefully lead to a decrease in asthma 
exacerbations and inappropriate medication use, as well as identifying 
some patients whose symptoms may not be due to asthma. 
Will travel expenses be reimbursed? 
Yes, taxi fares or a refund for mileage allowance will be available 
(maximum £10 allowance). 
What will happen to the results of the research study? 
We intend to publish the results in a medical respiratory journal. A 
summary of the results will be available to you should you wish. 
Who is organising and funding the research? 
The research is being organised and funded by the NIHR Nottingham 
Respiratory Biomedical Research Unit, which is part of Nottingham 
University Hospitals NHS Trust and the University of Nottingham. 
Please be aware that the research team involved in the study are not 
being paid for including you in this study. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of this 
study will be kept strictly confidential. Your G.P. will be informed of your 
participation in the study. 
What if there is a problem? 
Complaints: 
if you wish to complain or have any concerns about the way in which 
you have been treated, please get in touch with the research team (see 
below), who will do their best to answer any problems you might have. 
In addition, the normal NHS complaints procedures are also available to 
you (e.g. Patient Advice and Liaison Service - PALS). 
Your first point of contact should be the Chief Investigator Dr. Dominick 
Shaw. 
Nottingham Respiratory BRU, Clinical Sciences Building, Nottingham 
City Hospital, NG5 1 PB (0115) 82 31709. 
Harm: 
In the event that something does go wrong and you are harmed during 
the research study there are no special compensation arrangements. If 
you are harmed and this is due to someone's negligence then you may 
have grounds for legal action for compensation against (Nottingham 
University, Nottingham University Hospitals NHS Trust) but you may still 
have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you. 
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Clinical problems: 
If at any time you feel unwell or that you are suffering with your asthma 
more severely than usual, you will be able to contact our 24hour 
physicians for advice. You will be provided with all emergency contact 
details. Your GP will also be able to help you should you have any 
problems. 
What if I do not want to continue with the study? 
Your participation is voluntary and you are free to withdraw at any time, 
without giving any reason, and without your legal rights being affected. 
If you withdraw then the information collected so far cannot be erased 
and that this information may still be used in the project analysis. 
How willi obtain a summary of the results? 
When you come for your first visit we will make a note of whether you 
would like a copy of the results of the study sending to you. 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee, to protect your interests. This 
study has been reviewed and given favourable opinion by 
Leicestershire, Northamptonshire and Rutland Research Ethics 
Committee 2. 
Contact for further information: 
Emma Elizabeth Wilson 
Tel: 01158231935 
E-Mail: enquiries@nrbru.org 
Thank you for reading this information sheet. 
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Appendix Section 7: 
Asthma drug costs England and Wales: 
Brand Inhaler Dose Per Number Of Drug Name Inhalation Cost Name Device Type (mcg) Inhalations 
Salbutamol Generic MOl 100 200 £1.50 
Salbutamol IVAX® Aerosol 100 200 £1.97 Inhalation 
Salbutamol IVAX® Autohaler 100 200 £6.02 
Salbutamol UCB Asmasal 95 200 £5.65 Pharma® Clickhaler® 
Salbutamol Orion® Easyhaler® 100 200 £3.31 Salbutamol 
Salbutamol Orion® Easyhaler® 200 200 £6.63 Salbutamol 
Salbutamol Chiesi® Pulvinal® 200 100 £4.85 Salbutamol 
Salamol 
Salbutamol IVAX® Easi- 100 200 £6.30 
Breathe® 
Salbulin 
Salbutamol Meda® Novolizer® 100 200 £4.95 
MOl 
Salbutamol A&H® Ventolin® 200 60 £4.92 Accuhaler 
Salbutamol A&H® Ventolin® 100 200 £1.50 Evohaler 
Terbutaline Astra Bricanyl 500 100 £6.92 Zenica® Turbohaler® 
Beclometasone Generic MOl 100 100 £5.36 dipropionate 
Beclometasone Generic MOl 200 100 £9.89 dipropionate 
Beclometasone Generic MOl 200 200 £14.93 dipropionate 
Beclometasone Generic MOl 400 100 £19.61 dipropionate 
Beclometasone UCB Asmabec 100 200 £9.81 dipropionate Pharma® Clickhaler® 
Beclometasone UCB Asmabec 250 100 £12.31 dipropionate Pharma® Clickhaler® 
Beclometasone A&H® BecodiskS® 100 120 £11.30 dipropionate Oiskhaler 
Beclometasone A&H® BecodiskS® 200 120 £21.54 dipropionate Oiskhaler 
Beclometasone A&H® BecodiskS® 400 120 £42.52 dipropionate Oiskhaler 
Beclometasone Clenil Chiesi® Modulite® 50 200 £3.70 dipropionate MOl 
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Beclometasone Clenil 
dipropionate Chiesi® Modulite® 100 200 £7.42 MOl 
Beclometasone Clenil 
dipropionate Chiesi® Modulite® 200 200 £16.17 MOl 
Beclometasone Clenil 
dipropionate Chiesi® Modulite® 250 200 £16.29 MOl 
Beclometasone aVAR® 
dipropionate Teva UK® Aerosol 50 200 £7.87 Inhalation 
Beclometasone aVAR® 
dipropionate Teva UK® Aerosol 100 200 £17.21 Inhalation 
Beclometasone Teva UK® aVAR® 50 200 £7.87 dipropionate Autohaler 
Beclometasone TevaUK® aVAR® 100 200 £17.21 diQropionate Autohaler 
Beclometasone Teva UK® aVAR® 50 200 £7.74 dipropionate Easi-Breathe 
Beclometasone Teva UK® aVAR® 100 200 £16.95 dipropionate Easi-Breathe 
Budesonide Generic MOl 100 200 £8.86 
Budesonide Generic MOl 200 200 £17.71 
Budesonide Generic MOl 400 100 £17.71 
Budelin 
Budesonide Meda® Novolizer® 200 100 £14.86 
MOl 
Budesonide Astra Pulmicort 100 200 £11.84 Zenica® Turbohaler® 
Budesonide Astra Pulmicort 200 100 £11.84 Zenica® Turbohaler® 
Budesonide Astra Pulmicort 400 50 £13.86 Zenica® Turbohaler® 
Alvesco® 
Ciclesonide Takeda® Aerosol 80 120 £32.83 
Inhalation 
Alvesco® 
Ciclesonide Takeda® Aerosol 160 60 £19.31 
Inhalation 
Alvesco® 
Ciclesonide Takeda® Aerosol 160 120 £31.62 
Inhalation 
Fluticasone A&H® Flixotide 50 60 £6.38 dipropionate Accuhaler® 
Fluticasone A&H® Flixotide 100 60 £8.93 dipJopionate Accuhaler® 
Fluticasone A&H® Flixotide 250 60 £21.26 dipropionate Accuhaler® 
Fluticasone A&H® Flixotide 500 60 £36.14 dipropionate Accuhaler® 
Fluticasone A&H® Flixotide 50 120 £5.44 dipropionate Evohaler® 
Fluticasone A&H® Flixotide 125 120 £21.26 dipropionate Evohaler® 
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Fluticasone A&H® Flixotide 250 120 £36.14 dipropionate Evohaler® 
Mometasone furoate Schering- Asmanex 200 30 £15.70 Plough® Twisthaler® 
Mometasone furoate Schering- Asmanex 200 60 £23.54 Plough® Twisthaler® 
Mometasone furoate Schering- Asmanex 400 30 £21.78 Plough® Twisthaler® 
Mometasone furoate Schering- Asmanex 400 60 £36.05 Plough® Twisthaler® 
Salmeterol Generic MOl 25 120 £27.80 
Salmeterol A&H® Serevent 50 60 £29.26 Accuhaler® 
Salmeterol A&H® Serevent 25 120 £29.26 Evohaler® 
Salmeterol A&H® Serevent 50 60 £35.79 Oiskhaler® 
Formoterol fumarate Generic MOl 12 120 £23.75 
Atimos 
Formoterol fumarate Chiesi® Modulite® 12 100 £30.06 Aerosol 
Inhalation 
Foradil® 
Formoterol fumarate Nov arti S® Capsule 6 60 £23.38 
Inhaler 
Formoterol fumarate Astra Oxis 6 60 £24.80 Zenica® Turbohaler® 
Formoterol fumarate Astra Oxis 12 60 £24.80 Zenica® Turbohaler® 
Beclometasone 
dipropionate and Chiesi® Fostair® MOl 100/6 120 £29.32 
Formoterol fumarate 
Budesonide and Astra Symbicort 100/6 120 £33.00 Formoterol fumerate Zenica® Turbohaler® 
Budesonide and Astra Symbicort 200/6 120 £38.00 Formoterol fumerate Zenica® Turbohaler® 
Budesonide and Astra Symbicort 400/12 120 £38.00 Formoterol fumerate Zenica® Turbohaler® 
Fluticasone Flutiform® 
dipropionate and Napp® Aerosol 50/5 120 £18.00 
Formoterol fumarate Inhalation 
Fluticasone Flutiform® 
dipropionate and Napp® Aerosol 125/5 120 £29.26 
Formoterol fumarate Inhalation 
Fluticasone Flutiform® 
dipropionate and Napp® Aerosol 250/10 120 £45.56 
Formoterol fumarate Inhalation 
Fluticaone Seretide dipropionate and A&H® Accuhaler® 100/50 60 £31.19 Salmeterol 
Fluticaone Seretide dipropionate and A&H® Accuhaler® 250/50 60 £35.00 Salmeterol 
Fluticaone Seretide dipropionate and A&H® Accuhaler® 500/50 60 £40.92 Salmeterol 
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Fluticaone Seretide dipropionate and A&H® Evohaler® 50/25 120 £18.00 Salmeterol 
Fluticaone Seretide dipropionate and A&H® 125/25 120 £35.00 
Salmeterol Evohaler® 
Fluticaone Seretide dipropionate and A&H® Evohaler® 250/25 120 £59.48 Salmeterol 
Costs of inhalers for the treatment of asthma in the UK, information 
taken from www.bnf.org (valid until September 2013) (298). 
The current prescription cost in England and Wales is £7.65 per item 
(298). 
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Appendix Section 8: 
OOF Framework indicators for respiratory disease: 
QOF (Qualitv and Outcomes Framework) indicators for resDiratorv disorders 
Points are av.arded for achieving the listed indicators (staged in the case of proportional indicators) 'IIIlich are 
rev.arded by payments adjusted to account for the practice disease prevalence. Patients can be reported as 
'exceptions' for clinical reasons (such as terminal illness or if an intervention Kere contra-indicated) or if a patients 
declines care (e.g. does not respond to three invitations to aNend a revie't'.j. 
Indicator Points Payment stages 
Asthma 
Records: 
Asthma 1, 4 
The practice can produce a register of patients with asthma, excluding patients with 
asthma who have been prescribed no asthma-related drugs in the previous twelve 
Initial Management: 
Asthma 8. 15 40-80% 
The percentage of patients aged eight and over, diagnosed as having asthma from 1 
April 2006 with measures of variability or reversibility. 
Ongoing Management: 
Asthma 3. 6 40-80% 
The percentage of patients with asthma between the ages of 14 and 19 in whom 
there is a record of smoking status in the previous 15 months. 
Asthma 6. 20 40-70% 
The percentage of patients with asthma who have had an asthma review in the 
previous 15 months. 
Chronic Obstructive Pulmonary Disease 
Records: 
CO PO 1. 3 
The practice can produce a register of patients with COPO. 
Initial Management: 
COPO 12. 5 40-80% 
The percentage of all patients with COPO diagnosed after 1 April 2008 in whom the 
diagnosis has been confirmed by post bronchodilor spirometry. 
COPO 10. 
The percentage of patients with COPO with a record of FEV1 in the previous 15 7 40-70% 
months. 
COPO 13. 9 50-90% 
The percentage of patients with COPO who have had a review undertaken by a 
healthcare professional, including an assessment of breathlessness using the MAC 
dyspnoea score in the previous 15 months. 
COP08. 6 40-85% 
The percentage of patients with CO PO who have had influenze immunisation in the 
preceding 1 September to 31 March. 
Smoking Indicators 
Smoking 3. 30 40-90% 
The percentage of patients with any or any combination of the following conditions: 
coronary heart disease, stroke or TIA, hypertension, diabetes, COPO, CKO, asthma, 
schizophrenia, bipolar affective disorder or other psychoses whose notes record 
smoking status in the previous 15 months. 
Smoking 4. 30 40-90% 
The percentage of patients with any or any combination of the following conditions: 
coronary heart disease, stroke or TIA, hypertension, diabetes, COPO, CKO, asthma, 
schizophrenia, bipolar affective disorder or other psychoses whose notes record that 
smoking cessation advice or referral to a specialist service, where available, has 
been offered within the previous 15 months. 
Palliative Care Indicators 
Palliative Care 3. 3 
The practice has a complete register available of all patients in need of palliative 
care/support irrespective of age. 
Palliative Care 2. 3 
The practice has regular (at least 3 monthly) multidisciplinary case review meetings 
where all patients on the palliative care register are discussed. 
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Appendix Section 9: 
Figure 1: 
Scatter graph showing 
the correlation between 
log(FeNO) and FEV 1 
percent predicted. 
(R= -0.2278. p=0.0016) 
Figure 2: 
Scatter graph showing 
the correlation between 
log(FeNO) and FVC 
percent predicted. 
(R= -0.1018. p=0.1621) 
Figure 3: 
Scatter graph showing 
the correlation between 
log(FeNO) and 
FEV 1/FVC ratio. 
(R= -0.3155. p<0.0001) 
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Figure 4: 
Scatter graph showing the correlation between FeND 
and sputum eosinophils. Data have been anti-logged 
in order to display clinically relevant data on x/y axis. 
Figure 5: 
Scatter graph showing the correlation between 
log(FeND)and log(sputum eosinophils). 
R=O.2283, p=O.0392. 
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Figure 6: 
Scatter graph showing the correlation between FeNO 
and blood eosinophils. Data have been anti-logged in 
order to display clinically relevant data on x/y axis. 
Figure 7: 
Scatter graph showing the correlation between 
log(FeNO)and log(blood eosinophils). 
R=O.3543, p<O.0001. 
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Appendix Section 10: 
Correlation between asthma symptoms (as defined by ACO score) and log (blood eosinophils) Figure 1: 
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Appendix Section 11: 
B ox and wh isk e r plots s howin g s pread o f b ase line FeNO values categorise d by p ositive or negative ai rway hyperrsp onslven ess 
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Figure 1: 
Box and whisker plots showing the distribution of baseline FeND values categorised 
according to airway hyperresponsiveness. 
Negative group mean FeND = 23.68ppb (20.55 - 26.82) 
Positive group mean FeND = 30.26ppb (24.77 - 35.76) 
Between group T-test: p=0.0279 
B ox a nd whisker p lots s howing b aselin e F e ND va lue catego rised b y p osit ive o r n egative sputum eosinoph ilia 
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Figure 2: 
Box and whisker plots showing the distribution of baseline FeND values categorised 
according to sputum eosinophilia. 
Negative group mean FeND = 23.06ppb (19.76 - 25.69) 
Positive group mean FeND = 40.92ppb (30.62 - 51 .21) Page 256 of 260 
Between group T-test: p<0.0001 
Box and wh isk e r plot s howing d istribution of b aseli n e F e NO categorised b y s p irometry 
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Figure 3: 
Box and whisker plots showing the distribution of baseline FeND values categorised 
according to spirometry. 
>80% predicted group mean FeND = 22.66 (19 .66 - 25.35) 
<80% predicted group mean FeND = 35.02 (28.40 - 41.64) 
Between group T-test: p<0.0001 
Box and whisker plots showing the distribution of baseline FeNO categorised by the number of clinical tests indicating asthma 
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Figure 4: 
Box and whisker plots showing the distribution of baseline FeND values categorised 
according to number of clinical indicators of asthma. 
o tests mean FeND = 18.75ppb (14.39 - 23.11) , 1 test mean FeND = 28.44 (22.41 -
34.46) , 2 tests mean FeND = 35.05ppb (24.64 - 45.49) , 3 tests mean FeNO = 51.65ppb 
(18.96 - 84.34). Between groups ANDVA, p = 0.0004. 
Appendix Section 12: 
Box and whisker diagram showing distribution of FeNO across visits 1-4 and exacerbation. 
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Figure 1: 
Box and whisker plots showing the distribution of baseline FeNO values categorised 
according to visit number. 
Visit one mean FeNO = 25.98ppb (geometric mean: 20.79 (18.88 - 22.89) 
Visit two mean FeNO = 25.53ppb (geometric mean: 20.07 (18.22 - 22.11) 
Visit three mean FeNO = 26.96ppb (geometric mean: 21 .19 (19.17 - 23.44) 
Visit four mean FeNO = 27.21 ppb {geometric mean: 21.67 (19.53 - 24.05) 
Exacerbation mean FeNO = 40.28ppb (geometric mean: 28.51 (20.41 - 39.83) 
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Box and whisker d iagram showing d ist ribution o f baseline FeNO in stable and deterioration patients 
No loss of control or exacerbation (stable) Loss of control or exacerbation (deterioration) 
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Figure 2: 
Box and whisker plots showing the distribution of baseline FeNO values 
categorised according to stable or deterioration at ICS step-down. 
Stable mean FeNO: 2S.13ppb (geometric mean: 18.9 (16.8 - 21.5) 
Deterioration mean FeNO: 27.73ppb (geometric mean: 19.7 (16.4 - 23.6) 
T -test: P=0.76 
Box and whisker d iagram s howing change In FeNO between V2 a nd V3 In stable and d eterio rat ion pat ients 
o 
U') 
o 
Figure 3: 
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Box and whisker plots showing the absolute change in FeNO values 
between visit two and visit 3 (post-step down) categorised according to 
stable or deterioration at les step-down. 
Stable change FeNO: 1.58 ± 11.9 ppb 
Deterioration change FeNO: 1.03 ± 14.88 ppb (T -test: P=0.80) 
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